Chemically modified peptides and use thereof

Abstract

The present application relates to chemically modified peptides and uses thereof in treating certain diseases or disorders.

Description

Attorney Docket No. 14794-019-228 / 327.WO1.PCTCHEMICALLY MODIFIED PEPTIDES AND USE THEREOFRELATED APPLICATION[00011 This application claims priontv to U.S. Provisional Application No. 63 / 697,413, filed on September 20, 2024, and U.S. Provisional Application No 63 / 790,521, filed on April17, 2025. the entirety of each of which is incorporated herein by reference.SEQUENCE LISTING

[0002] This application contains a computer-readable Sequence Listing which has been submitted in XML file format with this application, the entire content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14794-019-228 SEQ LISTING.xml”, was created on September 17, 2025 and is 258,168 bytes in size.1. FIELD

[0003] The present application relates to chemically modified peptides and uses thereof in treating certain diseases or disorders.2. BACKGROUND

[0004] The urocortins (UCNs), UCN1, UCN2 and UCN3 are endogenous peptides that interact with corticotropin-releasing factor receptors 1 and 2 (CRFR1 and CRFR2). CRFR1 and CRFR2 are activated non-selectively by corticotropin releasing hormone (CRH) and UCN1, whereas UCN2 and UCN3 are CRFR2~selective agonists. UCN2 selectively activates CRFR2, including the known isoforms CRFR2-alpha (a), -beta (b) and -gamma (g).

[0005] CRFR2 agonists have demonstrated an effect prechnically in cardiovascular function via the reduction of vascular resistance, and kidney function. In clinical studies, UCN2 and UCN3 have been shown to have direct vasorelaxant actions in healthy volunteers and in patients with heart failure. Further, UCN2 has also been shown to increase cardiac output and reduce vascular resistance in patients with heart failure. However, the extremely short half-life of urocortins remains a major limitation to their therapeutic use, for example in the management of patients that require treatment suitable for long-standing and home selfadministration.1NAI-50022729563. SUMMARY

[0006] In one aspect, provided herein are chemically- modified peptides. In a further aspect, provided herein is a peptide comprising an amino acid sequence of Formula (1 ’) (SEQ ID NO: 63):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-G1n-Ala- Arg- A] a- Arg-Ala- Ala-Arg-Glu-Gln- Al a-R32-Thr- Asn-Rss-Gl u-lle-Rss-Gl u-R4e-R4 t-N H2O’), wherein:RN is selected from RL, Rr-Ser-Gly from N-terminus to C-terminus, Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGlu, or absent: Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;Rs is selected from Lys, amK. Arg, Gin. Glu, and Gly;R20 is selected from Glu, and Gin;R.32 IS selected from Glu, K*, and Thr;R35 is selected from Ala, Aib, and Ac3c;R.?8 is selected from NIe, and Leu;R<w is selected from Thr. Glu, and Arg;R4J is selected from He, V al, and Glu; and wherein:Ri. is -(Z)i-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH2)p-X, “(Z)1-(2-[2-(2-aminO"etlioxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(Trx)r(C())- (CH 2)P-X. or-((CO)-(PEG)k-(CH2)2-NH)r-(gGlu)t-(CO)-(CH2)u-zK; wherein the linkage to RL is via the nitrogen of the N-terminus;Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acety’r)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-etiioxy]-acetyi)b-((CO)-CH2-(PEG)w~NH)y-(gGlu)c-(Trx)d- (C())-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGIu)B-(CO)-(CH2)g-X;2NAI-5002272956each Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H, -P(O)(OH)2, -S(O): 2NH2, or -(lH-tetrazol-5-yl):1, n. v. m, j. and t are each independently 0. 1, 2 or 3; p and u are each independently 14-20; s is 1-36; optionally 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33. 34. 35. or 36; k is 2-16; optionally 2. 4, 6. 8, 10, 12, 14, or 16; r is 1 . 2, 3, or 4; a. b, y, c, d, and e are each independently 0, 1, 2, or 3; q and g are each independently 14-20; w is 1-36; optionally 1, 2, 3, 4, 5, 6, 7, 8. 9, 10. 11, 12. 13. 14. 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31. 32. 33. 34, 35, or 36; h is 2-16: optionally 2, 4. 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4; and with the proviso that when K* is present, RL is not present; and when RL is present, K* is not present. In a further aspect of the disclosure, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (I’) (SEQ ID NO:63).

[0007] In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (li'l (SEQ ID NO:64):RN-Ri-Ri-Rs-Tle-Thr-Leu-Ser-Leu-Asp-Val-Pro-lle-Gly-Leu-Gln-Gln-lle-Leu-Leu-Rso-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-Ala-R32-Thr-Asn-R35-Glu-Ile-Ris-Glu-R40-Ru-NH2(If), wherein:RM is selected from RL, Rr-Ser-Gly from N-temiinus to C-termmus, Tyr-Leu from N- terminus to C-terrmnus, His-Pro from N-tenninus to C -terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser. Aib. and Thr;R3 is selected from Lys. aniK. Arg. Gin, Glu. and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, K*, and Thr;R35 is selected from Ala. Aib, and Ac3c;R.38 is selected from Nle, and Leu;R40 is selected from Thr. Glu, and Arg;NAI-5002272956R41 is selected from lie, V al, and Glu; and wherein:RL IS -(2-[2-(2-ammo~ethoxy)-ethoxy]-acety’l)I!-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-etlioxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s"NHX-(gGlu);;i“(CO)"((;H2)p"X. n, v, and m are each independently 0, 1, 2 or 3; p is 14-20; s is 1-36; optionally 1. 2, 3. 4, 5. 6, 7, 8. 9, 10. 11. 12. 13. 14. 15. 16. 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36; wherein the linkage to RL is via the nitrogen of the N-terminus;Rz is -(Z)a-(2- [2-(2-amino-ethoxy )-ethoxy] -acetyl)b-(gGlu)s-(Trx)d-(CO)-(CH2)q-X,-(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)s-(CO)-(CH2)£-X; each Z is independently Gly. Glu, gGlu, Lys, eLys, Ala. Gin, or His;X is -CO2II, -P(O)(OH ): 2, -S(O)2NH2, or -(lH-tetrazoI-5-yl); a. b, y, c, d, and e are each independently 0, 1. 2, or 3; q and g are each independently 14-20; w is 1 -36; optionally 1, 2, 3, 4. 5. 6. 7, 8, 9, 10, 1 1. 12. 13. 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31. 32, 33, 34, 35. or 36; h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4; and with the proviso that when K* is present, RL IS not present; and when RL is present, K* is not present In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (li’) (SEQ ID NO:64).

[0008] In certain embodiments, the amino acid sequence of Formula (I’) or (If) is an amino acid sequence of Formula (la") (SEQ ID NO:65). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la’):RL-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Vd-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-GIu-Gln-Ala-RsL-Thr-Asn-Rss-Glu-Ile-R’S-Glu-Rw-Rri-Nl-hNAI-5002272956 4(la"), wherein:Ri is selected from Gly. Aib, Asp. Glu, and Pro:R? is selected from Gly, Ser, Aib, and Thr;Ra is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu. and Thr;R35 is selected from Ala, .Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:RL is -(2’[2-(2-amino-ethoxy)-ethoxy]-acety1)n-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethox^')-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X;X is -CO2H, -P(O)(OH)2, -S(O)2NH?„ or -(lH-tetrazol-5-yl); n, v, and rn are each independently 0, 1. 2 or 3; p is 14-20; s is 1-36; optionally 1, 2, 3, 4, 5, 6, 7, 8, 9. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34. 35, or 36; wherein the linkage to RL is via the nitrogen of the N-terminus. In a further embodiment, provided herein is a pharmaceutically acceptable salt of a peptide composing an ammo acid sequence of Formula (la") (SEQ ID N():65).

[0009] In certain embodiments, the amino acid sequence of Formula (I") or (IF) is an amino acid sequence of Formula (la-L) (SEQ ID NO:66). In certain embodiments, provided herein is a peptide comprising an ammo acid sequence of Formula (la- 1 ’):Rj.-Gly-R?-R3-Ile-Thr-Leu-Ser-Leu-AspA'al-Pro-Iie-Gly-Leu-Gln-Glrf-Ile-Leu-Leu-R2c>-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-I1e-R38-Glu-R40-R4i-NH2(la-1’), wherein:R2 is selected from Gly, Ser, Aib, and Thr;R3 is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu. and Thr;R35 is selected from Ala, Aib, and Ac3c:NAI-5002272956R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 IS selected from He, Vai, and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X;X is -CO2H, -P(O)(OH)2. -S(O)2NH2, or -( lH-tetrazol-5-yl): n. v, and m are each independently 0, 1, 2. or 3; p is 14-20; s is 1 -36; optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. 35. or 36; wherein the linkage to Ri, is via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (Ia-1 ‘) (SEQ ID NO:66).

[0010] In certain embodiments, the amino acid sequence of Formula (I’) or (If) is an ammo acid sequence of Formula (Ia-2'I (SEQ ID NO:67) In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-2’):RL-Ri-Gly-Rs-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Rio-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu"Gln~Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R4u-R4i-NH2(la-2’), wherein:Ri is selected from Gly, Aib, .Asp, Glu, and Pro;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly,R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and ArgR4J is selected from He, Vai. and Glu; and wherein:RL. IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)!.,-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NHV(gGlu)ia-(CO)-(CH2)p-X;X is -CO2II, -P(O)(OH ): 2, -S(O)2NH2, or -(iH-tetrazol-5-yl). n. v. and m are each independen tly 0, 1, 2 or 3;NAI-5002272956 6p is 14-20; s is 1 -36. optionally 1, 2, 3, 4, 5. 6, 7, 8, 9, 10, 1 1. 12. 13. 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24. 25, 26. 27, 28, 29, 30. 31. 32. 33, 34, 35. or 36; wherein the linkage to RL IS via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la-2’) (SEQ ID NO:67).[00111 In certain embodiments, the ammo acid sequence of Formula (!’) or (Ir ) is an ammo acid sequence of Formula (la-3’) (SEQ ID NO:68). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-3’):RL-Ri-R2-Lys-ne-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-I1e-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-Ala-Rs2-Thr-Asn4b5-Glu-Ile-R38-Glu-R4o-R4i-NH2 (Ta-3’), wherein :Ri is selected from Gly, Aib, .Asp, Glu, and Pro;Rz is selected from Gly, Ser, .Aib, and Thr;R20 is selected from Glu. and Gin;R32 is selected from Glu, and Thr;R35 is selected from .Ala, Aib, and Ac3c;Rss is selected from Nle, and Leu;R40 is selected from Thr. Glu, and Arg;R4J is selected from He. Vai. and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxv)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CIl2)p-CO2H or -(2-[2-(2- amino-ethoxy)-eihoxy]-acety1)n-((CO)-CH2-(PEG)s-NHX-(gGlu)m-(CO)-(CH2)p-X;X is -CO2H, -P(O)(OH)2, -S(O)2NH2, or -( lH-tetrazol-5-yl); n, v, and m are each independently 0, I , 2 or 3; p is 14-20; s is 1-36; optionally 1, 2, 3, 4, 5. 6, 7, 8, 9, 10. 11. 12. 13, 14, 15, 16. 17, 18, 19, 20, 21, 22. 23. 24. 25, 26, 27, 28, 29. 30, 31, 32, 33. 34. 35. or 36; wherein the linkage to RL is via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la-3’) (SEQ ID NO:68).

[0012] In certain embodiments, the amino acid sequence of Formula (L) or (li ’) is an amino acid sequence of Formula Ob') (SEQ ID NO:69). In certain embodiments, providedNAI-5002272956 7herein is a peptide comprising an amino acid sequence of Formula (lb’):RN-Ri-R2-R3-Ile-Tlir-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg-Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-K*~nir-Asn-R35-Glu-Ile-R38-Glu-R40-R4j-NH2(IbA wherein :RN is selected from Tyr-Leu from N-termimis to C -terminus, His-Pro from N-lerminus toC -terminus, Gly. and pGiu, or absent;Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from lie, Vai, and Glu; and wherein:Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-etlioxy]-acety'l)t,-(gGiu)e-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH).v-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)i>-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g-X; each Z is independently Gly. Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H, -P(O)(OI I) 2, -S(O)2NH2, or -(lH-tetrazol-5-yl); a, b, y, c, d. and e are each independently 0, 1 , 2, or 3; q and g are each independently 14-20; w is 1-36, optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. 35. or 36; h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4.In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptideNAI-5002272956 8comprising an amino acid sequence of Formula (lb") (SEQ ID N():69).

[0013] In certain embodiments, the amino acid sequence of Formula (F) or (If) is an amino acid sequence of Formula (lb-1 ’) (SEQ ID NO:70). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (lb- 1 ' ): pGlu-Ri-R2-R3-Ile*Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-I1e-Leu-Leu-R2o- Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-K*-Thr-Asn-R35-Glu-He-R38-Glu-R40-R4i- NH2(Ib-1 ’). wherein:Ri is selected from Gly, Aib, Asp, Glu, and Pro;Re IS selected from Gly. Ser, Aib, and Thr;R?, is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib. and Ac3c;R38 is selected from Nle, and Leu,Rro is selected from Thr. Glu. and Arg;R41 is selected from He, Vai, and Glu; and wherein: mino-ethoNy)-ethoxy']-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, xy )-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d--((CO)-(PEG)h-(CH2)2-NI-I)f-(gGluX-(CO)-(CH2)g-X; each Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H, -P(O)(OH)2, -S(O): 2NH2, or -(lH-tetrazol-5-yl); a. b, y, c, d, and e are each independently 0, 1. 2, or 3; q and g are each independently 14-20; w is 1 -36; optionally 1 , 2, 3, 4, 5, 6. 7. 8. 9. 10, 1 1 , 12, 13. 14. 15, 16. 17, 18, 19, 20, 21. 22, 23, 24, 25, 26, 27, 28, 29, 30, 31. 32, 33, 34, 35, or 36; h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16;NAI-5002272956 9f is 1, 2, 3, or 4.In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (lb-1 ’) (SEQ ID NO:70).

[0014] In a further aspect, provided herein is a peptide comprising an ammo acid sequence of Formula (I) (SEQ ID NO:32 );RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-I1e-Leu-Leu-R2o-Gln- Ala- Arg-Ala- Arg-Ala-Ala-Arg-Glu-Gln-Ala-Ri2-Thr-Asn-R35-Glu-lle-R38-Glu-R40-R4j-NH2 (I). wherein:RN IS selected from RL, Ru-Ser-Gly from N-terminus to C-terminus, Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGlu, or absent: Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2is selected from Gly, Ser. Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;Rzo is selected from Glu, and Gin,R32 IS selected from Glu, K*. and Thr;Rss IS selected from Ala, / Mb. and Ac3c;R.38 IS selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from He, Vai. and Glu; and wherein :RL is -(Z)i-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH2)p-X or -((CO)-(PEG)k-(CH2)2-NII)r-(gGlu)1-(CO)-(CH2)u-X; wherein the linkage to RL. IS via the nitrogen of the N-terminus;Rz is -(Z)a-(2-[2-(2-anuno-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH)f-(gGhi)e-(CO)-(CH2)g-X;Z is independently Gly, Glu. gGlu, Lys, eLys, Ala, Gin. or His;X is -CO?H or -P(O)(OH)2; i, n, m, j, and t are each independently 0, 1, 2 or 3;NAI-5002272956 10p and u are each independently 14-20; k is 2-16. optionally 2, 4, 6, 8, 10, 12, 14, or 16; r is 1, 2, 3, or 4; a, b, c, d, and e are each independently 0, 1, 2, or 3; q and g are each independently 14-20, h is 2-16; optionally 2, 4. 6, 8, 10, 12, 14, or 16; f is 1. 2, 3. or 4; and with the proviso that when K* is present, Ri, is not present; and when RL. is present. K* is not present. In a further aspect of the disclosure, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (I) (SEQ ID NO:32).

[0015] In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (li) (SEQ ID NO:62):RN-Ri-Ra-Rs-Ile-Thr-Leu-Ser-Leu-yVsp-Val-Pro-Ile-Gly-Leu-Gln-Gln-lle-Leu-Leu-Rzo-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-GIn-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2(li ). wherein:RN IS selected from RL, Rr-Ser-Gly from N-terminus to C-temnnus, Tyr-Leu from N- lerminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGlu, or absent; Ri is selected from Gly. Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser. Aib, and Thr;R.i is selected from Lys, aniK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, K*. and Thr;R35 is selected from .Ala, / lib, and Ac3c;R.3S is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:RL IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl):1-(gGlu)m-(CO)-(CH2)p-CO2H; n and m are each independently 0, 1 , 2 or 3; p is 14-20; wherein the linkage to RL. IS via the nitrogen of the N-terminus;NAI-5002272956 11Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH')f-(gGlu)e-(CO)-(CH2)g-X;Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H or -P(O)(OH)2; a. b. c, d, and e are each independently 0. 1. 2, or 3: q and g are each independently 14-20; h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4; and with the proviso that when K* is present, RL is not present; and when RL. is present, K* is not present In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (li) (SEQ ID NO:62).

[0016] In certain embodiments, the ammo acid sequence of Formula (I) is an amino acid sequence of Formula (la) (SEQ ID NO: 33). In certain embodiments, provided herein is a peptide comprising an ammo acid sequence of Formula (la):RL-Ri-R2-R3-Iie-Thr-Leu-Ser-Leu-Asp-Val-Pro-I]e-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-AIa-Arg-Ala-Arg-Ala-Ala-Arg-Ghi-Gln-Ala-R32-Thr-Asn-R35~Glu-Ile-R38-Glu-R40-R41~NH2(la), wherein:Ri is selected from Gly, Aib, Asp. Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, .Aib, and Ac3c;Rss is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from lie. Vai, and Glu; and wherein:RL is -(2-[2-(2-arnino-ethoxy)-ethoxy]-acetyl)n-(gGIu)m-(CO)-(CH2)p-CO2H;NAI-5002272956n and in are each independently 0, 1, 2 or 3; p is 14-20; wherein the linkage to RL IS via the nitrogen of the N-terminus. In a further embodiment, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la) (SEQ ID NO:33).

[0017] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (la-1) (SEQ ID NO:34). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-1):RL-Gly-R2-R3-Tle-Thr-Leu-Sei-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-Ala-R32-Thr-Asn-R35-G!u-Ile-R38-Glu-R40-R4i-NH2(la-1), wherein:R? is selected from Gly, Ser. Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;Rzo is selected from Glu, and Gin,R32 is selected from Glu. and Thr;R35 is selected from Ala, Aib, and Ac3c;R?,s is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R4i is selected from He, Vai. and Glu; and wherein :RL is -(2-[2-(2-amino-ethoxy)-etho.xy |-acetyl)n-(gGhi)m“(CO)-(CH2)p“CO2H; n and m are each independently 0, 1 , 2 or 3; p is 14-20; wherein the linkage to RL IS via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la-1) (SEQ ID NO:34),

[0018] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (la-2) (SEQ ID NO:35). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-2):RL-Ri-Gly-R3-ne-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-G1y-Leu-Gln-Gln-I1e-Leu-Leu-R2o-Gln- Ala-^Vg- Ala- Arg-Ala-Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R4w-R4i-NIH2 (la-2), wherein :NAI-5002272956 13Ri is selected from Gly, Aib, Asp, Glu, and Pro;Rs is selected from Lys, amK. Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R.32 IS selected from (flu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr. Glu, and ArgRu is selected from lie, Vai, and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H: n and m are each independently 0, 1, 2 or 3; p is 14-20; wherein the linkage lo RL is via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an ammo acid sequence of Formula (la-2) (SEQ ID NO:35).

[0019] In certain embodiments, the ammo acid sequence of Formula (I) is an amino acid sequence of Formula (la-3) (SEQ ID NO:36). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula da-3 LRL-Ri-R2-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R20-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-Rv2-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2 (la-3), wherein:Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R.38 is selected from Nle, and Leu;R40 is selected from Thr. Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:Ri. is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)ni-(CO)-(CH2)p-CO2H; n and m are each independently 0, I, 2 or 3; p is 14-20;NAI-5002272956 14wherein the linkage to RL is via the nitrogen of the N-terminus. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la-3) (SEQ ID NO:36).

[0020] In certain embodiments, the ammo acid sequence of Formula (I) is an ammo acid sequence of Formula (lb) (SEQ ID NO:37). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (lb):RN-Ri-R2-R3-lle-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-lle-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-K*-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2(Tb). wherein:RN IS selected from Tyr-Leu from N-terminus to C -terminus, His-Pro from N-terminus toC -terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;R3 is selected from Lys, amK. Arg, Gin, Glu, and Gly,R20 is selected from Glu. and Gin;R35 is selected from Ala, / lib. and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from lie, Vai. and Glu; and wherein :Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or-((CO)-(PEG)h-(CH2)2-NH)f-(gGiu)e-(CO)-(CH2)g-X;Z is independently Gly. Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H or -P(O)(OH)2; a. b, c, d. and e are each independently 0, 1, 2. or 3; q and g are each independently 14-20: h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4.NAI-5002272956In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (lb) (SEQ ID NO:37).

[0021] In certain embodiments, the ammo acid sequence of Formula (1) is an ammo acid sequence of Formula (Ib-1 ) (SEQ ID N():38). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (Ib-1): pGiu-Ri-R2-R3-Iie-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gin- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-K* -Thr- Asn-R35-Glu-lle-R38-Glu-R40-R4i-NFh(Ib-1 ), wherein:Ri is selected from Gly, Aib, Asp, Glu, and Pro;R? is selected from Gly, Ser. Aib, and Thr;R3 is selected from Lys, amK, Arg, Gin, Glu, and Gly:R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle. and Leu;R40 is selected from Thr, Glu. and Arg;R41 is selected from lie, Vai, and Glu; and wherein :Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)i,-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH)f-(gGluXCO)-(CH2)g-X,Z is independently Gly, Glu, gGlu. Lys, eLys, Ala, Gin. or His;X is -CO2H or -P(O)(OH)2; a. b, c, d, and e are each independently 0, I, 2, or 3; q and g are each independently 14-20; h is 2-16; optionally 2, 4, 6, 8, 10, 12, 14, or 16; f is 1 , 2, 3, or 4.In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (Ib-1) (SEQ ID NO:38).NAI-5002272956 16

[0022] In certain embodiments, RN IS RI -Ser-Gly from N-terminus to C-terminus. In certain embodiments, RN is Tyr-Leu from N-terminus to C-terminus. In certain embodiments, RN IS His-Pro from N-terminus to C-terminus. in certain embodiments, RN is Gly. In certain embodiments, RN IS absent. In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments. R2 is Gly. In certain embodiments. R? is Ser. In certain embodiments. R.i is Aib. In certain embodiments. R2 is Thr In certain embodiments, Rs is Lys In certain embodiments. R- is amK In certain embodiments, Rs is Arg. In certain embodiments. Rs is Gin. In certain embodiments, R3 is Glu. In certain embodiments, Rs is Gly. In certain embodiments, R20 is Glu, In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, Rs? is Aib In certain embodiments, R35 is Ac3c. In certain embodiments. Rss is Leu. In certain embodiments, Rss is Nle. In certain embodiments, IGu is Thr. In certain embodiments, Rio is Glu. In certain embodiments, R-w is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is Vai In certain embodiments, R41 is Glu.

[0023] In certain embodiments, 11 is 1, m is 1, p is 18. In certain embodiments, n is 2, m is I, p is 18. In certain embodiments, n is 3, m is 1, p is 18. In certain embodiments, n is 0, m is I , p is 18. In certain embodiments, n is 1, in is 2. p is 18. In certain embodiments, n is 2, m is 2. p is 18 In certain embodiments, n is 3, m is 2, p is 18. In certain embodiments, n is 0, m is 2. p is 18. In certain embodiments, n is L m is 3, p is 1 8 In certain embodiments. n is 2, ni is 3, p is 18. In certain embodiments, 11 is 3, m is 3, p is 18. In certain embodiments, n is 0, m is 3, p is 18. In certain embodiments, n is 1 , m is 0, p is 18. In certain embodiments, n is 2, m is 0, p is 18. In certain embodiments, n is 3, m is 0. p is 18 In certain embodiments, n is 1, m is 1. p is 16. In certain embodiments, 11 is 2, m is 1, p is 16. In certain embodiments, n is 3, m is 1 , p is 16. In certain embodiments, n is 0, m is 1, p is 16. In certain embodiments, n is I, m is 2, p is 16. In certain embodiments, n is 2, m is 2, p is 16. In certain embodiments, n is 3, m is 2, p is 16. In certain embodiments, n is 0, m is 2, p is 16. In certain embodiments, n is 1, m is 3. p is 16. hi certain embodiments, n is 2, m is 3, p is 16. In certain embodiments, n is 3, m is 3, p is 16. In certain embodiments, n is 0, m is 3, p is 16. In certain embodiments, n is i, m is 0, p is 16. In certain embodiments, n is 2, m is 0, p is 16. In certain embodiments, n is 3, m is 0, p is 16.

[0024] In certain embodiments, Rr is -(Z)i- (2-|2-(2-amino-ethoxy)-ethoxy|-acetyl)n- ((CO)-CH2-(PEG)s-NH)v-(gGiu)m-(Trx)J-(CO) {( H ■). -X. In certain embodiments, 1 is 0. n isNAI-50022729561 , v is 0, m is 1, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 0, m is 1, j is 0, p is18. In certain embodiments, i is 0, n is 3, v is 0. m is 1 , j is 0. p is 18. In certain embodiments, i is 0, n is 0, v is 0. m is 1, j is 0. p is 18. In certain embodiments, i is 0, n is 1, v is 0, m is 2, j is 0. p is 18. In certain embodiments, i is 0, n is 2, v is 0, m is 2, j is 0, p is 18 In certain embodiments, i is 0, n is 3, v is 0, m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 0, v is 0, m is 2. j is 0, p is 18. In certain embodiments, i is 0, n is 1. v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 3. v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 0. v is 0, rn is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 1 , v is 0, m is 0, j is 0, p is 18 In certain embodiments, i is 0, n is 2, v is 0, m is 0, j is 0, p is 18, In certain embodiments, i is 0, n is 3, v is 0, m is 0. j is 0, p is 18. In certain embodiments, i is 0, n is 1. v is 0, m is 1, j is 0, p is 16 In certain embodiments, i is 0, n is 2, v is 0, m is 1, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 0, m is I, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 0, ni is 1, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 0, ni is 2, j is 0, p is 16 In certain embodiments, i is 0, n is 2, v is 0, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 3. v is 0. m is 2. j is 0, p is 16. In certain embodiments, i is 0, n is 0. v is 0, m is 2, j is 0. p is 16. In certain embodiments, i is 0, n is 1 , v is 0, m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 2, v is 0, m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 0, in is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 0, ni is 3, j is 0, p is 16 In certain embodiments, i is 0. n is 1 , v is 0. m is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 2, v is 0. m is 0. j is 0, p is 16 In certain embodiments, i is 0, n is 3. v is 0, m is 0. j is 0, p is 16. In certain embodiments, i is 0, n is 1. v is 0, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 2. v is 0, m is I, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 0, m is 1 , j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 0, rn is 1 , j is 0, p is 20 In certain embodiments, i is 0, n is 1, v is 0. m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 0, m is 2. j is 0, p is 20 In certain embodiments, i is 0, n is 3. v is 0, m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 0, m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 1. v is 0, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 0. ni is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 0, m is 3, j is 0, p is 20 In certain embodiments, i is 0, n is 0, v is 0, in is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 1 , v is 0, m is 0, j is 0. p is 20. In certain embodiments, i is 0, n is 2, v is 0, m is 0, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 0, m is 0, j is 0, p is 20. In certain embodiments, i is 0, n is 1, v is 1 , m is 1, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 1. m is 1. j is 0, p is 18 In certain embodiments, i is 0, n is 3. v is I, m is 1. j is 0, p is 18NAI-5002272956 18In certain embodiments, i is 0, n is 0, v is 1, m is 1, j is 0, p is 18. In certain embodiments, i is 0, n is i , v is 1. m is 2. j is 0, p is 18. In certain embodiments, i is 0, n is 2. v is 1 , m is 2, j is 0. p is 18. In certain embodiments, i is 0, n is 3, v is 1, m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 0, v is 1, m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 1, v is 1, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is I, m is 3, j is 0, p is 18 In certain embodiments, i is 0, n is 3, v is I, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 0. v is 1, in is 3. j is 0, p is 18. In certain embodiments, i is 0, n is 1. v is 1, m is 0. j is 0, p is 18 In certain embodiments, i is 0, n is 2, v is 1, m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 3, v is I, m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 1, v is 1, m is 1 , j is 0, p is 16. In certain embodiments, i is 0, n is 2, v is 1, m is 1 , j is 0, p is 16 In certain embodiments, i is 0, n is 3, v is 1, m is 1 , j is 0, p is 16. In certain embodiments, i is 0, n is 0. v is 1 , m is L j is 0, p is 16 In certain embodiments, i is 0, n is L v is 1 , m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 2. v is 1 , m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 1, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 1, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 1, m is 3, j is 0, p is 16 In certain embodiments, i is 0. n is 2. v is 1. m is 3, j is 0. p is 16. In certain embodiments, i is 0, n is 3, v is 1 , m is 3, j is 0. p is 16. In certain embodiments, i is 0, n is 0, v is 1 , m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 1 , tn is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 2. v is 1 , m is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 1, m is 0. j is 0, p is 16 In certain embodiments, i is 0, n is 1. v is I, m is 1 , j is 0, p is 20 In certain embodiments, i is 0. n is 2, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 1 , v is 1, rn is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 2. v is 1, m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 1, m is 2, j is 0. p is 20. In certain embodiments, i is 0. n is 0, v is I, m is 2, j is 0. p is 20 In certain embodiments, i is 0, n is 1 , v is i , rn is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 1, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 1 , m is 3, j is 0, p is 20. in certain embodiments, i is 0, n is 0. v is 1, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 1, v is I, m is 0, j is 0, p is 20. In certain embodiments, i is 0. n is 2, v is 1 , rn is 0, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 1 , rn is 0, j is 0, p is 20

[0025] In certain embodiments, Rr is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-gGlu- (CO)-(CH2)IS~CO2H. In certain embodiments, Ri. is -(2-[2“(2-aniino-ethoxy)-ethoxy]- acelyl)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, Rr, is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)2-gGlu2-(CO)-(CH2)i8-CO2H. In certain embodiments, Ri, is -(2~[2-(2-amino-NAI-5002272956 19ethoxy )-etlioxy]-acetyl)2-gGlu3-(CO)-(CH2)i8-CO2H. In certain embodiments, RL IS -(2-[2- (2-amino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, RL is -(2-[2-(2-ammo-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)2o-CO'2H. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)2o- P(O)(OH)2. Tn certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acety1)2-gGlu- (CO)-(CH2)20-S(O)2NH2 In certain embodiments. RL is -(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl)2-gGlu-(CO)-(CH2>2o-(lH-tetrazol-5-yl) In certain embodiments, RL is -(2-[2-(2- amino-ethoxy)-ethoxy']-acetyl)2-(CO)-CH2-(PEG)i2-NH-gGlu-(CO)-(CH2)2o-C02H.

[0026] In certain embodiments, b is 2, c is 1, d is 0. In certain embodiments, b is 2, c is 2, d is 0. In certain embodiments, b is 1, c is I, d is 0. In certain embodiments, b is 0, c is I, d is I. In certain embodiments, b is 2. c is 1, d is I. In certain embodiments, b is I, c is 1, d is

[0027] In certain embodiments, Rzis "(Z)a~(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, Rzis -(eLys)a-(2-[2-(2-amino- ethoxy)-ethoxy[-acetyl)b-(gGIu)c-(CO)-(CH2)q-X. In certain embodiments, a is 0 or I, b is 1 or 2 and c is 1 or 2.

[0028] In certain embodiments, ft- is -(2-[2-(2-amino-ethoxy)-ethoxy]-acet}'l)2-(gGln)" (CO)-(CH?.)i6-CO2H. In certain embodiments, Rz is -(2-[2-(2-amino-ethoxy)-ethoxy]- acely])2-(gGlu)-(CO)-(CH2)i8-CO2H.

[0029] In certain embodiments, Rzis -((CO)-(PEG)h-(CH2)2-NH)f-(gGIu)e-(CO)-(CH2)g- X. In certain embodiments, Rz is -~(CO)-(PEG)i2-(CH2)2-NH-(gGlu)e-(CO)-(CH2)g-CO2H. In certain embodiments, e is 1 or 2 and g is 16 or 18.

[0030] In certain embodiments, in Formula (I), RN is RL, Ri is Gly, Re is Gly, and R3 is Lys. In certain embodiments, in Formula (I), RN is RL, RI is Gly. R2 is Gly, R3 is Lys, R20 is Glu, R32 is Glu, R35 is Ala. Ras is Nle, R40 is Thr, and R« is He. In certain embodiments, in Formula (I), RN is RL. RI is Gly, R2 is Gly. Ra is Lys, R20 is Glu, R32 is Glu. R35 is Ala, Ras is Nle, R40 is Thr, R41 is He, and RL IS -(2-[2-(2-amino-ethoxy)~ethoxy]-acetyl)r.-(gGIu)m-(CO)- (CH2)P-CO2H, and wherein 11 and m are each independently 0, 1, 2 or 3; p is 14-20.

[0031] In certain embodiments, the peptide comprises or consists of the ammo acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: I 3, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59. SEQ ID NO:60, or SEQ ID NO:61. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprisingNAI-5002272956 ,0or consisting of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NON, SEQ ID NO:9, SEQ ID NO: 10. SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO: 44. SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO: 59, SEQ ID NO:60. or SEQ ID NO:61. In certain embodiments, the peptide comprises or consists of the ammo acid sequence of SEQ ID NO: 14. SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17. SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO: 27, SEQ ID NO:28, or SEQ ID NO:29. In certain embodiments, provided herein is pharmaceutically acceptable salt of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 15. SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO:18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29.

[0032] In another aspect, provided herein is a peptide comprising the amino acid sequence of SEQ ID NO: 1. SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO.5. SEQ ID NON, SEQ ID \'():7 SEQ ID NON, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18. SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22. SEQ ID NO:23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27. SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO: 31. SEQ ID NO:43. SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO: 54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58. SEQ ID NO:59, SEQ ID NO: 60, or SEQ ID NO:61. In another aspect, provided herein is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NON. SEQ ID NON. SEQ ID NON, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NON, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16. SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24. SEQ ID NO:25. SEQ ID NO:26. SEQ ID NO-27. SEQ ID NO: 28, SEQ ID NO:29, SEQ ID NO :30, SEQ ID NON E SEQ ID NO:43, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61.NAI-5002272956 1

[0033] In yet another aspect, provided herein is a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 ,, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5. SEQ ID NO:6. SEQ ID NO:7, SEQ ID NO:8, SEQ ID NON, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13. SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22. SEQ ID NO:23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27. SEQ ID NO:28, SEQ ID NO:29. SEQ ID NO:30, SEQ ID NO: 31, SEQ ID NO: 43. SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID N():55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO: 60, or SEQ ID NO:61. In yet another aspect, provided herein is a pharmaceutically acceptable salt of a peptide comprising or consisting of SEQ ID NO: I, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON. SEQ ID NON. SEQ ID NON, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10. SEQ ID NO: 1 L SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22. SEQ ID NO:23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO:27. SEQ ID NO:28, SEQ ID NO:29. SEQ ID NO:30, SEQ ID NO:31. SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53. SEQ ID NO :54, SEQ ID NO:55, SEQ ID NO: 56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:6i.

[0034] In yet another aspect, provided herein are compounds comprising the peptide provided herein. In yet another aspect, provided herein are formulations comprising the peptide provided herein In certain embodiments, provided herein is a formulation comprising a peptide provided herein, in admixture with one or more pharmaceutically acceptable excipients. In yet another aspect, provided herein are formulations comprising a pharmaceutically acceptable salt of a peptide provided herein. In certain embodiments, provided herein is a formulation comprising a pharmaceutically acceptable salt of a peptide provided herein, tn admixture with one or more pharmaceutically acceptable excipients.

[0035] In another aspect, provided herein are methods of treating a disease or disorder.In certain aspects, provided herein is a method of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of the peptide provided herein, a compound comprising the peptide provided herein, a pharmaceutically acceptable salt of a peptide provided herein, or the formulation provided herein. In certain embodiments, the disease or disorder is selected from: (i) type 2 diabetes, type-2 diabetes associated with insulin resistance, rbeumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon,NAI-5002272956sarcopenia (including related to chronic kidney disease), gallbladder disease, and sleep apnea; (ii) a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity-linked inflammation, obesity-linked sarcopenia, obesity-linked gallbladder disease, and obesity-induced sleep apnea; (iii) a skeletal muscle wasting disease or age- related muscle loss; (iv) muscle wasting during cancer cachexia; (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure (for example, HFpEF), hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease and stroke; (vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis; (viii) addiction / nicotine withdrawal syndrome; (ix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) rare genetic causes of obesity such as Bardet-Biedl syndrome (BBS); (xii) muscular dystrophies in autoinflammatoiy and genetic diseases such as Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD); (xiii) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy from, for example, ICU / hospitalization; (xv i ) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction -associated fatty liver disease (MAFLD); and (xvii) alcohol use disorder.In certain embodiments, the disease or disorder is selected from type 2 diabetes, type-2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon, sarcopenia (including related to chronic kidney disease), gallbladder disease, and sleep apnea. In certain embodiments, the disease or disorder is selected from a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity -linked inflammation, obesity-linked sarcopenia, obesity -linked gallbladder disease, and obesity- induced sleep apnea. In certain embodiments, the treatment results in the combination of weight loss and the preservation or building of muscle mass. In certain embodiments, the disease or disorder is age-related muscle loss. In certain embodiments, the disease or disorder is muscle wasting during cancer cachexia. In certain embodiments, disease or disorder is a cardiovascular disease selected from heart failure (for example, HFpEF), hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease and stroke. In certain embodiments, disease or disorder is selected from chronic kidney disease, myalgic encephalomyelitis, and addiction / nicotine withdrawal syndrome. In certain embodiments, the disease or disorder is acute pancreatitis. In certain embodiments, the disease or disorder is Prader-Willi syndrome. In certain embodiments, the disease or disorder is rare genetic causes of obesity such as Bardet-Biedl syndrome (BBS). In certainNAI-5002272956 .3embodiments, the disease or disorder is muscular dystrophies in autoinflammatory and genetic diseases such as Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD). In certain embodiments, the disease or disorder is selected from anxiety7, depression, or stress. In certain embodiments, the disease or disorder is chronic fatigue syndrome. In certain embodiments, the disease or disorder is muscle atrophy from, for example, ICU / hospitaiization. In certain embodiments, the disease or disorder is metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated fatty’ liver disease (MAFLD). In certain embodiments, the disease or disorder is alcohol use disorder.

[0036] In another aspect, provided herein are methods of reducing body weight and / or of increasing weight loss. In certain embodiments, provided herein is a method of reducing body weight and / or of increasing weight loss in a subject comprising administering to the subject a therapeutically effective amount of the peptide provided herein, the compound comprising the peptide provided herein, or the formulation provided herein. In certain embodiments, the method further comprises preserving or building of muscle mass in the subject.

[0037] In another aspect, provided herein are peptides, compounds, or formulations for use in treating a disease or disorder. In certain embodiments, provided herein is a peptide, a compound, or a formulation for use in treating a disease or disorder selected from (i) type 2 diabetes, type-2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory' response due to gram-negative bacteria in the colon, sarcopenia (including related to chronic kidney disease), gallbladder disease, and sleep apnea; (ii) a disease associated with excess body weight selected from obesity, obesity - linked type 2 diabetes, obesity-linked inflammation, obesity-linked sarcopenia. obesity-linked gallbladder disease, and obesity-induced sleep apnea; (iii) a skeletal muscle wasting disease or age-related muscle loss; (iv) muscle wasting during cancer cachexia; (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure (for example, HFpEF), hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease and stroke; ( vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis; (viii) addiction / nicotine withdrawal syndrome; (ix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) rare genetic causes of obesity such as Bardet-Biedl syndrome (BBS); (xii) muscular dystrophies in autoinflammatory and genetic diseases such as Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD); (xiii) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy from, for example,NAI-5002272956 4ICU / hospitalization; ( xv i ) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated fatty liver disease (MAFLD): and (xvii ) alcohol use disorder..[0038 [ In another aspect; provided herein are peptides, compounds, or formulations for use in reducing body weight and / or increasing weight loss in a subject. In certain embodiments, peptides, compounds, or formulations are also for use in preserving or building of muscle mass in the subject.

[0039] In another aspect, provided herein are uses of a peptide, a compound, or a formulation in the manufacture of a medicament for the treatment of a disease or disorder. In certain embodiments, provided herein is the use of a peptide provided herein, a compound provided herein, or a formulation provided herein in the manufacture of a medicament for the treatment of a disease or disorder selected from (i) type 2 diabetes, type-2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon, sarcopenia (including related to chronic kidney disease), gallbladder disease, and sleep apnea; (ii) a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity-linked inflammation, obesity-linked sarcopenia, obesity -linked gallbladder disease, and obesity -induced sleep apnea, (iii) a skeletal muscle wasting disease or age-related muscle loss, (iv) muscle wasting during cancer cachexia, (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure (for example. HFpEF). hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary' heart disease and stroke; (vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis: (viii) addiction / nicotine withdrawal syndrome; (ix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) rare genetic causes of obesity such as Bardet-Biedl syndrome (BBS); (xii) muscular dystrophies in autoinfl ammatory and genetic diseases such as Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy' (DMD); (xiii) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy from, for example, ICU / hospitalization; (xvi) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction- associated fatty liver disease (MAFLD): and (xvii) alcohol use disorder.

[0040] In another aspect, provided herein are uses of a. peptide, a compound, or a formulation in the manufacture of a medicament for reducing body weight and / or increasing weight loss in a subject. In certain embodiments, the medicament is also for preserving or building of muscle mass in the subject.NAI-50022729564. BRIEF DESCRIPTION OF DRAWINGS

[0041] FIG. 1 depicts the structure of exemplar}- peptide of SEQ ID NO: i .

[0042] FIG. 2 depicts the structure of exemplary peptide of SEQ ID NO:2.

[0043] FIG. 3 depicts the structure of exemplary peptide of SEQ ID NON.

[0044] FIG. 4 depicts the structure of exemplary peptide of SEQ ID NO: 5.

[0045] FIG. 5 depicts the structure of exemplar}- peptide of SEQ ID NO: 19.

[0046] FIG. 6 depicts the structure of exemplar}; peptide of SEQ ID NO:22.

[0047] FIG. 7 depicts the structure of exemplary peptide of SEQ ID NO:23.

[0048] FIG. 8 depicts the structure of exemplar}- peptide of SEQ ID NO: 24.

[0049] FIG 9 depicts the structure of exemplar}- peptide of SEQ ID NO:25.

[0050] FIG. 10 depicts the structure of exemplary peptide of SEQ ID NO:26

[0051] FIG. 1 1 depicts the structure of exemplar}' peptide of SEQ ID NO:27

[0052] FIG. 12 depicts the structure of exemplar}' peptide of SEQ ID NO:285. DETAILED DESCRIPTION

[0053] Provided herein are peptides, such as chemically modified peptides, in particular corticotropin releasing factor receptor 2 (CRFR.2) agonists, and more particularly CRFR2 agonist peptides and related methods of treatments using each of the same. For example, in one aspect, provided herein are chemically modified CRF2 agonist peptides (e.g., the peptides as described in Section 5.2). In certain embodiments, the peptides provided herein comprises a fatty acid component (e g., a fatty acid component as described in Section 5.2.3). In another aspect, provided herein are methods of treating a disease or disorder (e.g,, methods as described in Section 5.4.1). In yet another aspect, provided herein are peptides for use in treating a disease or disorder (e.g.. the peptides for use in treating a disease or disorder as described in Section 5.4.2). In yet another aspect, provided herein is use of a peptide provided herein in the manufacture of a medicament for treating a disease or di sorder (e.g.. the use as described in Section 5.4.3). In another aspect, provided herein are pharmaceutical combinations (e.g.. the pharmaceutical combinations as described in Section 5.5). In yet another aspect provided herein are pharmaceutical compositions (e.g , the pharmaceutical compositions as described in Section 5.6). In yet another aspect, provided herein are processes for malting a peptide as provided herein (e.g., the processes as described in SectionNAI-5002272956 265.7).

[0054] Urocortins (UCNs) UCNi. UCN2 and UCN3 are endogenous peptides that interact with corticotropin-releasing factor receptors 1 and 2 (CRFR1 and CRFR2).[0055 [ Studies in mice have demonstrated that UCN2 and / or UCN3 gene transfer in mice improves not only cardiac function but also glucose disposal. In addition, subcutaneous delivery of pegylated UCN2 has been shown to improve glucose tolerance and increase glucose uptake in skeletal muscle while reducing body weight. These findings demonstrate that urocortins can be useful not only in the treatment of cardiovascular diseases but also in the treatment of diseases such as diabetes and obesity.

[0056] The extremely short half-life of urocortins remains a major limitation to their therapeutic use. Specifically, treatment with urocortins cannot be sustained without continuous intravenous infusion. However, the management of chronic diabetic or heart failure patients requires treatment suitable for long-standing and home self-administration,

[0057] To overcome these limitations, there remains a need for improved CRFR2 agonists which are useful as therapeutic agents in the treatment and prevention of diseases. There is a need for selective CRFR2 agonists having desirable efficacy, pharmacokinetic properties (e.g.. improved half-life) and / or physicochemical properties (e.g., improved stability and / or solubility), for the treatment of disease or disorders selected from, but not limited to, cardiovascular diseases, obesity, diabetes, sarcopenia, kidney disease, cachexia, heart failure and pulmonary hypertension. Provided herein are CRFR2 agonist peptides, pharmaceutical compositions comprising such peptides, and methods of using such peptides that meet such needs.

[0058] The peptides provided herein have a particular fatty acid component linked to the peptide chain at a particular amino acid position. The peptides provided herein have shown superior properties / results as compared to other CRFR2 agonist peptides in the art, for example, superior properties / results relative to reference peptides, such as the reference peptide of SEQ ID NO: 39. Such superior properties / results include but are not limited to, those described in Section 7 (Examples) below, including superior in vitro activities in CRFR2 expressing cells, superior in vivo pharmacokinetics properties (e.g., higher AUG level and / or longer half-life), superior in vivo activity and / or efficacy (e g. increased food intake inhibition, body weight reduction, fat mass reduction and muscle mass retention), superior target selectivity (e.g., very low or no CRFR1 agonist activity and potent CRFR2 agonist activity), superior solubility, superior properties for formulation, as well as the combination of one or two superior properties / results. Exemplary assays and results for demonstratingNAI-5002272956such superior properties are provided in Section 7 (Examples). In certain embodiments, the superior properties / results can lead to superior therapeutic activities and / or safety profile In certain embodiments, the superior therapeutic activities or safety' profile may be demonstrated in animal models or clinical studies, such as the ones provided in Section 7. In certain embodiments, without being bound by the theory, the amino-acid-sequence features of the peptides provided herein lead to superior results in comparison to known reference peptides. Such features include but are not limited to the fatty- acid at RL. Glu at R32, Nle at R38, Thr at R40 and He at R.-11, provided herein, such as the features in SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 10, SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO: 60. and SEQ ID NO:61.5.1 Definitions[0059| The nomenclature of by Schroder & Lubke, “The Peptides”, Academic Press (1965) is used to define the peptides provided herein, wherein, in accordance with conventional representation, the amino terminal group appears to the left and the carboxyl terminal group to the right. The standard 1 -letter or 3-letter abbreviations are used to identify the alpha-amino acid residues, and where the amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented unless otherwise expressly indicated, e.g., Ser=L-serine. Om=L-omithine, Aad=L-2-aminoadipic acid. Nle=L-norleucine. etc. It is understood that, if an amino acid residue (naturally occurring or non-naturally occurring) is shown in a sequence, the individual amino acid residues are ail connected via peptide bonds and are shown in amino-terminal-to-carboxy'l-terminal direction starting from the left.

[0060] Table I provides terms and structures used herein for exemplary' moieties or compounds.Table 1: Exemplary terms and corresponding structuresNAI-5002272956NAI-5002272956NAI-5002272956 3031NAI-5002272956NAI-500227295633NAI-5002272956NAI-5002272956 34NAI-5002272956I | |NAI-50022729561The three-dimensional spatial orientation and / or directionality of each moiety shown in Table 1 is readily understood by a person of ordinary skill in the art to be dependent on the substituent(s) to which it is attached, and therefore is not limited to only the exemplary- depictions provided in the instant table.

[0061] As used herein and unless otherwise indicated, the term “CRF Receptor (CRFR)” means a corticotropin-releasing hormone receptor or corticotropin-releasing factor (CRF) receptor belonging to the superfamily of G-protein-coupled receptors. Two CRF receptor subtypes have been identified, CRFR1 (or CRF1R or CRF1 receptor, also known as corticotropin-releasing hormone 1 receptor (CRH1R or CRHR1)) and CRFR2 (or CRF2R or CRF2 receptor, also known as corticotropin-releasing hormone 2 receptor (CRH2R or CRHR2)). CRFR1 receptors are widely distributed throughout neocortical, limbic and brainstem regions of the central nervous system while CRFR2 receptors are limited to discrete brain regions. CRFR2 has three major functional isoforms, alpha, beta, and gamma. In humans, CRFR2-beta is primarily expressed in the brain, while CRFR2-alpha is more broadly expressed in the brain and found in additional peripheral tissues.

[0062] As used herein and unless otherwise indicated, the terms '‘effective amount” or “therapeutically effective amount” refer to an amount of a therapeutic (e.g., a composition provided herein) which is sufficient to treat, prevent, delay the onset of, reduce and / or ameliorate the severity and / or duration of a given condition, disorder or disease and / or aNAI-5002272956 37symptom related thereto. These terms also encompass an amount necessary for the reduction, slowing, or amelioration of the advancement or progression of a given disease, reduction, slowing, or amelioration of the recurrence, development or onset of a given disease, and / or to improve or enhance the prophylactic or therapeutic effect(s) of another therapy or to serve as a bridge to another therapy. In some embodiments, “effective amount” as used herein also refers to the amount of a composition described herein to achieve a specified result. As used herein, the terms “subject” and “patient” are used interchangeably.

[0063] As used herein and unless otherwise specified, the term “pharmaceutically acceptable salt” encompasses non-toxic acid and base addition salts of the peptide to which the term refers. Acceptable non-toxic acid addition salts include those derived from organic and inorganic acids or bases know in the art, which include, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfomc acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embolic acid, enanthic acid, and the like. In certain embodiments, a pharmaceutically acceptable salt is free base, sodium, potassium, or other cationic salts. In certain embodiments, a pharmaceutically accepted salt is a salt as described in Gupta et al.. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. Molecules. 2018 Jul; 23(7): 1719, the disclosure of which is incorporated by reference in its entirety. In certain embodiments, a pharmaceutically accepted salt is a salt as described in Bharate, S.S.. Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts International Journal of Pharmaceutics Volume 607, 25 September 2021, 120993, the disclosure of which is incorporated by reference in its entirety

[0064] As used herein, and unless otherwise specified, the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined In certain embodiments, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 50%, 20%, 15%, 10%, 9%. 8%, 7%, 6%, 5%, 4%, 3%. 2%. 1%. 0.5%. or 0.05% of a given value or range. If there is a discrepancy between a depicted structure and a written description, the written description is to be accorded more weight.5.2 Peptides

[0065] In one aspect, provided herein are corticotropin releasing factor receptor 2NAI-5002272956 38(CRFR2) agonist peptides that are chemically modified. In another aspect, provided herein are salt forms of CRFR2 agonist peptides that are chemically modified. Tn a further aspect, the salt forms are selected from sodium, hydrochloride, potassium, magnesium, calcium, ammonium, acetate, trifluoroacetate, and formic acid. In certain embodiments, the peptides provided herein are capable of activating corticotropin releasing factor receptor 2 (CRFR2). In certain embodiments, the peptides provided herein are capable of activating corticotropin releasing factor receptor 2 (CRFR2) selectively over corticotropin releasing factor receptor 1 (CRFRl). In certain embodiments, the peptides provided herein have no detectable agonist activity towards CRFRl . In certain embodiments, the peptides provided herein can be used in the methods and uses provided in Section 5.4. In certain embodiments, the peptides provided herein can be used in the pharmaceutical combinations provided in Section 5.5. In certain embodiments, the peptides provided herein can be comprised by the pharmaceutical compositions provided in Section 5.6. In certain embodiments, the peptides provided herein can be made by the processes provided in Section 5.7. In certain embodiments, the peptides provided herein can be made or tested using the methods provided in Section 7.5,2.1 Formulae (I), (la), (lb), and sub-formulae thereof(i) Formulae (I), (la), and (lb)

[0066] In certain embodiments, provided herein is a peptide comprising an ammo acid sequence of Formula (I) (SEQ ID NO:32):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-G!u-Gln-Ala-Rs2-'riir-Asn-R;5-Glu-lle-Rs8-Glu-R40-R4i-NH2 (I).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (I) (SEQ ID NO:32). In certain embodiments, RN is RL. In certain embodiments, RN IS Ri -Ser-Gly from N-terminus to C- terminus. In certain embodiments, Rn is Tyr-Leu from N-terminus to C -terminus. In certain embodiments, RN is His-Pro from N-terminus to C-terminus. In certain embodiments, RN is Gly. In certain embodiments, RN is pGlu. In certain embodiments. RN IS absent. In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R2 is Gly. In certain embodiments, R2 is Ser In certain embodiments, R? is Aib. In certain embodiments, R2 is Thr. In certain embodiments. IG is Lys. In certain embodiments, R? is amK. In certain embodiments, Ra is Arg. In certain embodiments, Rs isNAI-5002272956Gin. In certain embodiments, R,? is Gin. in certain embodiments, Ra is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is K*. in certain embodiments. R32 is Thr. in certain embodiments, Rss is .Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c, In certain embodiments, Ras is Nle. In certain embodiments, Ras is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R40 is Glu In certain embodiments, R40 is Arg. In certain embodiments. R« is lie. In certain embodiments. Ru is Vai. In certain embodiments, R.n is Glu. In certain embodiments, Ri, is -(Z)i-(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL is -((CO)- (PEG)k-(CH2)2-NH)i-(gGlu)t-(CO)-(CH2)u-X. In certain embodiments, the linkage to RL IS via the nitrogen of the N -terminus. In certain embodiments,. In certain embodiments, R? is -(Z)»-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)- (CH2)C.-X. In certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g- X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His. In certain embodiments, X is -CO2H. In certain embodiments, X is - P(O)(OH)2. In certain embodiments, i, n, m, j, and t are each independently 0, 1, 2 or 3. In certain embodiments, p and u are each independently 14-20. In certain embodiments, k is 2- 16. In certain embodiments, k is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, r is 1, 2, 3, or 4. In certain embodiments, a, b, c, d, and e are each independently 0, 1, 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, h is 2- 16. In certain embodiments, h is 2, 4, 6, 8. 10. 12, 14. or 16 In certain embodiments, f is 1.2. 3, or 4 In certain embodiments, when K* is present, RL is not present; and when Ri is present, K* is not present.

[0067] In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (li) (SEQ ID NO:62):RN-Ri-R2-R3-IIe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-Ile-Leu-Leu-R2o-G1n- Ala- Arg-Ala- Arg-Ala-Ala- Arg-Glu-Gln-Ala-R^-Thr-xAsn-Ris-Glu-Ile-Rss-Glu^o-Rii-NH?.(li).NAI-5002272956 40In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (li) (SEQ ID NO:62). In certain embodiments, RN is RL. In certain embodiments. RN IS Rt-Ser-Gly from N-terminus to C- terminus. In certain embodiments. RN IS Tyr-Leu from N-terminus to C-terminus. In certain embodiments, RN is His-Pro from N-terminus to C-terminus. In certain embodiments, RN IS Gly. In certain embodiments, RN is pGlu. In certain embodiments. RN is absent. In certain embodiments, Ri is Gly. In certain embodiments. Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments. Rj is Pro. In certain embodiments, R is Gly. Tn certain embodiments, R2 is Ser In certain embodiments, R2 is Aib. In certain embodiments, R2 is Thr. In certain embodiments. R3 is Lys. In certain embodiments, R? is amK. In certain embodiments, Ra is Arg. In certain embodiments, Rs is Gin In certain embodiments, Rs is Glu. In certain embodiments, R? is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is K*. In certain embodiments, R52 is Thr. In certain embodiments, R 35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, Rss is Nle. In certain embodiments, Rss is Leu In certain embodiments, R40 is Thr. In certain embodiments, IGo is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R.11 is Vai. In certain embodiments, R41 is Glu. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl)r.-(gGlu)!!!-(CO)-(CH2)p-CO2H. In certain embodiments, n and m are each independently 0, 1 , 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, the linkage to RL is via the nitrogen of the N-terminus. In certain embodiments, K* is. In certain embodiments, Rz is -(Z)H.2-[2-(2-ammo-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, Rzis -((CO)-(PEG)h-(CH2')2-NH)f- (gGlu)s-(CO)-(CH2.)g-X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments. Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His. In certain embodiments, X is -CO2H. In certain embodiments, X is -P(O)(OH)2. In certain embodiments, a, b, c, d, and e are each independently 0, 1 , 2, or 3. In certain embodiments, q and g are each independently 14-20.41NAI-5002272956In certain embodiments, h is 2-16. In certain embodiments, h is 2, 4, 6, 8, 10, 12, 14, or 16.In certain embodiments, f is I. 2, 3, or 4. In certain embodiments, when K* is present, RL is not present; and when Ri. is present, K* is not present.[0068 [ In certain embodiments, the amino acid sequence of Formula (I) is an ammo acid sequence of Formula (la) (SEQ ID NO:33). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la): RL-Ri-Rs-Rs-lle-Thr-Leu-Ser-Leu-Asp-Vai-Pro-Ile-Gly-Leu-GIn-Gln-Ile-Leu-Leu-lbo-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R$8-Glu-R4od&ij-NH2(la).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la) (SEQ ID NO:33). In certain embodiments, Ri is Gly, In certain embodiments, Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R is Gly. In certain embodiments, Ri is Ser. In certain embodiments, Rz is Aib. In certain embodiments, Rz is Thr. In certain embodiments. Rs is Lys. In certain embodiments, R . is amK. In certain embodiments, Rs is Arg. In certain embodiments. Rs is Gin. In certain embodiments, Rs is Glu. In certain embodiments. Rs is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments. Rss is Nle In certain embodiments. Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R-io is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is Vai. In certain embodiments, R41 is Glu. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H. In certain embodiments, n and m are each independently 0. 1. 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, the linkage to RL is via the nitrogen of the N -terrain us.

[0069] in certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (lb) (SEQ ID NO:37). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (lb);RN-Ri-R2-R3-Iie-Thr-Leu-Ser-Leu-Asp-Val-Ibxi-Ile-Gly-Leu-GIn-Gln-ne-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Ghi-Ala-K*~Thr-Asn"IG5-Glu-Ile-R3s-Glu-R4o-R4i-NH2(lb).NAI-5002272956 4:In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (lb) (SEQ ID NO:37). In certain embodiments, RN is Tyr-Leu from N-terminus to C -terminus. In certain embodiments, RN IS His-Pro from N-terminus to C-terminus. In certain embodiments. RN is Gly. In certain embodiments, RN is pGlu. In certain embodiments, RN is absent. In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib In certain embodiments, Ri is Asp. In certain embodiments. Ri is GIu. In certain embodiments. Ri is Pro. In certain embodiments, R? is Gly. In certain embodiments, R? is Ser In certain embodiments, R2 is Aib. In certain embodiments, R. is Thr. In certain embodiments, R3 is Lys. In certain embodiments, Rs is amK. In certain embodiments, Rs is Arg. In certain embodiments, Rs is Gin In certain embodiments, R? is Glu. In certain embodiments. Rs is Gly. In certain embodiments, R20 is GIu In certain embodiments, R20 is Gin. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments. Rss is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R-w is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments. R41 is Vai. In certain embodiments. R41 is Glu. In certain embodiments,. In certain embodiments, Rzis -(Z)a-(2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, Rzis - ((C())-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g-X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments. Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His. In certain embodiments, X is - CO2H. In certain embodiments. X is -P(O)(OH)2. In certain embodiments, a. b, c, d. and e are each independent!}70, 1 , 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, h is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, f is 1 , 2, 3, or 4.(ii) Sub-formulae of Formulae (I), (la), and ( I b)

[0070] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (la-1) (SEQ ID NO:34). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-1):NAI-5002272956 43RL-Gly-R2-R3-IIe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Ghi-Gln-Ile-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-A1a-R32-Thr-Asn-R35-G1u-Ile-R38-Glu-R40-R4i-NH2 (la-1).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (Ta-1 ) (SEQ ID NO:34). In certain embodiments, R2 is Gly. In certain embodiments. Rz is Ser. In certain embodiments, Rz is Aib. In certain embodiments, R? is Thr. In certain embodiments. Rs is Lys. in certain embodiments, Rs is amK. In certain embodiments, Rs is Arg. In certain embodiments, Rs is Gin. In certain embodiments, R? is Gin. In certain embodiments, Rs is Gly. In certain embodiments, Rzo is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, R?s is Aib. In certain embodiments. R35 is Ac3c. In certain embodiments, Rss is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R40 is Glu. In certain embodiments, R40 is Arg. In certain embodiments, IGi is lie. In certain embodiments. R41 is Vai. In certain embodiments, R41 is Glu. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CJl2)p-CO2H. In certain embodiments, n and m are each independently 0, 1, 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, the linkage to RL is via the nitrogen of the N-terminus.

[0071] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (la-2) (SEQ ID NO: 35) In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-2):RL-R i-Gly -R3-TI e-Thr-Leu-Ser-Leu- Asp-Val -Pro-Ile-Gly-Leu-Gln-Gln-Il e-Leu-Leu-Rzo-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2 (la-2).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la-2) (SEQ ID NO:35). In certain embodiments, Ri is Gly. In certain embodiments. Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments. Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, Rs is Lys. In certain embodiments, R3 is amK. In certain embodiments, R3 is Arg. In certain embodiments, R3 is Gin. In certain embodiments, Rs is Glu. In certain embodiments, R3 is Gly. In certain embodiments, Ra> is Glu. In certain embodiments, Rzo is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala In certain embodiments, Rss is Aib In certain embodiments. R35 is44NAI-5002272956Ac3c. In certain embodiments, Rss is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R40 is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is Vai. In certain embodiments, R+i is Glu. In certain embodiments, Ri. is -(2-|2-(2-amino-ethoxy)-ethoxyJ- acelyl)r1-(gGlu)m-(CO)-(CH2)p-CO2l-I. In certain embodiments, n and m are each independently 0, 1 . 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, the linkage to Ri. is via the nitrogen of the N-terminus.

[0072] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (Ta-3) (SEQ ID NO:36). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (Ia-3):RL-Ri-R2-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-Ile-Leu-Leu-R2o-Gln- Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-R^-Thr-Asn-Rss-Glu-IIe-Ris-Glu-Rio-Rii-NFb.(la-3).In certain embodiments, provided herein is a pharmaceutically acceptable salt of Formula (la- 3) (SEQ ID NO:36). In certain embodiments, Ri is Gly. In certain embodiments, Rj is Aib. In certain embodiments, Ri is Asp. In certain embodiments. Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R2 is Gly. In certain embodiments, R2 is Ser. In certain embodiments, R2 is ,Aib. In certain embodiments, R2 is Thr. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala In certain embodiments, R35 is Aib. In certain embodiments. R35 is Ac3c. in certain embodiments, R?s is Nle. In certain embodiments, Ris is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R-io is Glu. In certain embodiments, Rio is Arg. In certain embodiments, Rn is He. In certain embodiments, R41 is Vai. In certain embodiments, R41 is Glu. In certain embodiments, Rr is -(2-[2-(2-amino-ethoxy)-ethoxv’]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H. In certain embodiments, n and m are each independently 0, 1 , 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, the linkage to Ri, is via the nitrogen of the N -terminus.

[0073] In certain embodiments, the amino acid sequence of Formula (I) is an amino acid sequence of Formula (Ib-1) (SEQ ID NO:38). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (Ib-1): pGlu-Ri-Rz-Rs-Ile-Tlir-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Rzo- Gln-Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-K*-Thr-Asn-R35-Glu-Ile-R38-Glu-R4o-R4i- NH2NAI-5002272956 45(Ib-1).In certain embodiments, provided herein is a pharmaceutically acceptable salt of Formula (Ib- I) (SEQ ID NO:38). In certain embodiments. Ri is Gly. In certain embodiments, Ri is Aib. In certain embodiments, Rj is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R2 is Gly In certain embodiments, R2 is Ser, In certain embodiments, R2 is Aib. In certain embodiments, R2 is Thr. In certain embodiments, R3 is Lys. In certain embodiments. R3 is amK. In certain embodiments. R3 is Arg. In certain embodiments, R? is Gin. In certain embodiments, Rs is Glu In certain embodiments, Rs is Gly. Tn certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, Rsg is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, Rio is Glu. In certain embodiments, R40 is Arg. In certain embodiments, Rn is He. In certain embodiments, Rn isVai. In certain embodiments, Rn is Glu. In certain embodiments,. In certain embodiments, R? is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)<i- (CO)-(CI-l2)q-X. In certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)r-(gGlu)c-(CO)- (CFhlg-X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His In certain embodiments, X is -CO2H. In certain embodiments. X is - P(O)(OH)2. In certain embodiments, a, b, c, d, and e are each independently 0, 1, 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, h is 2, 4. 6, 8, 10, 12, 14, or 16. In certain embodiments, f is L 2, 3. or 4.5.2.2 Formulae (I’), (la’), (lb’), and sub-formulae thereof(1) Formulae (I’), (la’), and (lb’)

[0074] In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (L ) (SEQ ID NO:63):RN-Ri-R-i-Rs-Iie-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Rzo-Gln-Ala-zXrg-Ala- Arg-Ala-Ala- Arg-Glu-Gin-Ala-Rs2-Thr-2Xsn-R35-Glu-I]e-R38-Glu-R4u-R4i-MI12(T’).NAI-5002272956 46In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (T) (SEQ ID NO:63). In certain embodiments, RN is RL. In certain embodiments. RN IS RI ,-Ser-Gly from N-terminus to C- terminus. In certain embodiments. RN IS Tyr-Leu from N-terminus to C-terminus. In certain embodiments, RN is His-Pro from N-terminus to C-terminus. In certain embodiments, RN IS Gly. In certain embodiments, RN is pGlu. In certain embodiments. RN is absent. In certain embodiments, Ri is Gly. In certain embodiments. Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments. Rj is Pro. In certain embodiments, R2 is Gly. Tn certain embodiments, R2 is Ser In certain embodiments, R2 is Aib. In certain embodiments, R2 is Thr. In certain embodiments. R3 is Lys. In certain embodiments, R? is amK. In certain embodiments, Ra is Arg. In certain embodiments, Rs is Gin In certain embodiments, Rs is Glu. In certain embodiments, R? is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is K*. In certain embodiments, R32 is Thr. In certain embodiments, R 35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, Rss is NIe In certain embodiments, Rss is Leu In certain embodiments, R40 is Thr. In certain embodiments, IGo is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R-u is lie. In certain embodiments, R.11 is Vai. In certain embodiments, R41 is Glu. In certain embodiments, RL is -(Z)i-(2-|2-(2-amino-ethoxy)- ethoxyl-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL is -(Z)i-(2-[2- (2-amino-ethoxy)-ethoxj']-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL. is -((CO)-(PEG)k-(CH2)2-NH)r-(gGlu)t-(CO)-(CH2)a-X. In certain embodiments, the linkage to RL is via the nitrogen of the N-lerminus. In certain embodiments,. In certain embodiments. Rzis -(Z)a-(2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, R? is -(Z)a- (2-|2-(2-amino-etlioxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)e-(Trx)d-(CO)- (CH2)q-X. In certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g- X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. in certain embodiments, Z is Ly s. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments, Z is Gin. In certainNAI-5002272956 47embodiments, Z is His. In certain embodiments, X is -CO2H. In certain embodiments, X is - P(O)(OH)2. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -(III- tetrazol-5-yl). In certain embodiments, 1, n. v, ni, j, and t are each independently 0, I, 2. or 3. In certain embodiments, p and u are each independently 14-20. In certain embodiments, s is 1-36. Tn certain embodiments, s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30. 31. 32. 33, 34, 35, or 36 In certain embodiments, k is 2-16. In certain embodiments, k is 2, 4, 6. 8, 10. 12. 14. or 16. In certain embodiments, r is 1, 2, 3, or 4 In certain embodiments, a. b, y, c, d, and e are each independently 0, 1. 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, w is 1-36. In certain embodiments, w is 1, 2, 3, 4, 5, 6, 7, 8. 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21. 22, 23. 24, 25. 26. 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36. In certain embodiments, h is 2-16. In certain embodiments, h is 2, 4, 6, 8. 10, 12, 14, or 16. In certain embodiments, f is 1, 2, 3, or 4 In certain embodiments, when K* is present, RL is not present; and when Ri is present, K* is not present.

[6075] In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (Ti ' ) (SEQ ID NO:64):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-VaI-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R20-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R3?.-Thr-Asn-Rs5-Glu-I]e-R38-Glu-R4u-R4i-NH?.(Ir ).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (Ji ’) (SEQ ID NO:64). In certain embodiments. RM is RL. In certain embodiments, RN is Rr-Ser-Gly from N-terminus to C- terminus. In certain embodiments, RN is Tyr-Leu from N-terminus to C-terminus. In certain embodiments, RN IS His-Pro from N-terminus to C-terminus. In certain embodiments, RN is Gly. In certain embodiments, RN IS pGlu. In certain embodiments, RN is absent. In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib. In certain embodiments, RJ is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R? is Gly. In certain embodiments. R2 is Ser. In certain embodiments, R2 is ,41b. In certain embodiments, R? is Thr. In certain embodiments. Rs is Lys. In certain embodiments, R3 is amK. In certain embodiments, Rs is Arg. In certain embodiments, R3 is Gin. In certain embodiments, Rs is Glu. In certain embodiments, Rs is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is K*. In certain embodiments, R32 is Thr. In certain embodiments. R?s is Ala Tn certain embodiments. R35 is Aib In certain embodiments. Rss isNAI-5002272956 48Ac3c. In certain embodiments, Rss is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R40 is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is Vai. In certain embodiments, R+i is Glu. In certain embodiments, Ri. is -(2-|2-(2-amino-ethoxy)-ethoxyJ- acetyl)r-(gGlu)m-(CO)-(CH2)p-CO2H. In certain embodiments, RL is -(2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X. In certain embodiments, X is -CO2H. In certain embodiments. X is -P(O)(OH)2. In certain embodiments, X is -S(())2NH2. In certain embodiments, X is -(lH-tetrazol-5-yl). In certain embodiments, n, v. and m are each independently 0, 1 , 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, s is 1-36. In certain embodiments, s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, I I, 12, 13, 14, 15, 16, 17, 18, 19. 20. 21, 22. 23, 24. 25. 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 In certain embodiments, the linkage to Ri. is via the nitrogen of the N-tenninus. In certain embodiments,. In certain embodiments, Rz is -(Z)a-(2-[2-(2- amino-etlioxy)-ethoxy]-aceh'l)b-(gGlu)c-(Trx)d"(CO)"(CH2)q-X. In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)<i- (CO)-(CI-l2)q-X. In certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)f-(gGh.t)c-(CO)- (CH2)g-X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His In certain embodiments, X is -CO2H. In certain embodiments. X is - P(O)(OH)2. In certain embodiments, X is -S(O)zNH2. In certain embodiments, X is -(IH- tetrazol-5-yl). In certain embodiments, a, b, y, c, d, and e are each independently 0. 1, 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, w is 1-36. In certain embodiments, w is 1 , 2, 3, 4, 5, 6, 7, 8. 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30. 31, 32, 33, 34, 35, or 36. In certain embodiments, h is 2-16. In certain embodiments, h is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, f is 1, 2. 3, or 4 In certain embodiments, when K* is present, RL is not present; and when RL is present, K* is not present.

[0076] In certain embodiments, the ammo acid sequence of Formula (T) is an ammo acid sequence of Formula (la') (SEQ ID NO:65). In certain embodiments, provided herein is aNAI-5002272956 49peptide comprising an amino acid sequence of Formula (la'):RL-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gin-Ile-Leu-Leu-R20-Gln- Ala~2Vg-.Ala-Arg-Ala-.Ala-Arg-Glu-Gln-Ala-lG2“Thr-Asn-R35-Glu-Ile-R?8-Glu-R40-R4i-NH2 (la’).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la’) (SEQ ID NO:65). In certain embodiments, Ri is Gly. In certain embodiments. Ri is Aib. In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments. Ri is Pro. In certain embodiments, R is Gly. Tn certain embodiments, R2 is Ser In certain embodiments, R2 is Aib. In certain embodiments, R2 is Thr. In certain embodiments. R? is Lys, In certain embodiments, R? is amK. In certain embodiments, Ra is Arg. In certain embodiments, Rs is Gin. In certain embodiments, Rs is Glu. In certain embodiments, Rv is Gly. In certain embodiments, R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, R38 is Nle. In certain embodiments. RBS is Leu. In certain embodiments. Rio is Thr. In certain embodiments, R40 is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R-n is Vai. In certain embodiments, R-n is Glu. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-elhoxy]~acetyi)n-(gGlu)m-(CO)-(Cl{2.)p-CO2.I-I. In certain embodiments, RL. is -(2-[2-(2-amino-etboxy)-ethoxy]-acetyl)n-((CO)-CH2-(I:>EG)s- NH)v"(gGlu).p.-(CO)-(CH2)p-X. in certain embodiments, X is -CO2H. In certain embodiments, X is -P(O)(OH)?.. In certain embodiments, X is -S(O)?.NH2. In certain embodiments, X is -(IH-tetrazol-5-yI). In certain embodiments, n, v, and m are each independently 0, 1. 2 or 3. In certain embodiments, p is 14-20, In certain embodiments, s is 1-36. In certain embodiments, s is 1, 2, 3. 4, 5, 6, 7, 8, 9, 10, 11. 12, 13, 14, 15, 16. 17, 18. 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36. In certain embodiments, the linkage to RL is via the nitrogen of the N-terminus.

[0077] In certain embodiments, the amino acid sequence of Formula (T) is an amino acid sequence of Formula (lb’ ) (SEQ I D NO:69). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula ( lb’ ):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-G1n-Ile-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala-Ala- Arg-Glu-Gln-Ala-K*-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4]-NH2 (lb’).NAI-5002272956 0In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (lb’) (SEQ ID NO:69). In certain embodiments, RN is Tyr-Leu from N-terminus to C -terminus. In certain embodiments, RN IS His-Pro from N-terminus to C-terminus. In certain embodiments. RN is Gly. In certain embodiments, RN is pGlu. In certain embodiments, RN is absent. In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib In certain embodiments, Ri is Asp. In certain embodiments. Ri is Glu. In certain embodiments. Ri is Pro. In certain embodiments, R? is Gly. In certain embodiments, R? is Ser In certain embodiments, R2 is Aib. In certain embodiments, R. is Thr. In certain embodiments, R3 is Lys. In certain embodiments, Rs is amK. In certain embodiments, Rs is Arg. In certain embodiments, Rs is Gin In certain embodiments, R? is Glu. In certain embodiments. Rs is Gly. In certain embodiments, R20 is Glu In certain embodiments, R20 is Gin. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments. Rss is Nle. In certain embodiments, Rss is Leu. In certain embodiments, R40 is Thr. In certain embodiments, R-w is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments. R41 is Vai In certain embodiments. R41 is Glu. In certain embodiments,. In certain embodiments, Rzis -(Z)a-(2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, Rzis -(Z)a- (2-|2-(2-amino-ethoxyj-ethoxy]-acetyl)b-((C())-CH2-(PEG)w-NH)y-(gGiu)c-(Trx)d-(CO)- (CH2)q-X. In certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g- X. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. in certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments. Z is Gin. In certain embodiments, Z is His. In certain embodiments, X is -CO2H. In certain embodiments, X is - P(O)(OH )?. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -(1H- tetrazol-5-yl). In certain embodiments, a, b, y, c, d, and e are each independently 0, 1, 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, w is 1 -36. In certain embodiments, w is 1, 2. 3. 4. 5, 6, 7, 8, 9, 10. 11. 12, 13, 14, 15. 16. 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36. In certain embodiments, h is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, f is 1, 2, 3, or 4.NAI-5002272956(ii) Sub-formulae of Formulae (I’), (la’), ami (lb')

[0078] In certain embodiments, the amino acid sequence of Formula (I’) is an amino acid sequence of Formula (la-1 ") (SEQ ID NO:66). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-T):RL-Gly-R2-R3-Tle-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-I]e-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala-Arg-Glu-Gln- Al a-Rsi-Thr- Asn-Rss-Gl u-Ile-Rss-Gl u-Rre-Rn-NEb (la-r).In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide comprising an amino acid sequence of Formula (la- 1’) (SEQ ID NO:66). In certain embodiments, R2 is Gly. In certain embodiments, R2 is Ser. In certain embodiments, R2 is Aib. In certain embodiments, R? is Thr. In certain embodiments, Rs is Lys. In certain embodiments, Rs is amK. In certain embodiments, Rs is Arg. In certain embodiments, Rs is Gin. In certain embodiments, R3 is Glu. In certain embodiments, Rs is Gly. In certain embodiments, R20 is Glu. In certain embodiments. R20 is Gin. In certain embodiments. R32. is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is .Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, Ras is Nle. In certain embodiments, Rss is Leu. In certain embodiments, Rro is Thr. In certain embodiments, R40 is Glu. In certain embodiments, R40 is Arg. In certain embodiments, Rai is He. In certain embodiments, Rri is Vai In certain embodiments, R41 is Glu. In certain embodiments, RL is -(2-[2-(2-arnino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H.In certain embodiments, RL is -(2-[2-(2-amiiio-ethoxy)-etlioxy]-acetyl)i>-((CO)-CH2-(PEG)s- NHK-(gGlu)iti“(CO)“(CH2)p“X. In certain embodiments, X is -CO2H. In certain embodiments, X is -P(O)(OH)2. In certain embodiments, X is -St'OhNI-b. In certain embodiments, X is -(lH-tetrazol-5-yl), In certain embodiments, n, v, and m are each independently 0, 1, 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, s is 1 -36. In certain embodiments, s is 1, 2, 3. 4, 5, 6, 7. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21. 22, 23. 24, 25, 26. 27. 28. 29, 30, 31, 32. 33. 34, 35, or 36. In certain embodiments, the linkage to Ri. is via the nitrogen of the N -terminus

[0079] In certain embodiments, the amino acid sequence of Formula (T) is an ammo acid sequence of Formula (la-2’) (SEQ ID NO:67). In certain embodiments, provided herein is a peptide comprising an amino acid sequence of Formula (la-2'):RL-Ri-Gly-R3~lle-'rhr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-A1a-R32-Thr-Asn-R35-Glu-Ile-R?8-Glu-R40-R<u-NH2NAI-5002272956da-2’).In certain embodiments, provided herein is a pharmacally acceptable salt of a peptide comprising an amino acid sequence of Formula (la-2.’) (SEQ ID NO:67). In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib. In certain embodiments, Rj is Asp. In certain embodiments, Ri is Gin. In certain embodiments, Ri is Pro. In certain embodiments, Rs is Lys. In certain embodiments. Rs is amK. In certain embodiments. Rs is Arg. In certain embodiments. Rs is Gin. In certain embodiments, Rs is Gin. In certain embodiments, R is Gly. In certain embodiments, R2.0 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R32 is Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, R38 is Nle. In certain embodiments, Rv: is Leu. In certain embodiments, Rio is Thr In certain embodiments, Rio is Glu. In certain embodiments, R40 is Arg. In certain embodiments, Rri is He In certain embodiments. Ru is Vai. In certain embodiments, Ru is Glu. In certain embodiments, RL is -(2-[2~(2-amino-ethoxy)-ethoxyJ- acetyl)n-(gGlu)m-(CO)-(CI-I?.)p-CO2H. In certain embodiments, RL is -(2-| 2-(2-amino- ethoxy)-ethoxy]-acet\d)n-((CO)-CH2-(PEG)5-NH)v-(gGlu)m-(CO)-(CH2)p-X. In certain embodiments, X is -CO2H. In certain embodiments, X is -P(O)(OH)2. In certain embodiments, X is -S(O)2NH?.. In certain embodiments, X is -(IH-tetrazol-5-yl). In certain embodiments, n, v. and m are each independently 0. 1, 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, s is 1-36. In certain embodiments, s is 1 , 2, 3. 4. 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16. 17, 18, 19, 20, 21. 22, 23, 24, 25, 26. 27. 28, 29, 30, 31, 32. 33. 34, 35, or 36. In certain embodiments, the linkage to RL is via the nitrogen of the N-terminus.

[0080] In certain embodiments, the amino acid sequence of Formula (F) is an amino acid sequence of Formula (la-3 ’) (SEQ ID NO:68). In certain embodiments, provided herein is a peptide comprising an ammo acid sequence of Formula (la-3’):RL-Ri-R?-Lys-IIe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-IIe-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-Ala-R32-Thr-Asn-R35~Glu-Ile-R38-Glu-R40-R41~NH2 (la-3’).In certain embodiments, provided herein is a pharmaceutically acceptable salt of Formula (las’) (SEQ ID NO:68). In certain embodiments. Ri is Gly. In certain embodiments, Ri is Aib In certain embodiments, Ri is Asp. In certain embodiments, R ■ is Glu. In certain embodiments, Ri is Pro. In certain embodiments, R2 is Gly. In certain embodiments, R2 is Ser In certain embodiments, R2 is Aib. In certain embodiments. R? is Thr. In certain embodiments. R20 is Glu. In certain embodiments. R20 is Gin. In certain embodiments, R32 isNAI-5002272956 3Glu. In certain embodiments, R32 is Thr. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, R38 is Nle. In certain embodiments, Rss is Leu. In certain embodiments. R40 is Thr. In certain embodiments, R+o is Glu. In certain embodiments, Rio is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is A7al. In certain embodiments, R-ii is Glu. In certain embodiments, RL is -(2-[2-(2-anuno-ethoxy)-ethoxy]-aceiyl)n-(gGlu)m-(CO)-(CH2)p-CO2H. In certain embodiments, RL IS -(2-[2-(2-ammo-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)3- NH)v-(gGlu)m-(C())-(CH2)p-X. In certain embodiments, X is -CO2H. In certain embodiments, X is -P(O)(OH)2. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -(IH-tetrazol-5-yi). In certain embodiments, n, v, and m are each independently 0, 1. 2 or 3. In certain embodiments, p is 14-20. In certain embodiments, s is 1-36. In certain embodiments, s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12. 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28. 29. 30. 31 , 32, 33, 34, 35, or 36 In certain embodiments, the linkage to RL is via the nitrogen of the N-terminus.

[0081] In certain embodiments, the amino acid sequence of Formula (I’) is an amino acid sequence of Formula (Tb-1 ’) (SEQ ID NO:70). In certain embodimen ts, provided herein is a peptide comprising an amino acid sequence of Formula (Ib-1 '): pGiu-Ri-R^-Rs-Iie-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-Ile-Leu-Leu-Rio- Gln-Ala-Arg*Ala- Arg- Ala-Ala- Arg-Glu-Gln- Ala-K*-Thr-Asn-R35-Glu-He-R38-Glu-R4o-R4i- NH2In certain embodiments, provided herein is a pharmaceutically acceptable salt of Formula (Ib- 1 ') (SEQ ID NO:70). In certain embodiments, Ri is Gly. In certain embodiments, Ri is Aib In certain embodiments, Ri is Asp. In certain embodiments, Ri is Glu. In certain embodiments, Ri is Pro. In certain embodiments. R?. is Gly. In certain embodiments, R2 is Ser. In certain embodiments, R2is Aib. In certain embodiments, R? is Thr. In certain embodiments, R3 is Lys. In certain embodiments, Ra is amK. In certain embodiments. Ra is Arg. In certain embodiments, Rs is Gin. In certain embodiments, Rs is Glu. In certain embodiments, R 3 is Gly. In certain embodiments. R20 is Glu. In certain embodiments, R20 is Gin. In certain embodiments, R35 is Ala. In certain embodiments, R35 is Aib. In certain embodiments, R35 is Ac3c. In certain embodiments, Ras is Nle. In certain embodiments, Ras is Leu. In certain embodiments, R40 is Thr. In certain embodiments, Rro is Glu. In certain embodiments, R40 is Arg. In certain embodiments, R41 is He. In certain embodiments, R41 is4NAI-5002272956Vai. In certain embodiments, R41 is Glu. In certain embodiments,. In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d- (CO)-(CH2)q-X. In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy')-ethoxy]- acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Tix)d-(CO)-(CH2)q-X. in certain embodiments, Rz is -((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g-X. In certain embodiments, Z is Giy. In certain embodiments, Z is Glu. In certain embodiments. Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments. Z is Ala. In certain embodiments, Z is Gin. In certain embodiments, Z is His. In certain embodiments, X is -CO2II. In certain embodiments, X is -P(O)(OH)2. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -( IH-tetrazol-5-yl). In certain embodiments, a, b, c. d, and e are each independently 0, 1. 2, or 3. In certain embodiments, q and g are each independently 14-20. In certain embodiments, w is 1-36. In certain embodiments, w is 1, 2, 3, 4. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16. 17, 18, 19, 20, 21, 22, 23, 24, 25, 2.6, 27, 28, 29, 30, 31, 32. 33, 34, 35, or 36. In certain embodiments, h is 2, 4, 6, 8. It), 12, 14, or 16. In certain embodiments, f is 1. 2, 3, or 4.5.2.3 Faty Acid Component

[0082] In one aspect, the peptide provided herein comprises a faty acid component. In certain embodiments, the fatty' acid component is linked to the N-terminus of the peptide provided herein. In certain embodiments, the fatty acid component is linked to an amino acid residue that is not at the N-ierminus of the peptide,(i) Faty add component Ri,

[0083] In certain embodiments, the fatty acid component is linked to the N -terminus of the peptide provided herein. In certain embodiments, the fatty' acid component is linked to the N-terminus of the peptide via the alpha amino group of the N-terminal amino acid residue In certain embodiments, the fatty7acid component is RL as provided herein. In certain embodiments, the linkage to Rj., is via the nitrogen of the N-terminus of a peptide (i.e., the alpha amino group of the N-terminal amino acid residue) provided herein

[0084] In certain embodiments, Ri is -(Z)i-(2-[2-(2-amino-ethoxy )-ethoxy]-acety'l)n- (gGIu)m-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL is -(Z)i-(2-[2-(2-amino-ethoxy)- eIhoxy]-acetyl)n-((CO)-CI-12-(PEG)s-NH)v-(gGlu)m-(Trx)j-(CO)-(CH2)p-X. In certainNAI-5002272956embodiments, when i is 2 or 3, each Z is independently Gly, Glu, gGlu, Lys, eLys, -Ala, Gin, or His. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments. Z is Ala. In certain embodiments. Z is Gin. In certain embodiments, Z is His. In certain embodiments, the gGlu is D-gGlu. In other embodiments, the gGlu is L-gGlu. In certain embodiments, X is -P(O)(OH)2. In other embodiments, X is - CO2H. In certain embodiments. ‘-(CO)-(CH2)P-CO2H” is collectively referred to as a diacid. In certain embodiments, the diacid is a C16, Cl 8, C20, or C22 diacid. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -(lH-tetrazol-5-yl). In certain embodiments, 1, v, n. m, and j are each independently 0. 1 , 2, or 3. In certain embodiments, n is 2, m is 1, j is 0. In certain embodiments, n is 2. m is 2, j is 0. In certain embodiments, n is 1. m is I , j is 0. In certain embodiments, n is 0, rn is 1 , j is 1. In certain embodiments, n is 2, m is 1 , j is 1. Tn certain embodiments, i is 0 or L n is 1 or 2 and m is 1 or 2 In certain embodiments, 11 is 1, m is 1, j is 1. In certain embodiments, p is 14-20. In certain embodiments, p is 14, 16, 18, or 20. In certain embodiments, p is 15. 17. or 19. In certain embodiments, s is 1-36. In certain embodiments, s is 1. 2, 3, 4. 5. 6, 7, 8, 9. 10, 1 1, 12. 13. 14, 15, 16, 17, 18, 19, 20, 21, 22. 23. 24. 25, 26, 27, 28. 29, 30, 31, 32, 33, 34, 35, or 36. In certain embodiments, RL is -(eLys)1-(2-]2-(2-amino-ethoxy)-etlioxy]-acetyl)n-(gGlu)m-(CO)- (CHz)p-X. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m- (Trx)j-(CO)-(CH2)P-X.

[0085] in certain embodiments, RL comprises one or more PEG units, i.e., -(CH2-CH2- ())- or -(O-CH2-CH2)-, as shown in Table 1. In certain embodiments, the PEG units in RL are linked to each other r ia a linker. In certain embodiments, RL is -(Z)i-(2-[2-(2-arnino-ethoxy)- ethoxy]-acetyl)n-(linker-(PEG)s-linker)v-(gGlu)m-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL is -(linker-(PEG)k-linker)1-(gGIu)t-(CO)-(CH2)u-X. In certain embodiments, the PEG units in RL are linked to each other directly. In certain embodiments, RL is -(Z)i~(2-[2-(2-amino-ethoxy)-etboxy]-acetyI)n-((PEG)s)v-(gGlii)iii-(Trx)j-(CO)-(CH2)p-X. In certain embodiments, RL IS -((PEG)k>-(gGlu)t-(CO)-(CH2)u-X. In certain embodiments, the PEG unit is linked to the rest of the RL moiety directly. In certain embodiments, the PEG units are linked to the rest of the RL moiety via a linker In certain embodiments, RL is -(Z)i- (2-[2-(2-amino-ethoxy)-ethoxy]-acety'l)!!-(iinker-(PEG)s)v-(gGlu)m-(Trx)j-(CO)-(CH2)p-X, - (Z)r(2-[2~(2-amino-ethoxy)-eth0xy]-acety4)n-((PEG)s-lmker)v-(gGlu)m-(Trx)j-(CO)-(CH2)p- X, -(Z)i-(2-[2-(2-amino-ethoxv)-ethoxy]-acetyI)n-linker-((PEG)s-linkerX-(gGluty-(Tix)r( CO)-(C IH: 2)p-X. -(Z)i-(2-[2-(2-amino-ethoxy)-etboxy]-acetyl)n~linker-((PEG)s)v-(gGlu)m-NAI-5002272956 56(Trx)j-(C0)-(CH2)p-X, -(Z)i-(2-[2-(2-ainino-ethoxy)-ethoxy]-acetyl)n-(linker-(PEG)s)v-linker- (gGIu)m-(Trx)j-(C0)-(CH2)p-X, -(Z)i-(2-[2-(2-amino-etlioxy)-ethoxy]-acetyl)n-((PEG)5X- linker-(gGlu)m-(Trx)j-(C0)-(CH2)p-X, or -(Z)i-(2-[2-(2-amino-ethoxy)-ethoxyl-acetyl)n~ linker-((PEG)s)v“linker-(gGlu)m-(Trx)j-(CO)-(CH2)p"X. In certain embodiments, Ri, is - (linker-(PEG)k)r“linker-(gGIii)t-(CO)-(CH2)u-X, -linker-((PEG)k-linker)r-(gGlu)i-(CO)- (CH2)u-X, -lmker-((PEG)k)i-(gGlu)t-(CO)-(CH2)u-X, or -((PEG)k)r-lmker-(gGiu)t-(CO)- (CH2)»-X. in certain embodiments, the linker is a peptide bond (i.e. , an amide group). In certain embodiments, the linker is an alkyl group. In certain embodiments, Ri is prepared using one or more PEG linkers known in the art In certain embodiments, RL is prepared using one or more PEG linkers such as alkyne PEG. amino PEG, aminooxy PEG, 3- arylpropiolonitrile (APN) PEG, bicyclo|6.1.0]nonyne (BCN)-PEG. benzyl-PEG. biotin PEG, bis-PEG-acid (PEG di(carboxylic acid)), bis-PEG-NHS, Boc-PEG (Boc-protected PEG linkers), branched PEG, bromo PEG, a cleavable linker (e.g., a disulfide linker, a enzymatically cleavable linker, a photocleavable linker, a photoreactive linker, a diazo linker), dibenzocyclooctyne (DBCO) PEG, diketone linker, 2,4-Dinitrophenol PEG (DNP- PEG), DOTA reagent (e.g., DOTA-PEG-amine, DOTA-PEG-azide, DOTA-(t-Butyl)3-PEG- azide. DOTA-PEG-DBCO, bromoacetamido-PEG-DOTA, DOTA(OtBu)3, fluorescein- triazole-PEG-DOTA, and DOTA-PEG-DSPE), a fluorescent reagent (e.g., Cy3-PEG-azide, Cy3-PEG-alkyne, Cy5-PEG-acid, Cy5-PEG-NHS ester. Cy5-PEG-alkyne, Cy5-PEG-amine, Cy5-PEG-azide, Cy5-PEG-biotin. Cy5-PEG-DBCO, Cy5-PEG-hydroxyl. Cy5-PEG- Malemiide, Cy7-PEG-azide, fluorescein-PEG. carboxyfluorescein-PEG, BDP FL-PEG. rhodamine-PEG, and pyrene-PEG), fluorine PEG, Fmoc PEG (e.g., Fmoc-NH-PEG8- CH2COOII), hybrid linker (bromoacetamido-PEG-aliphatic-acid, bromoacetamido-PEG- aliphatic-t-butyl ester, amine-PEG-aliphatic-t-butyl ester, azide-PEG-aliphatic-t-butyl ester, C18-PEG-acid, C18-PEG~azide, Palmitic acid-PEG-acid. palmitic acid-PEG-NHS ester. palmitamide-PEG-amine, and diethylene glycol monopentyl ether), hydroxy PEG ((PEG alcohols), Iodo PEG, lipid PEG, rn-PEG (Poly(etbylene glycol) monomethyl ether), a nialeimide linker. methylannno-PEG, non-PEG linker, NOTA reagent, PEG acid, PEG aldehyde, PEG azide, PEG hydrazide. PEGNHS ester, PEG PFP ester. PEG phosphorate, PEG PNP carbonate, PEG silane, PEG sulfonic acid, PEG tosylate, PEG-X-PEG (e.g., PEG- NH-PEG, PEG-Boc-PEG, PEG-Mal-PEG. PEG-N-Me-PEG, PEG-N-OH-PEG, PEG- Fiuorescein-PEG, PEG-Biotm-PEG. PEG-DBCO-PEG, PEG-Methyltetrazine-PEG, PEG- TCO-PEG. PEG-N-Benzyl-PEG, PEG-S-PEG, PEG-SO2-PEG), poly PEG (PEG polymer), propargyl PEG, a PROTAC linker. SPDP PEG, sugar PEG, TCO-PEG, tetrazine-PEG. andNAI-5002272956thiol PEG. In certain embodiments, k is 2-16. In certain embodiments, k is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, r is 1 , 2, 3, or 4. In certain embodiments, the gGlu is D- gGlu. in certain embodiments, the gGlu is L-gGlu. In certain embodiments, X is - P(O)(OH)2. In other embodiments, X is -CO2H. In certain embodiments, Ri. is -(CO)- (PEG)i2-(CH2)2-NH-(gGlu)t-(CO)-(CH2)u-CO2H. In certain embodiments, t is 0, 1 , 2, or 3 In certain embodiments, u is 14, 16, 18, or 20. In certain embodiments, u is 15, 17, or 19. In certain embodiments, t is I or 2. In certain embodiments, u is 16 or 18.

[0086] In certain embodiments, RL is -((CO)-(PEG)k-(CH2)2-NH)r-(gGlu)t-(CO)-(CH2.)u- X. In certain embodiments, k is 2-16. In certain embodiments, k is 2, 4, 6, 8, 10, 12, 14. or 16. In certain embodiments, r is 1, 2, 3, or 4. In certain embodiments, the gGlu is D-gGlu. In certain embodiments, the gGlu is L-gGlu. In certain embodiments, X is -P(O)(()H)2. In other embodiments. X is -CO2H. In certain embodiments, RL is -(CO)-(PEG)i2-(CH2)2-NH- (gGIu)t-(CO)-(CH2)u-CO2H. In certain embodiments, t is 0, 1 , 2, or 3. In certain embodiments, u is 14, 16, 18, or 2.0. In certain embodiments, u is 15, 17, or 19. In certain embodiments, t is 1 or 2. In certain embodiments, u is 16 or 18.

[0087] In certain embodiments, RL IS -(2-] 2-(2-amin o-ethoxy)-eth oxy ] -acetyl )n-(gGIu)m-(CO)-(CH2)p-CO2H. In certain embodiments. RL is -(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X. In certain embodiments, n is 1.In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 0. In certain embodiments, v is I . In certain embodiments, v is 2. In certain embodiments, v is 3. In certain embodiments, v is 0 In certain embodiments, m is L In certain embodiments, ni is 2. In certain embodiments, m is 3. In certain embodiments, m is 0. In certain embodiments, p is 14-20. In certain embodiments, p is 14, 16, 18, or 20. In certain embodiments, p is 1.5, 17, or 19. In certain embodiments, p is 16. In certain embodiments, p is 18. In certain embodiments, s is 1-36. In certain embodiments, s is 1, 2, 3, 4, 5, 6. 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34. 35, or 36 In certain embodiments, s is 12. In certain embodiments, n is 1 , m is 1, p is 18. In certain embodiments, n is 2, m is 1, p is 18. In certain embodiments, n is 3, m is 1, p is 18.In certain embodiments, n is 0, m is 1, p is 18. hi certain embodiments, n is I, m is 2, p is 18.In certain embodiments, n is 2, m is 2, p is 18. In certain embodiments, n is 3, m is 2, p is 18.In certain embodiments, n is 0, m is 2, p is 18. In certain embodiments, n is 1, m is 3, p is 18.In certain embodiments, n is 2, m is 3, p is 18. In certain embodiments, n is 3, m is 3, p is 18.In certain embodiments, n is 0. m is 3. p is 18. In certain embodiments, n is 1, m is 0, p is 18.In certain embodiments, n is 2, m is 0, p is 18. In certain embodiments, n is 3, m is 0. p is 18.NAI-5002272956 8In certain embodiments, n is 1, m is 1, p is 16. In certain embodiments, n is 2, m is 1 , p is 16. In certain embodiments, n is 3, m is 1. p is 16. In certain embodiments, n is 0, tn is 1 , p is 16. In certain embodiments, n is i, m is 2. p is 16. In certain embodiments, n is 2, m is 2. p is 16 In certain embodiments, n is 3. m is 2, p is 16. In certain embodiments, n is 0, m is 2, p is 16. In certain embodiments, n is 1, m is 3, p is 16. In certain embodiments, n is 2, m is 3, p is 16. In certain embodiments, n is 3, m is 3, p is 16. In certain embodiments, n is 0, m is 3, p is 16.In certain embodiments, n is 1 , m is 0. p is 16. In certain embodiments, n is 2, m is 0, p is 16. In certain embodiments, n is 3, m is 0, p is 16.

[0088] In certain embodiments, RL is -(Z)i-(2-[2-(2-amino-ethoxy)-ethoxy[-acetyl)n-((CO)-CH2-(PEG)&-NH)v-(gGlu)ffi-(Trx)j~(CO)-(CH2)p~X. In certain embodiments, i is 0. n isI, v is 0, m is I, j is 0, p is 18. In certain embodiments, i is 0. n is 2, v is 0. m is 1, j is 0, p is 18. In certain embodiments, i is 0, n is 3, v is 0, m is 1, j is 0, p is 18 In certain embodiments, i is 0, n is 0, v is 0, m is I, j is 0, p is 18. In certain embodiments, i is 0, n is 1 , v is 0, ni is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 0, ni is 2, j is 0, p is 18 In certain embodiments, i is 0, n is 3, v is 0, m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 0. v is 0. m is 2. j is 0, p is 18. In certain embodiments, i is 0, n is 1 . v is 0. m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 3, v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 0, v is 0, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 1, v is 0, m is 0, j is 0, p is 18 In certain embodiments, i is 0. n is 2, v is 0. m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 3. v is 0. m is 0, j is 0, p is 18 hi certain embodiments, i is 0, n is L v is 0, m is L j is 0, p is 16. In certain embodiments, i is 0, n is 2. v is 0, m is 1, j is 0, p is 16. In certain embodiments, i is 0, n is 3. v is 0, m is 1 , j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 0, m is 1 , j is 0, p is 16. In certain embodiments, i is 0, n is 1 , v is 0, tn is 2, j is 0, p is 16 In certain embodiments, i is 0, n is 2, v is 0. m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 0, m is 2. j is 0, p is 16 In certain embodiments, i is 0, n is 0. v is 0, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 0, m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 2. v is 0, m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 0. ni is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 0, m is 3, j is 0, p is 16 In certain embodiments, i is 0, n is 1, v is 0, m is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 2, v is 0, m is 0, j is 0. p is 16. In certain embodiments, i is 0, n is 3, v is 0, m is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 0, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 2. v is 0, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 0. m is 1. j is 0, p is 20. In certain embodiments, i is 0, n is 0. v is 0, m is 1. j is 0, p is 20NAI-5002272956In certain embodiments, i is 0, n is 1, v is 0, m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 0. m is 2. j is 0, p is 20. In certain embodiments, i is 0, n is 3. v is 0, m is 2, j is 0. p is 20. In certain embodiments, i is 0, n is 0, v is 0, m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 1, v is 0, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 0, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 0, m is 3, j is 0, p is 20 In certain embodiments, i is 0, n is 0, v is 0, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 1. v is 0, in is 0. j is 0, p is 20. In certain embodiments, i is 0, n is 2. v is 0, m is 0. j is 0, p is 20 In certain embodiments, i is 0, n is 3. v is 0, m is 0, j is 0, p is 20 In certain embodiments, i is 0, n is l. v is I, m is 1, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 1, m is 1 , j is 0, p is 18. In certain embodiments, i is 0, n is 3, v is 1 , m is 1 , j is 0, p is 18 In certain embodiments, i is 0, n is 0, v is 1, m is 1 , j is 0, p is 18. In certain embodiments, i is 0, n is 1. v is 1 , m is 2, j is 0, p is 18 In certain embodiments, i is 0, n is 2, v is 1 , m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 3. v is 1 , m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 0, v is 1, m is 2, j is 0, p is 18. In certain embodiments, i is 0, n is 1, v is 1, m is 3, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 1, m is 3, j is 0, p is 18 In certain embodiments, i is 0. n is 3. v is 1. m is 3, j is 0. p is 18. In certain embodiments, i is 0, n is 0, v is 1 , m is 3, j is 0. p is 18. In certain embodiments, i is 0, n is 1, v is 1 , m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 2, v is 1 , m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 3. v is I , m is 0, j is 0, p is 18. In certain embodiments, i is 0, n is 1, v is I, m is 1. j is 0, p is 16 In certain embodiments, i is 0, n is 2. v is I, m is 1 , j is 0, p is 16 In certain embodiments, i is 0. n is 3, v is 1, m is 1 , j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 1, m is 1, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is I, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 2, v is 1, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 3. v is 1, m is 2, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 1, m is 2, j is 0. p is 16. In certain embodiments, i is 0. n is 1, v is 1, m is 3, j is 0, p is 16 In certain embodiments, i is 0, n is 2, v is i , rn is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 3, v is 1, m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 0, v is 1 , m is 3, j is 0, p is 16. In certain embodiments, i is 0, n is 1, v is 1, m is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 2. v is I, m is 0, j is 0, p is 16. In certain embodiments, i is 0. n is 3, v is 1 , rn is 0, j is 0, p is 16. In certain embodiments, i is 0, n is 1 , v is 1 , rn is 1 , j is 0, p is 20 In certain embodiments, i is 0, n is 2, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 3, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 1, m is 1, j is 0, p is 20. In certain embodiments, i is 0, n is I, v is 1 , m is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 1 , ro is 2. j is 0. p is 20. In certain embodiments, i is 0, n is 3,NAI-5002272956 60v is 1, ni is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 1, ni is 2, j is 0, p is 20. In certain embodiments, i is 0, n is 1, v is 1, m is 3, j is 0, p is 20. In certain embodiments, i is 0. n is 2. v is 1, m is 3, j is 0. p is 20. In certain embodiments, i is 0, n is 3, v is 1, m is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 0, v is 1, tn is 3, j is 0, p is 20. In certain embodiments, i is 0, n is 1, v is 1 , m is 0, j is 0, p is 20. In certain embodiments, i is 0, n is 2, v is 1, m is 0. j is 0, p is 20. In certain embodiments, i is 0, n is 3. v is I, m is 0, j is 0, p is 20,

[0089] In certain embodiments. RL is -(2-[2-(2-amino-ethoxj')-ethoxy ]-acetyl)-gGlu- (C())-(CH2)i8-C()2H. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy|- acetyl)2-gGIu-(CO)-(CIl2)i6-CO2H. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)~ ethoxy]-acet\'l)2-(gGlu)2-(CO)-(CH2)i8-CO2H. In certain embodiments, RL is -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)2-(gGlu)3-(CO)-(CH2)i«-CO2H. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-eihoxy]-acety1)2-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, Ri is -(2-[2-(2-aminO’ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)2o-C02H. In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)2o~ P(O)(OH)?.. In certain embodiments, RL is -(2-|2-(2-amino-eihoxy)-ethoxy]-acetyl)2-gGlu- (CO)-(CH2)20-S(O)2NH2 In certain embodiments. RL is -(2-[2-(2-amino-ethoxy)-ethoxyj- acetjd)2-gGlu-(CO)-(CH2)2o-(lH-tetrazol-5-yl) In certain embodiments, RL is -(2-[2-(2- amino-ethoxy)-ethoxy ]-acetj'l)2-(CO)-CH2-(PEG)i2-NH-gGlu-(CO)-(CH2)20-CO2H.

[0090] In certain embodiments, RL is the corresponding moiety as shown in FIG. 1, 2, 3 or 4. In certain embodiments, RL is the fatty acid component tn the peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:30, SEQ ID NO.31, SEQ ID NO:43, SEQ ID NO:44. SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:56. In certain embodiments. RL is the fatty acid component in a pharmaceutically acceptable salt of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:1 1. SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:30, SEQ ID N():3I, SEQ ID NO:43. SEQ ID NO.44. SEQ ID NO:52, SEQ ID NO S3 SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61,

[0091] In certain embodiments, RL IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m- (CO)-(CI-I?.)P-CO?.H, wherein n is 1, m is I, and p is 18. In certain embodiments. RL isNAI-5002272956 61

[0092] In certain embodiments, RL is -(2-[2-(2-amiiio-ethoxy)-etlioxy]-acetyl)n-(gGlu)t«-(CO)-(CH2)p-CO2H, wherein n is 2, m is 1 , and p is 18. In certain embodiments, RL isin an alternative representation

[0093] In certain embodiments, RL is -(2-[2-(2-aiTiino-ethoxj')-ethoxy]-acetyl)n-(gGlu)m-(C())-(CH2)p-C()2H, wherein n is 2, m is I, and p is 20. In certain embodiments, RL IS

[0094] In certain embodiments, RL. IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGIu)m-(CO)-(CH2)p-P(O)(OH)2. wherein n is 2. m is 1. and p is 20. In certain embodiments, RL is

[0095] In certain embodiments, RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-S(O)2NH2, wherein n is 2, m is 1, and p is 20. In certain embodiments, RL is

[0096] In certain embodiments, RL IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyi)n-(gGIu)m- (CO)-(CH2)p-(lH-tetrazol-5-yl), wherein n is 2, m is L and p is 20. In certain embodiments, RL. IS

[0097] In certain embodiments, RL IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2"(PEG)s-NH)v”(gGIu)m-(CO)-(CH2)p-CO2H. wherein n is 2. s is 12, v is I, m is 1, and p is20. In certain embodiments, RL isNAI-5002272956 62

[0102] In certain embodiments, RL IS as provided in Table 2A below.Table 2A: Exemplary RL in the fatty acid componentNAI-5002272956 6364NAI-5002272956NAI-500227295666NAI-5002272956NAI-5002272956 68NAI-5002272956(ii) Fatty acid component K*

[0103] In certain embodiments, the fatty7acid component is connected to the peptide via a side chain of an amino acid residue. In certain embodiments, the fatty acid component is connected to the peptide via the side dram of lysine. In certain embodiments, the fatty acidNAI-5002272956 71component is connected to the peptide via the epsilon amino group of lysine. In certain embodiments, the connection of the fattv acid component to the peptide through the side chain ot a lysine residue is represented by K* that is ot the structure

[0104] In certain embodiments, Rz is -(Z)a-(2-[2-(2-a.mino-ethoxy)-ethoxy]-acetyl)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy)- ethoxy] -acety l)b-((C O)-CH2-(PEG)»-NH)y-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, when a is 2 or 3, each Z is independently Gly, Glu, gGlu, Lys, eLys, .Ala, Gin, or His. In certain embodiments, Z is Gly. In certain embodiments, Z is Glu. In certain embodiments, Z is gGlu. In certain embodiments, Z is Lys. In certain embodiments, Z is eLys. In certain embodiments, Z is Ala. In certain embodiments. Z is Gin. In certain embodiments, Z is His. In certain embodiments, the gGlu is D-gGlu. In other embodiments, the gGlu is L-gGki. In certain embodiments, X is -P(O)(OH)2. In other embodiments, X is - CO2H. In certain embodiments,i‘-(CO)-(CH2)q-CO2H” is collectively referred to as a diacid. In certain embodiments, the diacid is a C16, C18, C20, or C22 diacid. In certain embodiments, X is -S(O)2NH2. In certain embodiments, X is -(lH-tetrazol-5-yl). In certain embodiments, a, b, c, and d, are each independently 0, 1 , 2, or 3. In certain embodiments, b is 1. In certain embodiments, b is 2. In certain embodiments, b is 3. In certain embodiments, b is 0. In certain embodiments, y is 1 . In certain embodiments, y is 2. In certain embodiments, y is 3. In certain embodiments, y is 0, In certain embodiments, c is 1. In certain embodiments, c is 2. In certain embodiments, c is 3. In certain embodiments, c is 0. In certain embodiments, b is 2, c is I, d is 0. In certain embodiments, b is 2, c is 2, d is 0. In certain embodiments, b is 1 , c is 1, d is 0. In certain embodiments, b is 0. c is 1 , d is 1. In certain embodiments, b is 2, c is 1 , d is I . In certain embodiments, a is 0 or I, b is 1 or 2 and c is 1 or 2. In certain embodiments, b is 1, c is 1, d is 1. In certain embodiments, q is 14-20. In certain embodiments, q is 14, 16, 18, or 20. In certain embodiments, q is 15, 17, or 19. In certain embodiments, w is 1-36. In certain embodiments, w is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23. 24. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36.

[0105] In certain embodiments, Rzis -(eLys)«-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b- (gGlu)c-(CO)-(CH2)q-X, In certain embodiments, Rzis ~(2-[2-(2-amino~ethoxy)-ethoxy]-NAI-5002272956acetjd)b-(gGlu)c-(Trx)d-(C0)-(CH2)q-X. In certain embodiments, Rz is -(2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)2-(gG1u)-(CO)-(CH2)i6-CO2H. In certain embodiments, Rz is ~(2-[2- (2-amino-etho^)-ethoxy]-acetyl)2-(gGlu)2-(CO)-(CH2)i8-CO2H,

[0106] In certain embodiments, Rz comprises one or more PEG units, i.e., -(CH2-CH2-O)- or -(O-CH2-CH2)-, as shown in Table 1 . In certain embodiments, the PEG units in Rz are linked to each other via a linker. In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy)- ethoxy]-acet}4)b-(linker-(PEG)w-linker)y-(gGlu)c-(lrx)d-(CO)-(CH2)q-X. In certain embodiments, Rz is -(linker-(PEG)h-linker)r-(gGlu)e-(CO)-(CH2)g-X. In certain embodiments, the PEG units in Rz are linked to each other directly. In certain embodiments. Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)"(CH?.)«,"X. In certain embodiments, Rz is -((PEG)iiXgGlu)e-(CO)-(CH2)g-X. In certain embodiments, the PEG unit is linked to the rest of the Rz moiety directly. In certain embodiments, the PEG units are linked to the rest of the Rz moiety via a linker. In certain embodiments, Rz is -(Z)a-(2-[2-(2 -amino-ethoxy )-ethoxy]-acetyl)b-(linker-(PEG)w)y-(gGlu)c- (Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((PEG)w-linker)y- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z).-.-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-linker- ((PEG)w-linker)y-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-edioxy)-ethoxy]- acetyl)b-lmker-((PEG)w)y-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)- eihoxy]-acetyl)b-(linker-(PEG)w)y-linker-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2- ammo~ethoxy)-ethoxy]-acety l)b-(PEG)w)y-Iinker-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. or -(Z)a-(2- [2-(2-amino-efhoxy)-ethoxy ] -acetyl )b-linker-(PEG)w)y-l inker-(gGlu)c-(Trx)d-(CO)-(C H2)q-X . In certain embodiments, Rz is -(linker-(PEG)h)f-lmker-(gGlu)e-(CO)-(CH2)g-X, -linker- ((PEG)h-linker)f-(gGlu)6-(CO)-(CIl2)g-X, -linker-((PEG)h)f-(gGlu)e-(CO)-(CII2)g-X, or - ((PEG)h)i-linker-(gGlu)e-(CO)-(CH2)g-X. In certain embodiments, the linker is a peptide bond (i.e., an amide group). In certain embodiments, the linker is an alkyl group. In certain embodiments, Rz is prepared using one or more PEG linkers known in the art. In certain embodiments, Rz is prepared using one or more PEG linkers such as alkyne PEG, amino PEG. ammooxy PEG, 3-arylpropiolonitrile (APN) PEG, bicyclo[6. 1.0]nonyne (BCN)-PEG, benzyl- PEG. biotin PEG, bis-PEG-acid (PEG di(carboxylic acid)), bis-PEG-NHS. Boc-PEG (Boc-protected PEG linkers), branched PEG, bromo PEG, a cleavable linker (e.g., a disulfide linker, a enzymatically cleavable linker, a photocleavable linker, a photoreactive linker, a diazo linker), dibenzocyclooctyne (DBCO) PEG, diketone linker, 2,4-Dinitrophenol PEG(DNP-PEG). DOTA reagent (e.g., DOTA-PEG-atnine, DOTA-PEG-azide, DOTA-(t-Butyl)3- PEG-azide, DOTA-PEG-DBCO, bromoacetamido-PEG-DOTA. DOTA(OtBu)3. fluorescein-NAI-5002272956 73triazole-PEG-DOTA, and DOTA-PEG-DSPE), a fluorescent reagent (e.g., Cy3-PEG-azide, Cy3-PEG-alkyne, Cy5-PEG-acid, Cy5-PEG-NHS ester, Cy5-PEG-alkyne, Cy5-PEG-amine, Cy5-PEG-azide, Cy5-PEG-biotin, Cy5-PEG-DBCO, Cy5-PEG-hydroxyl, Cy5-PEG- Maleimide, Cy7-PEG-azide, fluorescein-PEG, carboxyfluorescein-PEG, BDP FL-PEG, rhodamine-PEG, and pyrene-PEG), fluorine PEG, Fmoc PEG (e.g., Fmoc-NH~PEG8- CH2COOH). hybrid linker (bromoacetamido-PEG-aliphatic-acid, bromoacetamido-PEG- aliphatic-t-butyl ester, amine-PEG-aliphatic-t-buty l ester. azide-PEG-aliphatic-t-butyl ester, C18-PEG-acid, C18-P EG- azide. Palmitic acid-PEG-acid, palmitic acid-PEG-NHS ester, palmitamide-PEG-amine, and diethylene glycol monopentyl ether), hydroxy PEG ((PEG alcohols). Iodo PEG, lipid PEG, m-PEG (Poly(ethylene glycol) monomethyl ether), a maleimide linker, methylamino-PEG, non-PEG linker, NOTA reagent, PEG acid, PEG aldehyde, PEG azide, PEG hydrazide, PEGNHS ester, PEG PFP ester, PEG phosphonate, PEG PNP carbonate, PEG silane, PEG sulfonic acid, PEG tosylate, PEG-X-PEG (e.g., PEG- NH-PEG, PEG-Boc-PEG, PEG-Mal-PEG, PEG-N-Me-PEG, PEG-N-OH-PEG, PEG- Fluorescein-PEG, PEG-Biotin-PEG, PEG-DBCO-PEG, PEG-Methyltetrazine-PEG, PEG- TCO-PEG. PEG-N-Benzyl-PEG, PEG-S-PEG, PEG-SO2-PEG), poly PEG (PEG polymer), propargyl PEG. a PROTAC linker, SPDP PEG, sugar PEG, TCO-PEG, tetrazine-PEG, and thiol PEG.[00l07| In certain embodiments, h is 2-16. In certain embodiments, h is 2, 4, 6, 8, 10. 12. 14. or 16. In certain embodiments, f is J , 2, 3, or 4. In certain embodiments, the gGlu is D- gGlu. In certain embodiments, the gGlu is L-gGlu. In certain embodiments, X is - P(O)(OH)?.. In other embodiments, X is -COzH. In certain embodiments, R,- is --(CO)- (PEG)i2-(CI:l2)2-NH~(gGlu)e-(CO)-(CH2)g-CO2H. In certain embodiments, e is 0, 1 , 2, or 3. In certain embodiments, g is 14, 16, 18, or 20. In certain embodiments, g is 15, 17. or 19. In certain embodiments, e is 1 or 2. In certain embodiments, g is 16 or 18.

[0108] In certain embodiments, FL is -((CO)-(PEG)h-(CHz)2-NH)f-(gGlu)e-(CO)-(CHz)8- X. In certain embodiments, h is 2-16. In certain embodiments, h is 2, 4, 6, 8, 10, 12, 14, or 16. In certain embodiments, f is 1. 2, 3, or 4. In certain embodiments, the gGlu is D-gGlu. In certain embodiments, the gGlu is L-gGlu. In certain embodiments, X is -P(O)(OH)z. In other embodiments, X is -CO2H. In certain embodiments. Rzis -(CO)-(PEG)i2-(CH2)2-NH- (gGlu)e-(CO)-(CH2)8-CO2H. In certain embodiments, e is 0, I, 2, or 3. In certain embodiments, g is 14, 16, 18, or 20. In certain embodiments, g is 15, 17, or 19. In certain embodiments, e is 1 or 2 In certain embodiments, g is 16 or 18.74NAI-5002272956

[0109] In certain embodiments, Rz is the corresponding moiety as shown in any one of FIGs. 5-12 In certain embodiments, Rz is the fatty acid component in the peptide comprising or consisting of the amino acid sequence of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16. SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:2I, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29, In certain embodiments, Rz is the fatly acid component of a pharmaceutically acceptable salt of SEQ ID NO: 14. SEQ ID NO: 15. SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:2I, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29.

[90110] In certain embodiments, R / is -(Z)a-(2-[2-(2-amiiio-ethoxy)-ethoxy ]-acetyl)b- ((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d-(CO)-(CH2)q-X. In certain embodiments, a is 0, b is I. y is 0, c is L d is 0, q is 18. In certain embodiments, a is 0, b is 2, y is 0, c is I , d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is 0, c is 1, d is 0, q is 18. In certain embodiments, a is 0, b is 0, y is 0, c is I, d is 0, q is 18. In certain embodiments, a is 0, b is 1, y is 0. c is 2. d is 0. q is 18 In certain embodiments, a is 0. b is 2, y is 0, c is 2, d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is 0, c is 2. d is 0, q is 18. In certain embodiments, a is 0, b is 0, y is 0, c is 2, d is 0, q is 18. In certain embodiments, a is 0, b is 1 , y is 0, c is 3, d is 0, q is 18. In certain embodiments, a is 0, b is 2, y is 0, c is 3, d is 0, q is 18. In certain embodiments, a is 0. b is 3, y is 0, c is 3, d is 0, q is 18. In certain embodiments, a is 0, b is 0, y is 0. c is 3, d is 0. q is 18. In certain embodiments, a is 0, b is 1 , y is 0, c is 0, d is 0. q is 18. In certain embodiments, a is 0, b is 2, y is 0, c is 0, d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is 0, c is 0, d is 0, q is 18. In certain embodiments, a is 0, b is I, y is 0, c is 1, d is 0, q is 16. In certain embodiments, a is 0. b is 2, y is 0, c is 1 , d is 0, q is 16. In certain embodiments, a is 0, b is 3, y is 0. c is I, d is 0. q is 16. In certain embodiments, a is 0, b is 0, y is 0, c is 1, d is 0, q is 16. In certain embodiments, a is 0, b is 1 , y is 0, c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 2, y is 0, c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 3, y is 0, c is 2, d is 0. q is 16. In certain embodiments, a is 0, b is 0, y is 0, c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 1 , y is 0, c is 3, d is 0. q is 16. In certain embodiments, a is 0, b is 2, y is 0, c is 3, d is 0, q is 16. In certain embodiments, a is 0, b is 3, y is 0, c is 3, d is 0, q is 16. In certain embodiments, a is 0, b is 0. y is 0, c is 3, d is 0, q is 16. In certain embodiments, a is 0, b is 1, y is 0, c is 0, d is 0, q is 16. In certain embodiments, a is 0, b is 2, y is 0, c is 0, d is 0. q is 16. In certain embodiments, a is 0, b is 3, y is 0, c is 0. d is 0, q is 16 In certain embodiments, a is 0, b is 1, y is 0, c is I. d is 0, q is 20. In certainNAI-5002272956embodiments, a is 0, b is 2, y is 0, c is 1. d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 0, c is 1, d is 0. q is 20 In certain embodiments, a is 0, b is 0, y is 0, c is 1. d is 0, q is 20. In certain embodiments, a is 0, b is 1, y is 0, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 2, y is 0, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 3. y is 0, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 0, y is 0, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 1, y is 0, c is 3, d is 0, q is 20. In certain embodiments, a is 0, b is 2, y is 0, c is 3. d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 0, c is 3. d is 0, q is 20. In certain embodiments, a is 0. b is 0, y is 0, c is 3, d is 0, q is 20 In certain embodiments, a is 0, b is 1 , y is 0, c is 0, d is 0, q is 20 In certain embodiments, a is 0, b is 2, y is 0, c is 0, d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 0, c is 0, d is 0, q is 20. In certain embodiments, a is 0, b is 1, y is I, c is 1, d is 0, q is 18. In certain embodiments, a is 0, b is 2, y is 1, c is 1, d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is 1, c is I , d is 0. q is 18. In certain embodiments, a is 0. b is 0, y is 1, c is 1 , d is 0, q is 18. In certain embodiments, a is 0, b is I, y is 1, c is 2, d is 0, q is 18. In certain embodiments, a is 0, b is 2. y is I, c is 2, d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is I, c is 2, d is 0, q is 18. In certain embodiments, a is 0. b is 0. y is 1, c is 2. d is 0, q is 18. In certain embodiments, a is 0, b is 1, y is 1. c is 3, d is 0, q is 18. In certain embodiments, a is 0, b is 2. y is 1 , c is 3, d is 0, q is 18. In certain embodiments, a is 0, b is 3, y is 1, c is 3, d is 0, q is 18. In certain embodiments, a is 0, b is 0, y is 1, c is 3, d is 0. q is 18. In certain embodiments, a is 0, b is 1 , y is I, c is 0, d is 0, q is 18. In certain embodiments, a is 0. b is 2, y is 1 . c is 0, d is 0, q is 18. In certain embodiments, a is 0, b is 3. y is I , c is 0, d is 0, q is 18. In certain embodiments, a is 0, b is 1 , y is 1, c is 1, d is 0, q is 16. In certain embodiments, a is 0, b is 2, y is 1 , c is 1, d is 0, q is 16. In certain embodiments, a is 0. b is 3, y is 1, c is I, d is 0, q is 16. In certain embodiments, a is 0, b is 0, y is 1, c is 1, d is 0. q is 16. In certain embodiments, a is 0, b is 1. y is 1, c is 2. d is 0, q is 16. In certain embodiments, a is 0, b is 2, y is 1, c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 3, y is 1 , c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 0, y is I, c is 2, d is 0, q is 16. In certain embodiments, a is 0, b is 1 , y is 1, c is 3, d is 0, q is 16. In certain embodiments, a is 0. b is 2, y is 1, c is 3, d is 0, q is 16. In certain embodiments, a is 0, b is 3. y is I, c is 3, d is 0. q is 16. In certain embodiments, a is 0, b is 0, y is 1 , c is 3, d is 0, q is 16. In certain embodiments, a is 0, b is 1 , y is I, c is 0, d is 0, q is 16. In certain embodiments, a is 0, b is 2, y is 1, c is 0, d is 0, q is 16. In certain embodiments, a is 0. b is 3, y is 1, c is 0, d is 0, q is 16. In certain embodiments, a is 0, b is 1, y is 1, c is 1, d is 0, q is 20. In certain embodiments, a is 0. b is 2, y is 1. c is 1, d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 1 , c is 1, d is 0, q is 20. In certain embodiments, a is 0, b is 0, y is 1, c is I , dNAI-5002272956 76is 0, q is 20. In certain embodiments, a is 0, b is 1, y is 1, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 2, y is 1, c is 2. d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 1, c is 2, d is 0, q is 20. In certain embodiments, a is 0, b is 0. y is 1, c is 2. d is 0. q is 20. In certain embodiments, a is 0, b is 1, y is I, c is 3, d is 0, q is 20. In certain embodiments, a is 0, b is 2, y is 1 , c is 3, d is 0, q is 20. In certain embodiments, a is 0, b is 3, y is 1, c is 3, d is 0, q is 20. In certain embodiments, a is 0, b is 0, y is 1 , c is 3, d is 0, q is 20. In certain embodiments, a is 0. b is I, y is 1, c is 0, d is 0, q is 20. In certain embodiments, a is 0, b is 2. y is 1. c is 0, d is 0. q is 20 In certain embodiments, a is 0, b is 3, y is 1 , c is 0, d is 0, q is 20.

[0111] In certain embodiments, R., is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 2, c is 1, d is 0, q is 18, and X is -CO2H. In certain embodiments, R? isin an alternative representation.

[0112] In certain embodiments, Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 2, c is 1, d is 0, q is 16, and X is -CO2H. In certain embodiments, Rz isin an alternative representation.

[0113] In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyI)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 1, c is 1, d is 0, q is 18, and X is -CO2H. In certain embodiments, RzisNAI-5002272956

[0114] In certain embodiments, Rz is -(Z)a-(2-[2-(2-amino-etlioxy)-ethoxy]-acetyl)b- (gGlu)c-(Trx)a-(CO)-(CH2)q-X, whereinCO2H. In certain embodiments, Rz isor, in an alternative representation,[001 15] In certain embodiments, Rzis -(Z)a-(2-[2-(2-amino~ethoxj )-ethoxy]-acetyl)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 2, c is 2, d is 0, q is 18, and X is -CO2H.In certain embodiments, Rzisor, m an alternative representation.

[0116] In certain embodiments, Rz is -(Z),-,-(2-]2-(2-amino-ethoxy)-ethoxy]-acetyi)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 2, c is 1, d is 0, q is 18, and X is -P(O)(OH )r In certain embodiments, Rz isor, in an alternative representation,

[0117] In certain embodiments, Rz is -(Z)«-(2-[2-(2-amino-ethox\')-ethoxy]-acetyl)b- (gGIu)c-(Trx)d-(CO)-(CH2)q-X, wherein a is 0, b is 2, c is 1, d is 0, q is 16, and X is - P( O)( OH )?„ In certain embodiments, Rz isNA1-5002272956 78or, in an alternative representation,[1)0118] In certain embodiments, Rz is '(Z)a-(2-[2-(2~amino-ethoxy)-ethoxy]-acet}'l)b- (gGlu)c-(Trx)d-(CO)-(CH2)q-X, wherein a=0, b=;2. c=l, d=l, q=:l 8, and X is -CO2H. In certain embodiments, Rz isor, in an alternative representation,

[0119] In certain embodiments, Rz is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(CO)-(CH2)q-CO2H, wherein b is 2, c is 1, and q is 20. In certain embodiments, Rz is

[0120] In certain embodiments, Rz is -(2-[ 2-(2-amino-ethoxy )-ethoxy ]-acety l)b-(gGl u)c-(CO)-(CH2)q-P(O)(OH)2, wherein b is 2, c is 1, and q is 20. In certain embodiments. Rz is

[0121] In certain embodiments, Rz is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyi)b-(gG1u)<-(CO)-(CH2)q-S(O)2NH2, wherein b is 2, c is 1 , and q is 20. In certain embodiments, Rz is

[0122] In certain embodiments, Rz is -(2-[2-(2-amino-eihoxy)-ethoxy]-acetyl)b-(gGlu)c-(CO)"(CH2)q"(lH-tetrazol-5-yi), wherein b is 2, c is 1 , and q is 20. In certain embodiments.NAI-5002272956Rz is

[0128] In certain embodiments, Rz is as provided in Table 2B below.NAI-5002272956 80Table 28: Exemplary Rzin the fatty acid component82NAI-5002272956NAI-5002272956 8384NAI-5002272956NAI-5002272956 8688NAI-50022729565.2.4 Exemplary PeptidesJ00129] In certain embodiments, provided herein is a peptide of Formula (I), (la) or (b) or Sub-formulae thereof Formula (la-1), (la-2), (la-3), or (Ib-1 ). In certain embodiments, provided herein is a peptide of Formula (I'), (li ’), (la’) or (Ib‘) or Sub-formulae thereof Formula (la-T), (la-2"), (la-3’), or ( I b- 1 ' ). Depending on the pH of the composition, a peptide provided herein can be present as free base or as free acid. In certain embodiments, the peptide provided herein is in a free base form. In certain embodiments, the peptide provided herein is in a free acid form. In certain embodiments, the peptide comprises the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID N():6, SEQ ID NO: 7. SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10. SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO.20. SEQ ID NO: 21, SEQ ID NO:22. SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29. SEQ ID NO:30, SEQ ID NO:31. SEQ ID NO:43. SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54. SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61. In certain embodiments, the peptide consists of the ammo acid sequence of SEQ ID NO: I, SEQ ID NO:2, SEQ ID NO:3. SEQ ID NO:4. SEQ ID NO:5. SEQ ID NO.6. SEQ ID NO:7, SEQ ID NO.8. SEQ ID NON. SEQ ID NO: 10. SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO:16, SEQ ID NO: 17. SEQ ID NO: 18. SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26. SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 , SEQ ID NO:43, SEQ ID NO:44. SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55. SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61. In certain embodiments, provided herein is a pharmaceutically acceptable salt of of a peptide comprising the ammo acid sequence of SEQ ID NO: I . SEQ ID NO:2. SEQ ID NO:3. SEQ ID NO 4. SEQ ID NO:5. SEQ ID NO:6. SEQ ID NO-7. SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11. SEQ ID NO: 12. SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16. SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:2L SEQ ID NO: 22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO: 25, SEQ ID NO:2.6, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29. SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:43. SEQ ID NO:44, SEQ ID NO:52,NAI-5002272956 89SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61 . In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO: I, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5, SEQ ID NON, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11. SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16. SEQ ID NO: 17, SEQ ID NO: 18. SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:3 I, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NON 7. SEQ ID NO:58. SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61. In certain embodiments, the pharmaceutically acceptable salts are selected from sodium, hydrochloride, potassium, magnesium, calcium, ammonium, acetate, tri fluoroacetate, and formic acid. In certain embodiments, provided herein is a free base form of a peptide comprising the amino acid sequence of SEQ ID NO: I, SEQ ID NON, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5, SEQ ID NON. SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12. SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ I D NO: 19, SEQ ID NO:20, SEQ ID NO:21. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26. SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31. SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54. SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61 . In certain embodiments, provided herein is a free acid form of a peptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3. SEQ ID NON.SEQ ID NON. SEQ ID NON. SEQ ID NO: 7. SEQ ID NO :8, SEQ ID NON. SEQ ID NO: 10, SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23. SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27. SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NONE SEQ ID NO:43. SEQ ID NO.44. SEQ ID NO:52, SEQ ID NO :53, SEQ ID NON4, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61. In certain embodiments, provided herein is a free base form of a peptide consisting of the amino acid sequence of SEQ ID NO: 1. SEQ ID NO:2, SEQ ID NON, SEQ ID NON, SEQ ID NON. SEQ ID NON, SEQ ID NO:7, SEQ ID NO:8. SEQ ID NON, SEQ ID NO: 10. SEQ IDNAI-5002272956 90NO:11, SEQ ID N0:12, SEQ ID N0:13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO; 17, SEQ ID NO: 18. SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:21 , SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24. SEQ ID NO:25. SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID N0:31, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO: 60, or SEQ ID N0:61. In certain embodiments, provided herein is a free acid form of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NON, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18. SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:2I. SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61.

[0130] In certain embodiments, provided herein is a peptide of Formula (I), (la). (T). or (la’). In certain embodiments, the peptide comprises or consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NON, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NON, SEQ ID NON, SEQ ID NO: 10, SEQ ID NO: 1 1, SEQ ID NO: 12, SEQ ID NO: 13. SEQ ID NO: 30. SEQ ID NON 1, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO: 52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55. SEQ ID NO:56. SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:6(), or SEQ ID NO:61. In certain embodiments, provided herein is a pharmaceutically acceptable salt of SEQ ID NO: 1 , SEQ ID NON. SEQ ID NON, SEQ ID NO:4. SEQ ID NO:5. SEQ ID NO:6. SEQ ID NON, SEQ ID NON, SEQ ID NO 9. SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO: 44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO: 56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60. or SEQ ID NO:61. In certain embodiments, the pharmaceutically acceptable salts are selected from sodium, hydrochloride, potassium, magnesium, calcium, ammonium, acetate, tri fluoroacetale, and formic acid

[0131] In certain embodiments, provided herein is a peptide of Formula (I), (lb), (I ’ ), or (Ib‘). In certain embodiments, the peptide comprises or consists of the amino acid sequence of SEQ ID NO: 14. SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19. SEQ ID NO:20, SEQ ID NO:21 , SEQ ID NO:22, SEQ ID NO:23. SEQ ID NO:24.NAI-5002272956 91SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29. In certain embodiments,, provided herein is a pharmaceutically acceptable salt of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16. SEQ ID NO: 17. SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:2I , SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29, In certain embodiments, the pharmaceutically acceptable salts are selected from sodium, hydrochloride, potassium, magnesium, calcium, ammonium, acetate, trifluoroacetate, and formic acid. In certain embodiments, pro vided herein is a peptide comprising or consists of the amino acid sequence as depicted in FIGs. 1-12.

[0132] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 1. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 1. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 1. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 . In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence ofRu-Gly-Gly-Lys-lle-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu- Gln -Gln-Ile-Leu-Leu-GIu-Gln-Ala- Arg- Al a- Arg-Ala- Al a-Arg-Glu-Gln-Al a-Glu-Thr-Asn- Ala-Glu-Ile-Nle-Glu-Thr-Tle-NHz; wherein RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)- gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 1 . In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide as depicted in FIG. 1. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: I is an IIC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 1 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 1 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: I is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:1 is an acetate salt.

[0133] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 2. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ 92NAI-5002272956ID N0:2. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:2. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:2. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of RL-Gly-Ser-Lys-Tle-Thr-Leu-Ser-Leu-Asp-V al-Pro-Ile-Gly-Leu- Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-GIu-Thr-Asn- Ala-Giu-Ile-hUe-Glu-nir-Ile-NH?: wherein Rj„ is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)- gGlu-(CO)-(CH?.)j8-CO?.H. In certain embodiments, provided herein is a peptide as depicted in FIG. 2. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide as depicted in FIG. 2. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:2 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:2 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:2 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:2 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:2 is an acetate salt

[0134] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 3 In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:3. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:3. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:3. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 3 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:3 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 3 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:3 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 3 is an acetateNAI-5002272956 93salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Rt-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly -Leu-Gln- Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg-Ala- Ala-Arg-Glu-Gln-Ala-Glu-Thr-Asn- Ala- GIu-IIe-NIe-Glu-Glu-Val-NI-b; wherein RL IS -(2-[2-(2-amino-etho.xy)-ethoxy]-acetyl)-gGIu- (CO)-(CH2)I«-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO;3 as illustrated below:

[0135] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:4. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID N():4. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 4. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:4. hi certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:4 is an HCI salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:4 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:4 is a potassium salt. In certain embodiments, the pharmaceutical ly acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:4 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:4 is an acetateNAI-5002272956 94salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Rt-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly -Leu-Gln- Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg-Ala- Ala-Arg-Glu-Gln-Ala-Glu-Thr-Asn-Aib- GIu-IIe-NIe-Glu-Glu-Val-NFb; wherein RL IS -(2-[2-(2-amino-etho.xy)-ethoxy]-acetyl)-gGIu- (CO)-(CH2)I«-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 3. In certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide as depicted in FIG. 3.

[0136] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:5. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:5. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 5 In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:5. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:5 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 5 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 5 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 5 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 5 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rr-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-lle-Gly -Leu-Gln- Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg-Ala- Ala-Arg-Glu-Gln-Ala-Glu-Thr-Asn-Ac3c- Glu-Ile-Nle-Glu-Glu-Val-NH2; wherein RL is -(2-[2-(2-amino~ethoxy)-ethoxy]-acetyI)-gGlu- (CO)-(CH2)IS-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 4. in certain embodiments, provided herein is a pharmaceutically acceptable salt of a peptide as depicted in FIG. 4.

[0137] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:6. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:6. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 6 In certain embodiments, provided herein is a peptide that isNAI-5002272956 95a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:6. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:6 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:6 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 6 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:6 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a pepti de that comprises or consists of the amino acid sequence of SEQ ID NO: 6 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Ri -Aib-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Tle-Gly-Leu-GIn- Gln-Ile’Leu-Leu-Glu-Gln-Aia- Arg- Ala-Arg-Ala- AJa-Arg-Glu-Gln-AIa-Glu-Thr-Asn-Aib- Glu-Ile-Nle-Glu-Glu-Val-NHa; wherein Rr. is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-gGlu- (CO)-(CH2)IS-CO?.H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:6 as illustrated below:

[0138] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 7. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo aci d sequence of SEQ ID NO:7. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO: 7. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQNAI-5002272956 96ID N0:7. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:7 is an HC1 salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:7 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 7 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 7 is a TEA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 7 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Ri.-Gly-Aib-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln- Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala- Arg-Ala- Ala-Arg-Glu-Gln-Ala-Glu-Thr-Asn-Aib- Glu41e-Nle-G1u-Glu-Val-NH2; wherein RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-gGlu- (CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 7 as illustrated below:[001391 In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 8. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:8. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 8. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQNAI-5002272956 97ID NO:8. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 8 is an HC1 salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 8 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 8 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 8 is a TEA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 8 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rj -Aib-Aib-Lys-Ile-Thr-Leu-Ser-Leu-zlsp-Val-Pro-Ile-Gly-Leu-Ghi- Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala- Arg-Ala- Ala-Arg-Glu-Gln-Ala-Glu-Thr-Asn-Aib- Ghi-He-Nle-Glu-Glu-Val-NHr; wherein RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-gGIu- (CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 8 as illustrated below:

[0140] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NON. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NON. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NON In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQNAI-5002272956 98ID NON. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NON is an HC1 salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NON is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 9 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NON is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NON is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rr -Gly -Gly-amK-Ile-TIir-Leu-Ser-Leu-Asp-V al-Pro-IIe-Gly-Leu- Gln-Gln-Be-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg-Ala- Ala- Arg-Glu-Gln- Al a-Glu-Thr-Asn- Aib-Glu-He-Nle-Glu-Glu-Val-NH2; wherein RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetv'l)- gGlu-(CO)-(CH?.)i8“CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NON as illustrated below:

[0141] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 10. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:10. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 10. In certain embodiments, provided herein is a peptide that isNAI-5002272956a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 10. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 10 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 10 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 10 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 10 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 10 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence ofRt.-Aib-GJy-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg- Ala-Arg- Ala- Ala-Arg-Gl u-Gln-Ala- Glu-l’hr-Asn-Aib-Glu-Ile-Nle-Glu-l'hr-Ile-NH?; wherein Rr is -(2-[2-(2-anuno-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH?.)j8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 10 as illustrated below:

[0142] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 1 1. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQID NO: 11. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO: 11. In certain embodiments, provided herein is a peptide that isNAI-5002272956 100a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 1 . In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 11 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 11 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 11 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 1 1 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 11 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence ofRi.-Gly-Aib-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg- Ala-Arg- Ala- Ala-Arg-Gl u-Gln-Ala- Glu-l’hr-Asn-Aib-GIu-Ile-NIe-Glu-l'hr-Ile-NH?; wherein Rr is -(2-[2-(2-amino-ethoxy )- ethoxyl-acetvl)-gGlu-(CO)-(CH?.)]S"CO?.H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 11 as illustrated below:

[0143] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 12. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 12. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO: 12. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 12. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 12 is an HCI salt. In certainNAI-5002272956 101embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 12 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 12 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 12 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 12 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of RL-Aib-Aib-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Aib-Glu-Ile-Nle-Glu-Thr-lle-NH?; wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 12 as illustrated below:0' ^Aib-Lysdte-ThrLeu-Ser-Leu-Asp-Val-Pradle-GlyLeu-GIn-Glnrtte-Leu-Leu-Giu-GIn-Ala-i d(_ ILArg"Ala“Arg"Ala-Ala-Arg-Glu”Gln"Ala-Glu"Thr-Asn-Aib”Glu-Ne-Nle-Glu-Thr-lte-NH2

[0144] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 13. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 13. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 13. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO: 13. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 13 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 13 is a sodium salt In certain embodiments, theNAI-5002272956 102pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 13 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 13 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 13 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rj,-Gly-Gly-amK-lIe-l'hr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Tlir-Asn-Aib-Glu-Ile-Nle-Glu-Thr-Ile-NHe; wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 13 as illustrated below:

[0145] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 14. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 14. In certain embodiments, provided herein is a peptide that consists of ths amino acid sequence of SEQ ID NO: 14. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO: 14. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 14 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 14 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acidNAI-5002272956 103sequence of SEQ ID NO: 14 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 14 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 14 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Tyr-Leu-Asp-Thr-Arg-Ile-Thr-Leu-Ser-Leu-Asp- Val-l’ro-lle-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln- Ala-K*-Thr-Asn-AIa-Glu-Ile-Leu-Glu-Ghi“Val-Nl-h; wherein-antino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(Clhjie-COzH. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 14 as illustrated below:SEQ ID NO:14Tyr-Leii-Asp-Thr-Arg-fe-Thr-Leu-Ser-Leti-Asp-VabPro-lle-Gly-Leu-GIn-Gln-fe-Leu-Leii-Glu-GIn-Ala-'Arg'Aia-Arg-i

[80146] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 15 In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 15. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 15. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQNAI-5002272956 104ID NO: 15. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 15 is an HC1 sal t. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 15 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 15 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 15 is a TFA salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 15 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Asp-Thr-Arg-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro- ne-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-K*- Thr-Asn-Ala-Glu-Ile-I.,eU"Glu-Glu-Val"NH2; wherein-amino-ethoxy)-ethoxy]-acetyl.)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 15 as illustrated below:SEQ ID ^0:15Asp-Thr Arg-lle-Thr-Leu-Ser-Leu-Asp-Vai-Pro-ile-Gly-Leu-GIn-GIn-lie-Leu-Leu-Giu-Gin-^a-Arg-Ala-Arg-j

[0147] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 16. In certain embodiments, provided herein is a peptide that isNAI-5002272956 105a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 16. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 16. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO: 16. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 16 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 16 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 16 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 16 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 16 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Glu-Thr-Arg-lle-Thr-Leu-Ser-Leu-Asp-Vai-Pro- Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-GIu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-GIn-Ala-K*- Ihr-Asn-Ala-GluJle-Leu-Glu-Glu-Vd-NEh; wherein-ethoxy]-acetyl)2-gGIu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 16 as illustrated below:NAI-5002272956 106SEQ ID MQ:16Giu-Thr-Arg-lle-Thr-Leu-Ser-Leu-Asp-VakPra-lle-Gly-Leu-Gh-GIn-ile-Leu-Leii-Glu-GIn-Ala-Arg-Ala-Arg-i

[0148] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 17. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 17. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 17. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO: 17. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 17 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 17 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 17 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 17 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 17 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Glu-Thr-Gln-Ile-Tbr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-lle-Leu-Leu-Glu-Gln-Ala-yVg- Ala-Arg-Ala- Ala-Arg-Glu-Gln- Ala-K*- Thr-Asn-Ala-Gl u-Ile-Leu-Gl u-Glu-Val -NH2;NAI-5002272956 107wherein-amino-ethoxy )-elhoxy]-acetyl)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 17 as illustrated below:

[0149] In certain embodiments, provided herein is a peptide that comprises the ammo acid sequence of SEQ ID NO: 18. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO: 18. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 18. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 18. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 18 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 18 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 18 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 18 is aTFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ IDNAI-5002272956 108NO: 18 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of His-Pro-Gly-Ser-Arg-Ile-Thr-Leu-Ser-Leu-Asp- Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg-Ala- Ala-Arg-Glu-Gln-AIa-K*-Thr-Asn-Ala-Glu-Ile-Leu-GIu-Glu-Val-NH2.: whereinamino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CHshfi-COsH. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 18 as illustrated below:

[0150] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 19. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:19. in certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 19 In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO: 19. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 19 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 19 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acidNAI-5002272956 109sequence of SEQ ID NO: 19 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 19 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 19 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of pGlu-Gly-Ser-Arg-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Iie-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- K*-Thr-Asn-Ala-Glu-Ile-Leu-Glu-Glu-Val-NH2; wherein-ammo-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(Clhjie-COzH. In certain embodiments, provided herein is a peptide as depicted in FIG. 5 or a pharmaceutically acceptable salt thereof

[0151] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:20. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:20. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:20. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:20. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:20 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:20 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 20 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 20 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:20 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of pGiu-Gly-Ser-Gln-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ue-Gly -Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala- Ala- Arg-Glu-Gln-Ala- K*-Thr-Asn~AIa-Glu-Ile-Leu-Glu-Glu-Val -NH2;NAI-5002272956 110wherein-amino-ethoxy )-elhoxy]-acetyl)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:20 as illustrated below:SEQ ^0:20 pGItj-Gly-Ser-Gin-lle-Thr-Leu-Ser-Leu-Asp-Vai-Pro-lle-Giy-Leu-Gin-GIn-ite-Leu-Leu-Gri-GIn-Ala-Arg-Ala-Arg

[0152] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:21 . In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:21. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:21. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID N():21. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:21 is an TIC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:21 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:21 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:21 is a TFA salt. In certain embodiments, the pharmaceuticallyNAI-5002272956 111acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:21 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of pGlu-Gly-Ser-Glu-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala- K*-Thr-Asn-Ala-Glu-Ile-Leu-Glu-GIu-Val-NH2; wherein(CH?.)i6-C()2H. in certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:21 as illustrated below:SEQ ID N0:21 pGlu"G^ySer-Glu-lie-Thr-Leu-Ser-Leu-Asp-Val~Pfo-lie-G!y-Leu-Gln-Gin-i!e-Leu-Leu-G!u“Gln-Ala-Arg-Aia-Arg-

[0153] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO: 22. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:22. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:22. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQNAI-5002272956 112ID N():22. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:22 is an HC1 sal t. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:22 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:22 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 22 is a TFA salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:22 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of pGlu-Gly-Ser-Lys-Ile-Thr-Leu-Ser-Leu-A^p-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Gln-Gln-Ala- Arg-Ala-Arg- Ala-Ala-Arg-Glu-Gln-Ala- K* -Thr-Asn- Al a-Glu-Ile-N le-Gl u-Thr-Ile-NH2; wherein-amino-ethoxy)-ethoxy]-acetyl.)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 6 or a pharmaceutically acceptable salt thereof

[0154] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:23. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:23. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:23. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:23. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:23 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:23 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 23 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:23 is a TEA salt. In certain embodiments, the pharmaceuticallyNAI-5002272956 113acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:23 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of pGlu-Gly-Ser-Gly-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-lle-Gly-Leu-Gin-Gln-Ile-Leu-Leu-Gln-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala- K*-Thr-Asn-Ala-Glu-He-Nle-Glu-Thr-Tle-NH2; wherein.-ammo-ethoxy)"ethoxy]-acety’l)2"gGlu-(CO)-(CI-bJifi-COcH. in certain embodiments, provided herein is a peptide as depicted in FIG. 7 or a pharmaceutically acceptable salt thereof

[0155] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:24. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:24. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:24. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:24. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:24 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:24 is a sodium salt. In certain embodiments, the pharmaceutically acceptable sail of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 24 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 24 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:24 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of pGlu-Gly-Gly-Gly-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Gln-Gln- Ala-Arg- Ala-Arg- Ala- Ala-Arg-Gl u-Gln-Ala- K*-Thr-Asn-Ala-Glu-Ile-Nle-Glu-l'hr-Ile-NH2;NAI-5002272956 114wherein-amino-ethoxy )-elhoxy]-acetyl)2-gGlu-(CO)-■ CH.J H -CO / H In certain embodiments, provided herein is a peptide as depicted in FIG. 8 or a pharmaceutically acceptable salt thereof.

[0156] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:25, In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:25. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:25. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:25. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:25 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:25 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 25 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 25 is aTFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:25 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of pGlu-Gly-Ser-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Ghr-Gln-Ile-Leu-Leu-Glu-Ghi- Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- K*-Thr-Asn-Ala-Glu-IIe-Nle-Glu-Thr-Ile-NFl2; wherein-amino-ethoxy)-ethoxy |-acetyl)2-gGlu-(CO)- (CH?.)i6-CO?.H. In certain embodiments, provided herein is a peptide as depicted in FIG. 9 or a pharmaceutically acceptable salt thereofNAI-5002272956 115

[0157] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:26. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:26. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:26. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:26. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:26 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:26 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 26 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 26 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:26 is an acetate salt. In certain embodiments, provided herein is a. peptide that comprises or consists of the ammo acid sequence of pGlu-Gly-Ser-Lys-Ile'-Thr-Leu-Ser-Leu-Asp-Val" Pro41e-Gly-Leu-Gln-GIn41e-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala- K* -Thr-Asn- Al a-GIu-II e-Nle-Gl u-Gl u-Il e-NHi; wherein-amino-ethoxy)-ethoxy'j-acety l)2-gGlu-(CO)-(CH2)i6-C()2H. in certain embodiments, provided herein is a peptide as depicted in FIG. 10 or a pharmaceutically acceptable salt thereof.

[0158] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:27. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:27. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:27. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:27. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:27 is an HC1 salt. In certainNAI-5002272956 116embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:27 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:27 is a potassium salt. In certain embodiments, the pharmaceutically acceptable sail of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:27 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:27 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of pGlu-Gly-Ser-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ue-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- K*-Thr-Asn-Aib-Glu-Ile-Nle-Glu-Thr-Ile-NH2i whereinamino-ethoxy)-ethoxj']-acetyl)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 11 or a pharmaceutically acceptable salt thereof.

[0159] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:28. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:28. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:28. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID N():28. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:28 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:28 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a. peptide that comprises or consists of the amino acid sequence of SEQ ID NO:28 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 28 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:28 is an acetate salt. In certain embodiments, provided herein is a peptide that comprisesNAI-5002272956 117or consists of the amino acid sequence of pGlu-Gly-Ser-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ue-Gly-Leu-GIn-Gln-Ile-Leu-Leu-Glu-GIn- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- K.*-l'hr-Asn-Aib-Glu-Ile-Nie-Glu-Glu-Ile-NH2; wherein-amino-ethoxj')-etihoxy]-acetyl)2-gGIu-(CO)- (CHi)i6-CO2H. In certain embodiments, provided herein is a peptide as depicted in FIG. 12 or a pharmaceutically acceptable salt thereof

[0160] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:29. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:29. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:29. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:29. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:29 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:29 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:29 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 29 is a TFA salt, in certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:29 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of pGlu-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-GIn-Ile-Leu-Leu-Glu-GIn- Ala-Arg-Ala- Arg- Ala-Ala- Arg-GIu-Gln-Aia- K*-Thr-Asn-Aib-Glu-Ile-Nle-Glu-Glu-Val-NH2;NAI-5002272956 118wherein-amino-ethoxy )-elhoxy]-acetyl)2-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:29 as illustrated below:SEQ ID W:29 pGiu-GlyGly-Lys-ile-Thr-Leu-Ser Leu Asp Val-Pro-lle-Gly-Leu GIn-Gln-fle-Leu-Leu-Giu-GIn-Aia A^ AIa-Ai^-

[0161] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:30. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:30. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 30. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:30. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:3() is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:30 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 30 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acidNAI-5002272956 119sequence of SEQ ID NO: 30 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:30 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Ri,-Pro-Gly-Gly-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro- Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln-Ala- Arg- Ala-Arg- Ala- Ala-Arg-Glu-Gln-Ala-Thr- Thr-Asn-Ala-Glu-Ile-Leu-Glu-Glu-Val-NH?; wherein RL is -(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl)2-gGlu-(CO)-(CH?)]8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID N():30 as illustrated below:Arg-Ala-Arg- Ala“Ala-Arg"Glt!”Gh“Alg-Thr"Thr“Asn-Ala-Glu-ite-Leu-Glu-Glu-VanNH2

[0162] In certain embodiments, provided herein is a peptide that comprises the ammo acid sequence of SEQ ID NO:31. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:31 . In certain embodimen ts, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO: 31 . In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:31. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:31 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:31 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 31 is a potassium salt. In certain embodiments, theNAI-5002272956 120pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 31 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:31 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of RL-Ser-Gly-G1y-Gly-Gly-I1e-Thr-Leu-Ser-Leu- Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-lle-Leu-Leu-Gl u-Gln- Ala- Arg-Ala- Arg- Aia-Ala-Arg- Glu-Gln-Ala-rThr-Thr-Asn-Ala-Glu-Ile-Leu-Glu-Glu-Val-NH2L wherein Ri, is ~(2~[2~(2~ amino-ethoxy )-ethoxy']-acetyl)2-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:31 as illustrated below:SEQ ID NG:31LGhvAla-Arg-Ala-Arg-Ala-Ala-Arg-Glu~Gln-Ala-Thr-Thr-Asn-Ala~GliHle-Leii~Glu“G!u-Val~NH2

[0163] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:43. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:43. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:43. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:43. In certain embodiments, the pharmaceutically acceptable salt of a peptide thatNAI-5002272956 121comprises or consists of the amino acid sequence of SEQ ID NO:43 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:43 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:43 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 43 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:43 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Ru-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-lle-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Ile-NHz; wherein RT. is -(2-[2-(2-aroino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:43 as illustrated below:

[0164] in certain embodiments, provided herein is a peptide that comprises the ammo acid sequence of SEQ ID NO: :44 In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:44. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:44. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:44. In certain embodiments, the pharmaceutically acceptable salt of a peptide thatNAI-5002272956 122comprises or consists of the amino acid sequence of SEQ ID NO:44 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consis ts of the ammo acid sequence of SEQ ID NO:44 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:44 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 44 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:44 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of RL-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-lle-Gly-Leu-Gln-GIn-Ile-Leu-Leu-Glu-GIn-Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Ile-NHz; wherein Ri. is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)2-gGlu-(CO)-(CH2)i6-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:44 as illustrated below:

[0165] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:52. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:52. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:52. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:52. In certain embodiments, the pharmaceutically acceptable salt of a peptide thatNAI-5002272956 123comprises or consists of the amino acid sequence of SEQ ID NO:52 is an HCI salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:52 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 52 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 52 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:52 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Ru-Gly-Gly-Lys-Ue-Thr-Leu-Ser-Leu-Asp-Val- Pro-lle-Gly-Leu-Gln-GIn-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Ala-Thr-Asn-Ala-Glu-He-Nle-Glu-Thr-Ue-NHs: wherein Ri, is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:52 as illustrated below:Arg-Aia-Arg-Aia-ASa-Arg-GkrGSn-Ala-Ala-Thr-Asn-Aia-GluHSe~Nte“Glu-Thrlle--NH2

[0166] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:53. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:53. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:53. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:53. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:53 is an HCi salt. In certainNAI-5002272956 124embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:53 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 53 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 5.3 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 53 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of RL-Gly-GIy-Lys-I1e-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-GIy-Leu-Gin-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Thr-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Ile-NI-h; wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:53 as illustrated below:

[0167] Tn certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:54. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:54. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:54. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:54. In certain embodiments, the pharmaceutically acceptable salt of a peptide thatNAI-5002272956 125comprises or consists of the amino acid sequence of SEQ ID NO:54 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consis ts of the ammo acid sequence of SEQ ID NO:54 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 54 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 54 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:54 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of RL-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-lle-Gly-Leu-Gln-GIn-Ile-Leu-Leu-Glu-GIn-Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Leu-Glu-Thr-Ile-NHs: wherein Ri is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:54 as illustrated below:OH

[0168] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:55. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:55. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID N( ): 55. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:55. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:55 is an HC1 salt. In certainNAI-5002272956 126embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:55 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 55 is a potassium salt. In certain embodiments, the pharmaceutically acceptable sail of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 55 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 55 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of RL-Gly-Gly-Lys-I1e-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ue-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Arg-Ile-NHa; wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:55 as illustrated below:

[0169] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:56. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:56. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:56. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:56. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:56 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists ofNAI-5002272956 127the amino acid sequence of SEQ ID NO:56 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 56 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 56 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 56 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Ri-GIv-Gly-Lys-IIe-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-He-Leu-Leu-Glu-GIn- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn- Al a-Glu-Il e-Nle-Gl u-Thr-Gl u-NHz; wherein RL is -(2- [2-(2- amino-ethoxy )- ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:56 as illustrated below:

[0170] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:57. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo aci d sequence of SEQ ID NO:57. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:57. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:57. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 57 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:57 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acidNAI-5002272956 128sequence of SEQ ID NO: 57 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 57 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:57 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rt-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Ghi-Gln-ne-Leu-Leu-Glu-Gln- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Me-Gki-Thr-lle-NFh; wherein RL is -(2-|2-(2-amino-ethoxy)- ethoxy]-acetyl)2-gGlu-(CO)-(CH2)20-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:57 as illustrated below:

[0171] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:58. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:58. In certain embodiments, provided herein is a peptide that consis ts of the amino acid sequence of SEQ ID NO:58. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:58. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 58 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists ofNAI-5002272956 129the amino acid sequence of SEQ ID NO:58 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 58 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 58 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 58 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Ri-GIv-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-He-Leu-Leu-Glu-GIn- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Ile-NHs; wherein RL IS -(2-[2-(2-amino-ethoxy)- ethoxy|-acetyl)2-gGlu-(CO)-(CH2)20-P(O)(OH)?„ In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:58 as illustrated below:

[0172] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:59. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQ ID NO:59. In certain embodiments, provided herein is a peptide that consists of the ammo acid sequence of SEQ ID NO:59. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:59. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 59 is an HC1 salt. In certainNAI-5002272956 130embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:59 is a sodium salt In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 59 is a potassium salt. In certain embodiments, the pharmaceutically acceptable sail of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 59 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 59 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of RL-Gly-Gly-Lys-I1e-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-GIn- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Ile-NHz; wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)2-gGlu-(CO)-(CH2)20-S(O)2NH2. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:59 as illustrated below:

[0173] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:60. In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the ammo acid sequence of SEQ ID NO:60. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:60. In certain embodiments, provided herein is a peptide that isNAI-5002272956 131a pharmaceutically acceptable salt of a peptide consisting of the amino acid sequence of SEQ ID NO:60. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:60 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:60 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 60 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO: 60 is a TFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:60 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the ammo acid sequence of Ri.-Gly-GJy-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg- Ala-Arg- Ala- Ala-Arg-Gl u-Gln-Ala- Glu-Thr-Asn-Ala-Glu-Ile-Nle-Giu-Thr-Ile-NHi; wherein RL is -(2-[2-(2-amino-ethoxj-)- ethoxy]-acetyl)2-gGlu-(CO)-(CH?.)2o-(lI-I-tetrazol-5-yl). In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO:60 as illustrated below:

[0174] In certain embodiments, provided herein is a peptide that comprises the amino acid sequence of SEQ ID NO:61 . In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide comprising the amino acid sequence of SEQNAI-5002272956 132ID N0:61. In certain embodiments, provided herein is a peptide that consists of the amino acid sequence of SEQ ID NO:61 . In certain embodiments, provided herein is a peptide that is a pharmaceutically acceptable salt of a peptide consisting of the ammo acid sequence of SEQ ID NO:61. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:61 is an HC1 salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 61 is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the ammo acid sequence of SEQ ID NO:61 is a potassium salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO: 61 is aTFA salt. In certain embodiments, the pharmaceutically acceptable salt of a peptide that comprises or consists of the amino acid sequence of SEQ ID NO:61 is an acetate salt. In certain embodiments, provided herein is a peptide that comprises or consists of the amino acid sequence of Rr-Gly-Gly-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val- Pro-Ile-Gly-Leu-Ghi-Gln-IIe-Leu-Leu-Glu-Gln- Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala- GIu-Thr-Asn-Ala-Glu-Ile-Nle-Glu-Thr-Tle-NH2: wherein RL is -(2-[2-(2-amino-ethoxy)- ethoxy]-acetyl)2-(CO)-CH2-(PEG)i2-lMH-gGlu-(CO)-(CH2)20-CO2H. In certain embodiments, provided herein is a peptide that comprises or consists of the structure of SEQ ID NO: 61 as illustrated below:NAI-5002272956 1335.3 Chararteristics of the Peptides

[90175] The peptides described in the present disclosure have characteristics that are beneficial for treating diseases and disorders in a subject, or for alleviating one or more symptoms or conditions, such as for reducing body fat, reducing body weight, and / or increasing weight loss in a subject; and / or have characteristics that are beneficial for producing a pharmaceutical composition comprising the peptides of the present disclosure, such as for producing a pharmaceutical composition or formulation with high solubility and / or high physical and / or chemical stability Such characteristics include. but are not limited to, superior solubility, superior physical stability, superior chemical stability, superior relative activity profile against the corticotropin-releasing factor receptor 1 (CRFR1) and / or the corticotropin-releasing factor receptor 2 (CRFR2), and / or superior pharmacokinetic profiles such as superior long in vivo half-life, high bioavailability, and / or high exposure, as compared to, for example, one or more reference peptides (e.g., peptides represented by SEQ ID NOs:39-42 and 45-51 ). In certain embodiments, the provided peptides are demonstrated to result in superior biological effects in vivo (e.g., reduction of body weight, food intake and / or loss of fat mass) when administered to a subject, as compared to, for example, one or more reference peptides (e g, peptides represented by SEQ ID NOs:39-42 and 45-51).NAI-5002272956 134

[0176] In certain embodiments, the peptides described herein exhibit superior solubility. In certain embodiments, such superior solubility of the peptides described herein are advantageous for the generation of pharmaceutical compositions or formulations comprising the peptides, particularly if high concentrations of the peptides are needed.

[0177] In certain embodiments, the peptides described herein have a solubility of about 1 to about 100 mg / mL, or about 2 to about 50 mg / mL (e.g., about 2 to about 50 mg / mL, about 2 to about 49 mg / mL, about 2 to about 48 mg / mL, about 2 to about 47 mg / mL. about 2 to about 46 mg / mL, about 2 to about 45 mg / mL, about 2 to about 44 mg / mL, about 2 to about 43 mg / mL, about 2 to about 42 mg / mL, about 2 to about 41 mg / mL, about 2 to about 40 mg / mL, about 2 to about 39 mg / mL. about 2 to about 38 mg / mL, about 2 to about 37 mg / mL, about 2 to about 36 mg / mL, about 2 to about 35 mg / mL, about 2 to about 34 mg / mL. about 2 to about 33 mg / mL. about 2 to about 32 mg / mL, about 2 to about 31 mg / mL, about 2 to about 30 mg / mL, about 2 to about 29 mg / mL, about 2 to about 28 mg / mL, about 2 to about 27 mg / mL, about 2 to about 26 mg / mL, about 2 to about 25 mg / mL, about 2 to about 24 mg / mL, about 2 to about 23 mg / mL, about 2 to about 22 mg / mL, about 2 to about 21 mg / mL. about 2 to about 20 mg / mL, about 2 to about 19 mg / mL, about 2 io about 18 mg / mL. about 2 to about 17 mg / mL, about 2 to about 16 mg / mL, about 2 to about 15 mg / mL, about 2 to about 14 mg / mL, about 2 to about 13 mg / mL, about 2 to about 12 mg / mL, about 2 to about 11 mg / mL, about 2 to about 10 mg / mL, about 2 to about 9 mg / mL, about 2 to about 8 mg / mL, about 2 to about 7 mg / mL, about 2 to about 6 mg / mL, about 2 to about .5 mg / mL, about 2 to about 4 mg / mL, about 2 to about 3 mg / mL, about 2 to about 50 mg / mL, about 3 to about 50 mg / mL, about 4 to about 50 mg / mL, about 5 to about 50 mg / mL, about 6 to about 50 mg / mL. about 7 to about 50 mg / mL, about 8 to about 50 mg / mL, about 9 to about 50 mg / mL, about 10 io about 50 mg / mL, about 11 to about 50 mg / mL, about 12 to about 50 mg / mL. about 13 to about 50 mg / mL, about 14 to about 50 mg / mL, about 15 to about 50 mg / mL. about 16 to about 50 mg / mL, about 17 to about 50 mg / mL, about 1 8 to about 50 mg / mL, about 19 to about 50 mg / mL, about 20 to about 50 mg / mL, about 21 to about 50 mg / mL, about 22 to about 50 mg / mL., about 23 to about 50 mg / mL, about 24 to about 50 mg / mL, about 25 to about 50 mg / mL, about 26 to about 50 mg / mL, about 27 to about 50 mg / mL. about 28 to about 50 mg / mL, about 29 to about 50 mg / mL, about 30 to about 50 mg / mL, about 31 to about 50 mg / mL. about 32 to about 50 mg / mL, about 33 to about 50 mg / mL, about 34 to about 50 mg / mL, about 35 to about 50 mg / mL, about 36 to about 50 mg / mL, about 37 to about 50 mg / mL. about 38 to about 50 mg / mL, about 39 to about 50 mg / mL, about 40 to about 50 mg / mL, about 41 to about 50 mg / mL, about 42 to about 50 mg / mL, about 43 toNAI-5002272956 135about 50 mg / mL, about 44 to about 50 mg / mL, about 45 to about 50 mg / mL, about 46 to about 50 mg / mL, about 47 to about 50 mg / mL, about 48 to about 50 mg / mL, or about 49 to about 50 mg / mL). In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL. Tn some embodiments, the peptides described herein have a solubility of about 1 mg / mL, . about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL. about 7 mg / mL, about 8 mg / mL, about 9 mg / mL. about 10 mg / mL.. about 11 mg / mL, about 12 mg / mL, about 13 mg / mL, about 14 mg / mL, about 15 mg / mL. about 16 mg / mL, about 17 mg / mL, about 18 mg / mL, about 19 mg / mL, about 20 mg / mL, about 21 mg / mL, about 22 mg / mL, about 23 mg / mL, about 24 mg / mL, about 25 mg / mL, about 26 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL, about 31 mg / mL, about 32 mg / mL, about 33 mg / mL, about 34 mg / mL, about 35 mg / mL, about 36 mg / mL, about 37 mg / mL, about 38 mg / mL, about 39 mg / mL, about 40 mg / mL, about 41 mg / mL, about 42 mg / mL, about 43 mg / mL, about 44 mg / mL, about 45 mg / mL. about 46 mg / mL, about 47 mg / mL, about 48 mg / mL, about 49 mg / mL, or about 50 mg / mL. In some embodiments, the peptides described herein have a solubility of at least about 2 mg / mL. In some embodiments, the peptides described herein have a solubility of at least about 5 mg / mL. In some embodiments, the peptides described herein have a solubility of at least about 10 mg / mL. In some embodiments, the peptides described herein have a solubility of at least about 20 mg / mL. In some embodiments, the peptides described herein have a solubility of about 20 mg / mL.[0017§| In certain embodiments, the solubility of the peptides described herein is determined under certain pH conditions, such as at a pH between about 6.5 and about 8, such as at about pH 7.0 or about pH 7,5. In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, or at least 2 mg / mL. In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 2.0 to about 50 mg / mL, or at least 2 mg / mL. at about pH 7.0 or about pH 7.5. In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL. about 20 to about 100 mg / mL. or about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, at about pH 7.5. In certain embodiments, the peptides described herein haveNAI-5002272956 136a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, or at least 10 mg / mL. In certain embodiments, the peptides described herein have a solubility' of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL. or about 20 to about 50 mg / mL, or at least 10 mg / mL, at about pH 7.0 or about pH 7.5. In certain embodiments, the peptides described herein have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL. about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL. or at least 10 mg / mL. at about pH 7 0 In certain embodiments, the peptides described herein have a solubility of at least 10 mg / mL, at about pH 7.5. In certain embodiments, the peptides described herein have a solubility of about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, or at least 20 mg / mL. In certain embodiments, the peptides described herein have a solubility of about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, or at least 20 mg / mL, at about pH 7.0 or about pH 7.5. In certain embodiments, the peptides described herein have a solubility of about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, or at least 20 mg / mL, at about pH 7.0. In certain embodiments, the peptides described herein have a solubility' of about 20 to about 100 mg / mL. or about 20 to about 50 mg / mL, or at least 20 mg / mL. at about pH 7.5.

[0179] In certain embodiments, the peptides represented by any7one of SEQ ID NOs:l, 2, 4, 5, 6, 7, 8, 9, 10, 11, 13, 18, 20, 21 , 24, 29, 31, and 39, have a solubility of about 1 to about 100 mg / mL, about 2 to about 50 mg / mL, or about 20 to about 50 mg / mL (e.g., about 2 to about 50 mg / mL, about 2 to about 49 mg / mL, about 2 to about 48 mg / mL, about 2 to about 47 mg / mL, about 2 to about 46 mg / mL, about 2 to about 45 mg / mL, about 2 to about 44 mg / mL, about 2 to about 43 mg / mL, about 2 to about 42 mg / mL, about 2 to about 41 mg / mL, about 2 to about 40 mg / mL. about 2 to about 39 mg / mL, about 2 to about 38 mg / mL, about 2 to about 37 mg / mL, about 2 to about 36 mg / mL, about 2 to about 35 mg / mL. about 2 to about 34 mg / mL, about 2 to about 33 mg / mL, about 2 to about 32 mg / mL, about 2 to about 31 mg / mL, about 2 to about 30 mg / mL, about 2 to about 29 mg / mL, about 2 to about 28 mg / mL, about 2 to about 27 mg / mL, about 2 to about 26 mg / mL, about 2 to about 25 mg / mL, about 2 to about 24 mg / mL, about 2 to about 23 mg / mL, about 2 to about 22 mg / mL, about 2 to about 21 mg / mL, about 2 to about 20 mg / mL, about 2 to about 19 mg / mL. about 2 to about 18 mg / mL, about 2 to about 17 mg / mL, about 2 to about 16 mg / mL, about 2 to about 15 mg / mL, about 2 to about 14 mg / mL, about 2 to about 13 mg / mL, about 2 to about 12 mg / mL, , about 2 to about 11 mg / mL, about 2 to about 10 mg / mL, about 2 to about 9 mg / mL, about 2 to about 8 mg / mL, about 2 to about 7 mg / mL. about 2 to about 6 mg / mL, about 2 to about 5 mg / mL, about 2 to about 4 mg / mL, about 2 to about 3 mg / mL, about 2 to about 50 mg / mL.NAI-5002272956 137about 3 to about 50 mg / mL, about 4 to about 50 mg / mL, about 5 to about 50 mg / 'mL, about 6 to about 50 mg / mL, about 7 to about 50 mg / mL, about 8 io about 50 mg / mL, about 9 to about 50 mg / mL, about 10 to about 50 mg / mL, about 11 to about 50 mg / mL, about 12 to about 50 mg / mL, about 13 to about 50 mg / mL, about 14 to about 50 mg / mL, about 15 to about 50 mg / mL, about 16 to about 50 mg / mL, about 17 to about 50 mg / mL, about 18 to about 50 mg / mL, about 19 to about 50 mg / mL, about 20 to about 50 mg / mL, about 21 to about 50 mg / mL, about 22 to about 50 mg / mL, about 23 to about 50 mg / mL. about 24 to about 50 mg / mL, about 25 to about 50 mg / mL, about 26 to about 50 mg / mL. about 27 to about 50 mg / mL, about 28 to about 50 mg / mL, about 29 to about 50 mg / mL. about 30 to about 50 mg / mL, about 31 to about 50 mg / mL, about .32 to about 50 mg / mL. about 3.3 to about 50 mg / mL, about 34 to about 50 mg / mL, about 35 to about 50 mg / mL. about 36 to about 50 mg / mL, about 37 to about 50 mg / mL, about 38 to about 50 mg / mL, about 39 to about 50 mg / mL, about 40 to about 50 mg / mL, about 41 to about 50 mg / mL, about 42 to about 50 mg / mL, about 43 to about 50 mg / mL, about 44 to about 50 mg / mL, about 45 to about 50 mg / mL, about 46 to about 50 mg / mL, about 47 to about 50 mg / mL. about 48 to about 50 mg / mL, or about 49 to about 50 mg / mL). In certain embodiments, the peptides represented by any one of SEQ ID NOs: l, 2, 4, 5, 6, 7, 8, 9, 10, 1 1 , 13, 18, 20, 21, 24, 29, 31 , and 39. have a solubility of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 1 1 mg / mL, about 12 mg / mL, about 13 mg / mL, about 14 mg / mL, about 15 mg / mL. about 16 mg / mL, about 17 mg / mL, about 18 mg / mL, about 19 mg / mL, about 20 mg / mL. about 21 mg / mL, about 22 mg / mL, about 23 mg / mL, about 24 mg / mL, about 25 mg / mL, about 26 mg / mL, about 27 mg / mL, about 28 mg / mL, about 29 mg / mL, about 30 mg / mL. about 31 mg / mL, about 32 mg / mL , about 33 mg / mL, about 34 mg / mL, about 35 mg / mL, about 36 mg / mL, about 37 mg / mL, about 38 mg / mL. about 39 mg / mL, about 40 mg / mL., about 41 mg / mL, about 42 mg / mL, about 43 mg / mL, about 44 mg / mL, about 45 mg / mL, about 46 mg / mL, about 47 mg / mL, , about 48 mg / mL, about 49 mg / mL, or about 50 mg / mL. In certain embodiments, the peptides represented by any one of SEQ IL) N0s:L 2, 4, 5. 6, 7, 8, 9, 10. 11, 13, 18, 20, 21. 24. 29. 31. and 39. have a solubility of about 10 to about 100 mg / ml,, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, at about pH 7.0 or at about pH 7.5, In certain embodiments, the peptides represented by any one of SEQ ID NOs: 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, and 29, have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptides represented by anyNAI-5002272956 138one of SEQ ID NOs: 13, 18, 20, 21, 24, 31 , and 39, have a solubility of about 10 to about 100 mg / mL, about 10 to about 50 mg / mL, about 20 to about 100 mg / mL, or about 20 to about 50 mg / mL. at about pH 7.5,

[0180] In certain embodiments, the peptide represented by SEQ ID NO: 1 has a solubility of about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO: 2 has a solubility of about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO:4 has a solubility of about 20 to about 50 mg / mL, at about pH 7 0 In certain embodiments, the peptide represented by SEQ ID NO:5 has a solubility of about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO:6 has a solubility of about 20 to about 50 mg / mL. at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO:7 has a solubility of about 20 to about 50 mg / mL. at about pH 7 0. In certain embodiments, the peptide represented by SEQ ID NO:8 has a solubility- of about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO:9 has a solubility of at least about 20 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO: 10 has a solubility of about 20 to about 50 mg / mL. at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO: 1 1 has a solubility of about 20 to about 50 mg / mL, at about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO: 13 has a solubility of about 20 to about 50 mg / mL, at about pH 7.5. In certain embodiments, the peptide represented by SEQ ID NO: 18 has a solubility’ of about 20 to about 50 mg / mL, at about pH7.5. In certain embodiments, the peptide represented by SEQ ID NO:20 has a solubility of about 20 to about 50 mg / mL, at about pH 7.5. In certain embodiments, the peptide represented by SEQ ID NO:21 has a solubility of about 20 to about 50 mg / mL. at about pH7.5. In certain embodiments, the peptide represented by’ SEQ ID NO:24 has a solubility of about 20 to about 50 mg / mL. at about pH 7.5. In certain embodiments, the peptide represented by SEQ ID NO:29 has a solubility of about 20 to about 50 mg / mL, al about pH 7.0. In certain embodiments, the peptide represented by SEQ ID NO:31 has a solubility of about 20 to about 50 mg / mL, at about pH 7.5. In certain embodiments, the peptide represented by SEQ ID NO:39 has a solubility of about 20 to about 50 mg / mL, at about pH7.5

[0181] In certain embodiments, the peptides represented by any one of SEQ ID NOs: 14, 15, 16, 17, 19, 23, 25. 26. 27. 28. 30. 57. 58, 59, 60, and 61 , have a solubility of about 10 to about 50 mg / mL., al about pH 7.5.NAI-5002272956 139

[0182] In certain embodiments, the peptides described herein exhibit high physical stability, including a high level of physical stability even after storage for an extended time. In certain embodiments, such superior physical stability of the peptides described herein are advantageous for storing pharmaceutical compositions or formulations comprising the peptides, particularly if long-term storage or storage at particular conditions is needed.

[0183] In certain embodiments, the peptides described herein exhibit high physical stability as shown by low or undetectable aggregate formation, for example, as observed based on size exclusion chromatography (SEC) of a solution comprising the provided peptides. In certain embodiments, the peptides described herein have a % aggregation (as indicated by the area under the curve of peaks with estimated molecular weight of greater than 150.000 Da on SEC) of undetectable (about 0%, indicating high physical stability over time) to about 85% (e.g . about 0% to about 85%, about 0. 1% to about 85%, about 0.25% to about 85%, about 0.5% to about 85%, about 1% to about 85%, about 2% to about 85%, about 3% to about 85%, about 4% to about 85%, about 5% to about 85%, about 6% to about 85%, about 7% to about 85%, about 8% to about 85%, about 9% to about 85%, about 10% to about 85%. about 20% to about 85%, about 30% to about 85%. about 40% to about 85%. about 50% to about 85%, about 60% to about 85%, about 70% to about 85%, or about 80% to about 85%, about 0% to about 0.1 %, about 0% to about 0.25%, about 0% to about 0.5%, about 0% to about 1 %, about 0% to about 2%, about 0% to about 3%, about 0% to about 4%. about 0% to about 5%, about 0% to about 6%. about 0% to about 7%. about 0% to about 8%. about 0% to about 9%, about 0% to about 10%, about 0% to about 20%. about 0% to about 30%, about 0% to about 40%, about 0% to about 50%. about 0% to about 60%, about 0% to about 70%, or about 0% to about 80%). In certain embodiments, the peptides described herein have a % aggregation of about 0%, about 0. 1%, about 0.25%. about 0.5%, about 1%. about 2%, about 3%, about 4%. about 5%. about 6%, about 7%. about 8%. about 9%, about 10%, about 20%. about 30%, about 40%. about 50%, about 60%, about 70%, about 80%, or about 85%. In certain embodiments, the % aggregation of the peptides described herein is determined after storage of a solution comprising the peptides for a period of time, such as about 3 days, about 5 days, about 7 days, about 14 days, about 28 days, about 30 days, about 60 days, or about 90 days, for example, about 7 days or about 30 days.

[0184] In certain embodiments, the peptides described herein have % aggregation of less than about 0.1%, such as about 0%, after storage for about 7 days. In certain embodiments, the peptides described herein have % aggregation of about 0% to about 78% (e.g , about 0% to about 78%, about 0 1% to about 78%. about 0.25% to about 78%, aboutNAI-5002272956 1400.5% to about 78%, about 1% to about 78%, about 2% to about 78%, about 3% to about 78%, about 4% to about 78%, about 5% to about 78%, about 6% to about 78%, about 7% to about 78%, about 8% to about 78%, about 9% to about 78%. about 10% to about 78%. about 20% to about 78%, about 30% to about 78%, about 40% to about 78%. about 50% to about 78%, about 60% to about 78%, or about 70% to about 78%, about 0% to about 0 1%, about 0% to about 0.25%. about 0% to about 0.5%, about 0% to about 1 %, about 0% to about 2%, about 0% to about 3%. about 0% to about 4%. about 0% to about 5%. about 0% to about 6%, about 0% to about 7%, about 0% to about 8%, about 0% to about 9%, about 0% to about 10%, about 0% to about 20%, about 0% to about 30%), about 0% to about 40%, about 0% io about 50%, about 0% to about 60%, or about 0% to about 70%, such as of about 0%, about 0.1%, about 0.25%). about 0.5%, about 1%, about 2%, about 3%. about 4%>, about 5%, about 6%. about 7%, about 8%, about 9%, about 10%, about 20%s, about 30%), about 40%. about 50%, about 60%, about 70%, or about 78%), after storage for about 30 days. In certain embodiments, the peptides represented by any one of SEQ ID NOs:l. 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 20, 22, 25, 26, 27, 28, 29, and 39, have a % aggregation of about 0%>, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: I has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:4 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:5 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:6 has a % aggregation of about 0%>. after about 7 days tn certain embodiments, the peptide represented by SEQ ID NO: 7 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:8 has a % aggregation of about 0%), after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:9 has a % aggregation of about 0%>, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 10 has a % aggregation of about 0%), after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 11 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 12 has a %> aggregation of about 9%), after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 15 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 16 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 17 has a %> aggregation of about 0%, after about 7 days, hi certain embodiments, the peptide represented by SEQ ID NO:20 has a % aggregation of about 0%. after about 7 daysNAI-5002272956 141In certain embodiments, the peptide represented by SEQ ID NO:22 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:25 has a % aggregation of about 0%. after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:26 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO: 27 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:28 has a % aggregation of about 0%, after about 7 days. In certain embodiments, the peptide represented by SEQ ID NO:29 has a % aggregation of about 0%, after about 7 days In certain embodiments, the peptide represented by SEQ ID NO:39 has a % aggregation of about 0%, after about 7 days.

[90185] In certain embodiments, the peptides represented by any one of SEQ ID NOs: 1 , 4, 5. 6. 7, 9, 10, 15, 16, 25, 26, 27, 28, and 39, have a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: I has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:5 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:5 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:6 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: 7 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:9 has a % aggregation of about 0%. after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: 10 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: 15 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: 16 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:25 has a % aggregation of about 0%, after about 30 day s. In certain embodiments, the peptide represented by SEQ ID NO: 26 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:2.7 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:28 has a % aggregation of about 0%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:.39 has a % aggregation of about 0%, after about 30 days.

[0186] In certain embodiments, the peptide represented by SEQ ID NO:2 has a % aggregation of about 78%. after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO: 18 has a % aggregation of about 63%, after about 30 days. InNAI-5002272956 142certain embodiments, the peptide represented by SEQ ID NO: 19 has a % aggregation of about 4%, after about 30 days. In certain embodiments, the peptide represented by SEQ ID NO:20 has a % aggregation of about 63%, after about 30 days.

[0187] In certain embodiments, the peptides described herein exhibit high physical stability, including stability maintained over extended storage times and at elevated temperatures compared to typical storage conditions. In certain embodiments, such superior physical stability of the peptides described herein is advantageous for storing pharmaceutical compositions or formulations comprising the peptides, particularly when long-term storage or storage at particular conditions such as high temperature is needed.

[0188] In certain embodiments, the physical stability of the peptides described herein is advantageous for maintaining stability and bioavailability' of the peptides over time when administered to a subject. In certain embodiments, the peptides described herein exhibit high physical stability as demonstrated by dynamic light scattering (DLS) analysis showing a consistent apparent hydrodynamic diameter (reported as the “main peak diameter” in the DLS distribution), low poly dispersity index (PDI), and stable mass contribution (M) values over a 2-week incubation period. In certain embodiments, the peptides described herein exhibit no substantial change in main peak diameter when stored at 2-8 °C, over a 2-week period. In some embodiments, the peptides described herein have a main peak diameter, after 0, 1, or 2 week(s) storage at 2-8 °C, within a range of about 6 nm to about 8 nrn (e.g., about 6 nm to about 8 nm, about 6. 1 nm to about 8 nm, about 6.2 nm to about 8 nm. about 6.3 nm to about 8 nm, about 6.4 nm to about 8 nm, about 6.5 nm to about 8 nm, about 6.6 nm to about 8 nm. about 6.7 nm to about 8 nm, about 6.8 nm to about 8 nm, about 6.9 nm to about 8 nm, about 7.0 nrn to about 8 nm, about 7.1 nm to about 8 nm, about 7.2 nm to about 8 nm, about 7.3 nm to about 8 nm, about 7.4 nm to about 8 nm, about 7.5 nm to about 8 nm, about 7.6 nm to about 8 nm. about 7.7 nm to about 8 nm, about 7.8 nm to about 8 nm, about 7.9 nm to about 8 nm, about 6.1 nm to about 7.9 nm, about 6.1 nm to about 7.8 nm, about 6.1 nm to about 7.7 nm, about 6. 1 nm to about 7.6 nm, about 6, 1 nm to about 7.5 nm, about 6. 1 nm to about 7.4 nm, about 6. 1 nm to about 7.3 nm. about 6. 1 nm to about 7.2 nm, about 6. 1 nm to about 7. 1 nm, about 6. 1 nm to about 7.0 nm. about 6. 1 nm to about 6.9 nm. about 6. 1 nm to about 6.8 nm. about 6. 1 nrn to about 6 7 nm, about 6. 1 nm to about 6.6 nm, about 6. 1 nm to about 6.5 nm. about 6. 1 nm to about 6.4 nm, about 6. 1 nm to about 6.3 nm, about 6. 1 nm to about 6,2 nm). In certain embodiments, the peptides described herein have a main peak diameter, after 0. I, or 2 week(s) storage at 2-8 °C, of about 6 nm, about 6. 1 nm. about 6.2 nrn, about 6.3 nm, about 6.4 nm. about 6.5 nm, about 6 6 nm, about 6.7 nm, about 6.8 nm. about 6.9 nm. aboutNAI-5002272956 1437.0 nm. about 7.1 nm, about 7.2 nm, about 7.3 nm, about 7.4 run. about 7.5 nm, about 7.6 nm, about 7.7 nm, about 7.8 nm, about 7.9 run. or about 8.0 nm.

[0189] In certain embodiments, the peptides described herein exhibit no substantial change in main peak diameter when stored at 37 °C. over a 2-week period. In some embodiments, the peptides described herein have a main peak diameter, after 0, 1 , or 2 week(s) storage at 2-8 °C, within a range of about 6 nm to about 8 nm (e.g., about 6 nm to about 8 nm, about 6. 1 nm to about 8 nm, about 6.2 nm to about 8 nm. about 6.3 nm to about 8 nm, about 6 4 nm to about 8 nm, about 6.5 nm to about 8 nm, about 6 6 nm to about 8 nm, about 6 7 nm to about 8 nm, about 6 8 nm to about 8 nm, about 6.9 nm to about 8 nm, about 7.0 nm to about 8 nm, about 7.1 nm to about 8 nm, about 7.2 nm to about 8 nm, about 7.3 nm to about 8 nm, about 7.4 nm to about 8 nm, about 7.5 nm to about 8 nm, about 7.6 nm to about 8 nm, about 7.7 nm to about 8 nm, about 7.8 nm to about 8 nm, about 7.9 nm to about 8 nm, about 6. 1 nm to about 7.9 nm, about 6. 1 nm to about 7.8 nm, about 6. 1 nm to about 7.7 nm, about 6.1 nm to about 7.6 nm, about 6. 1 nm to about 7.5 nm, about 6. 1 nm to about 7.4 nm, about 6. 1 nm to about 7.3 nm. about 6. 1 nm to about 7.2 nm, about 6. 1 nm to about 7. 1 nm, about 6. 1 nm to about 7.0 nm. about 6. 1 nm to about 6 9 nm. about 6. 1 nm to about 6.8 nm. about 6. 1 nm to about 6.7 nm, about 6. 1 nm to about 6 6 nm, about 6. 1 nm to about 6.5 nm, about 6. 1 nm to about 6.4 nm, about 6. 1 nm to about 6.3 nm, about 6. 1 nm to about 6.2 nm). In certain embodiments, the peptides described herein have a main peak diameter, after 0, I, or 2 week(s) storage at 37 °C, of about 6 nm. about 6. 1 nm, about 6.2 nm. about 6.3 nm, about 6.4 nm. about 6.5 nm, about 6.6 nm, about 6 7 nm, about 6.8 nm, about 6.9 nm. about 7.0 nm, about 7.1 nm, about 7.2 nm, about 7.3 nm, about 7.4 nm, about 7.5 nm, about 7.6 nm, about 7.7 nm, about 7.8 ran, about 7.9 nm. or about 8.0 nm.

[0190] In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 0 week storage at 2.-8 °C. of about 6.08 nm to about 8.30 nm. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 1 week storage at 2-8 °C, of about 5.60 nm to about 8.06 nm. In certain embodiments, the peptide represented by SEQ ID NO: I has a main peak diameter, after 2 weeks storage at 2-8 °C. of about 5.93 nm to about 8.08 nm. In certain embodiments, the peptide represented by SEQ ID NO: I has a main peak diameter, after 0 week storage at 37 °C, of about 6.08 nm to about 8.30 nm. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 1 week storage at 37 °C, of about 5.75 nm to about 8.47 nm. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 2 weeks storage at 37 °C. of about 5.77 nm to about 7.89 nm.NAI-5002272956 144

[0191] In certain embodiments, the peptides described herein exhibit no substantial change in polydispersity index (PDI) when stored at 2-8 °C. over a 2-week period. In some embodiments, the peptides described herein have a PDI, after 0, 1, or 2 week(s) storage at 2-8 °C, within a range of about 0.160 to about 0.280 (e.g., about 0.160 to about 0.280, about 0. 160 to about 0.270, about 0. 160 to about 0.260, about 0 160 to about 0.250, about 0. 160 to about 0.240, about 0.160 to about 0.230, about 0.160 to about 0.220, about 0, 160 to about 0.210, about 0.160 to about 0.200. about 0.170 to about 0.280, about 0.180 to about 0.280. about 0 190 to about 0.2.80, about 0 200 to about 0.280, about 0.210 to about 0.2.80. about 0.220 to about 0.280. about 0.230 to about 0.280, about 0.240 to about 0.280. about 0.250 to about 0.280, about 0.260 to about 0.280. or about 0.270 to about 0.280). In certain embodiments, the peptides described herein have a PDI, after 0, 1 , or 2 week(s) storage at 2-8 °C, of about 0. 160, about 0. 170, about 0. 180, about 0. 190, about 0.200, about 0.210, about 0.220, about 0.230. about 0.240, about 0 250, about 0.260, about 0.270, or about 0.280.

[0192] In certain embodiments, the peptides described herein exhibit no substantial change in polydispersity index (PDI) when stored at 37 °C, over a 2-week period. In some embodiments, the peptides described herein have a PDI. after 0. 1, or 2 week(s) storage at 37 °C. within a range of about 0.160 to about 0.280 (e.g., about 0.160 to about 0.280, about 0.160 to about 0.270, about 0.160 to about 0.260, about 0.160 to about 0.250. about 0.160 to about 0.240, about 0.160 to about 0.230, about 0.160 to about 0.220, about 0.160 to about 0.210, about 0.160 to about 0.200. about 0.170 to about 0.280, about 0.180 to about 0.280. about 0.190 to about 0.280, about 0.200 to about 0.2.80. about 0.210 to about 0.280. about 0.220 to about 0.280, about 0.230 to about 0.280, about 0.240 to about 0.280, about 0.250 to about 0.280, about 0.260 to about 0.280. or about 0.270 to about 0.280). In certain embodiments, the peptides described herein have a PDI. after 0, 1, or 2 week(s) storage at 37 °C. of about 0.160. about 0.170. about 0.180, about 0. 190. about 0.200. about 0.210, about 0.220, about 0.230. about 0.240, about 0.250, about 0.260, about 0.270, or about 0.280.

[0193] In certain embodiments, the peptide represented by SEQ ID NO: 1 has a poly dispersity index (PDI), after 0 week storage at 2-8CC, of about 0. 184 to about 0.276. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a poly dispersity index (PDI), after 1 week storage at 2-8 °C, of about 0. 159 to about 0.219. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a poly dispersity index (PDI), after 2 weeks storage at 2-8 °C, of about 0.160 to about 0.200. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a poly dispersity index (PDI), after 0 week storage at 37 °C, of about 0. 184 to about 0 276. In certain embodiments, the peptide represented by SEQ IDNAI-5002272956 145NO:1 has a polydispersity index (PDI), after 1 week storage at 37 °C, of about 0.208 to about 0.262. In certain embodiments, the peptide represented by SEQ ID NO:1 has a polydispersity index (PDI), after 2 weeks storage at 37 °C. of about 0.203 to about 0.205.

[0194] In certain embodiments, the peptides described herein exhibit no substantial change in stable mass contribution (M) percentage when stored at 2-8 °C, over a 2-week period. In some embodiments, the peptides described herein have a stable mass contribution (M) percentage, after 0, 1. or 2 week(s) storage at 2-8 °C, within a range of about 99.75% to about 100% (e.g., about 99.75% to about 100%, about 99.80% to about 100%, about 99.85% to about 100%, about 99.90% to about 100%, about 99.95% to about 100%, about 99.75% to about 99.95%, about 99.75% to about 99.90%, about 99.75% to about 99.85%, or about 99.75% to about 99.80%,). In certain embodiments, the peptides described herein have a stable mass contribution (M) percentage, after 0, 1 , or 2 week(s) storage at 2-8 °C, of about 99.75%, about 99.80%, about 99.85%, about 99.90%, about 99.95%, about 99.99%, or about 100%.

[0195] In certain embodiments, the peptides described herein exhibit no substantial change in stable mass contribution (M) percentage when stored at 37 °C. over a 2-week period. In some embodiments, the peptides described herein have a stable mass contribution (M) percentage, after 0, 1, or 2 week(s) storage at 37 °C, within a range of about 99.75% to about 100% (e.g., about 99.75% to about 100%. about 99.80% to about 100%, about 99.85% to about 100%. about 99 90% to about 100%, about 99.95% to about 100%, about 99.75% to about 99.95%, about 99 75% to about 99.90%, about 99.75% to about 99 85%, or about 99.75% to about 99.80%,). In certain embodiments, the peptides described herein have a stable mass contribution (M) percentage, after 0, 1, or 2 week(s) storage at 37 °C, of about 99.75%, about 99.80%, about 99.85%. about 99.90%, about 99.95%, about 99.99%, or about 100%.

[0196] In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 0 week storage at 2-8 °C, of about 99,72% to about 99.97%. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a mam peak diameter, after 1 week storage at 2-8 °C. of about 99.94% to about 100%. In certain embodiments, the peptide represented by SEQ ID NO:1 has a main peak diameter, after 2 weeks storage at 2-8 °C, of about 99 98% to about 100%. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 0 week storage at 37 °C, of about 99.72% to about 99.97%. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 1 week storage at 37 °C, of about 5.75% to about 8.47%. In certainNAI-5002272956 146embodiments, the peptide represented by SEQ ID NO: 1 has a main peak diameter, after 2 weeks storage at 37 °C, of about 579.84% to about 99.98%.

[0197] In certain embodiments, the peptides described herein exhibit high chemical stability, including a high level of chemical stability even after storage for an extended time, at a higher temperature compared to typical storage conditions. In certain embodiments, such superior chemical stability of the peptides described herein are advantageous for storing pharmaceutical compositions or formulations comprising the peptides, particularly’ if longterm storage or storage at particular conditions such as high temperature is needed

[0198] In certain embodiments, the chemical stability of the peptides described herein are advantageous for maintaining stability and bioavailability of the peptides over time when administered to a subject. In certain embodiments, the peptides described herein exhibit high chemical stability as shown by low or undetectable aggregate formation, for example, as observed based on reverse-phase high-performance liquid chromatography (RP-HPLC)- ultraviolet (UV) spectroscopy of a solution comprising the provided peptides. In certain embodiments, the peptides described herein have a % purity' loss (as indicated by the difference in the area under the curve of the peak of the UV absorption trace at 220 nm based on RP-HPLC-UV, before storage of a solution compnsing the peptides for a period of time (i.e., at day 0) and after storage (e.g., at day 7 or day 30)) of about 0% to about 78% (e.g., about 0% to about 78%, about 0. 1% to about 78%, about 0.25% to about 78%, about 0.5% to about 78%. about 1 % to about 78%. about 2% to about 78%, about 3% to about 78%, about 4% to about 78%. about 5% to about 78%. about 6% to about 78%, about 7% to about 78%, about 8% to about 78%, about 9% to about 78%, about 10% to about 78%, about 20% to about 78%. about 30% to about 78%, about 40% io about 78%, about 50% to about 78%, about 60% to about 78%, or about 70% to about 78%. about 0% to about 0. 1%, about 0% to about 0.25%, about 0% to about 0.5%, about 0% to about 1%. about 0% to about 2%, about 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, about 0% to about 8%, about 0% to about 9%, about 0% to about 10%, about 0% to about 20%, about 0% to about 30%, about 0% to about 40%, about 0% to about 50%. about 0% to about 60%, or about 0% to about 70%), or is undetectable (about 0%. indicating high chemical stability over time). In certain embodiments, the peptides described herein have a % purity loss of about 0%, about 0.1%, about 0.25%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%. about 6%, about 7%, about 8%, about 9%, about 10%. about 20%. about 30%, about 40%, about 50%, about 60%. about 70%, or about 78%. In certain embodiments, the % purity loss of the peptides described herein is determined afterNAI-5002272956 147storage of a solution comprising the peptides for a period of time, such as about 3 days, about 5 days, about 7 days, about 14 days, about 28 days, about 30 days, about 60 days, or about 90 days, for example, about 7 days or about 30 days. In certain embodiments, the % purity' loss of the peptides described herein is determined after storage of a sol ution comprising the peptides at a physiological temperature or typical human body temperature, for example, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, or about 39°C, such as at about 37°C. In certain embodiments, the % purity loss of the peptides described herein is determined under agitating conditions, for example, agitating or shaking the solution at particular speeds, such as 300 revolutions per minute (rpm), 400 rpm, 500 rpm, 600 rpm or more. In certain embodiments, the peptides provided herein result in minimal purity loss despite exposure to high temperatures or agitating conditions.

[0199] In certain embodiments, the peptides described herein have % purity loss of about 0% to about 78% (e.g., about 0% to about 78%, about 0.1% to about 78%, about 0.25% to about 78%, about 0.5% to about 78%, about 1% to about 78%, about 2% to about 78%, about 3% to about 78%, about 4% to about 78%, about 5% to about 78%, about 6% to about 78%. about 7% to about 78%, about 8% to about 78%, about 9% to about 78%, about 10% to about 78%, about 20% to about 78%, about 30% to about 78%, about 40% to about 78%. about 50% to about 78%, about 60% to about 78%, or about 70% to about 78%, about 0% to about 0.1%, about 0% to about 0.25%, about 0% to about 0.5%, about 0% to about 1%, about 0% to about 2%. about 0% to about 3%. about 0% to about 4%. about 0% to about 5%, about 0% to about 6%, about 0% to about 7%. about 0% to about 8%, about 0% to about 9%, about 0% to about 10%, about 0% to about 20%. about 0% to about 30%, about 0% to about 40%, about 0% to about 50%, about 0% to about 60%, or about 0% to about 70%), such as about 0%, about 0. 1%, about 0.25%. about 0,5%, about 1%. about 2%, about 3%, about 4%, about 5%, about 6%. about 7%. about 8%, about 9%. about 10%. about 20%, about 30%, about 40%, about 50%, about 60%. about 70%, or about 78%, after storage for about 7 days, at about 37°C. In certain embodiments, the peptides described herein have % purity loss of about 0% to about 78% (e.g., about 0% to about 78%. about 0.1% to about 78%, about 0.25% to about 78%, about 0.5% to about 78%, about 1% to about 78%. about 2% to about 78%, about 3% to about 78%, about 4% to about 78%, about 5% to about 78%, about 6% to about 78%, about 7% to about 78%, about 8% to about 78%, about 9% to about 78%, about 10% to about 78%. about 20% to about 78%, about 30% to about 78%, about 40% to about 78%, about 50% to about 78%. about 60% to about 78%, or about 70% to about 78%, about 0% to about 0.1%. about 0% to about 0 25%, about 0% to about 0.5%. about 0% to about 1%. aboutNAI-5002272956 1480% to about 2%, about 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, about 0% to about 8%. about 0% to about 9%, about 0% to about 10%, about 0% to about 20%, about 0% to about 30%, about 0% to about 40%, about 0% to about 50%, about 0% to about 60%, or about 0% to about 70%), such as about 0%, about 0.1 %, about 0.25%, about 0.5%, about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 20%, about 30%. about 40%. about 50%. about 60%, about 70%, or about 78%, after storage for about 30 days, at about 37°C.

[0200] In certain embodiments, the peptides represented by any one of SEQ ID NOs:l, 2, 3, 1 1, 12, 14, 16, 17, 18, 19, 20, 22, 24, 25, 26, 27, 28, and 29, have a % purity loss of about 0% to about 78% (e.g. , about 0% to about 78%, about 0.1 % to about 78%, about 0.25% io about 78%, about 0.5% to about 78%, about 1% to about 78%, about 2% to about 78%, about 3% to about 78%, about 4% to about 78%, about 5% to about 78%. about 6% to about 78%, about 7% to about 78%, about 8% to about 78%, about 9% to about 78%, about 10% to about 78%, about 20% to about 78%, about 30% to about 78%. about 40% to about 78%. about 50% to about 78%, about 60% to about 78%. or about 70% to about 78%, about 0% to about 0. 1%, about 0% to about 0.25%, about 0% to about 0.5%, about 0% to about 1 %, about 0% to about 2%, about 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 1%, about 0% to about 8%, about 0% to about 9%, about 0% to about 10%, about 0% to about 20%, about 0% to about 30%, about 0% to about 40%. about 0% to about 50%, about 0% to about 60%. or about 0% to about 70%), such as about 0%, about 0.1%, about 0.25%, about 0.5%, about 1%. about 2%, about 3%, about 4%, about 5%, about 6%, about 2%, about 8%, about 9%, about 10%, about 20%, about 30%, about 40%. about 50%, about 60%, about 70%, or about 78%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 1 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:2 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 11 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 12 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 14 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 16 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 17 has a % purity lossNAI-5002272956 149of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 18 has a % purity loss of about 78%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 19 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:20 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 22 has a % purity loss of about 4%. after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:24 has a % purity loss of about 4%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:25 has a % purity loss of less than 1 %, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID N():26 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:27 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:28 has a % purity loss of less than 1%, after about 7 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 29 has a % purity loss of less than 1 %, after about 7 days at about 37°C.

[0201] In certain embodiments, the peptides represented by any one of SEQ ID NOs:l, 2, 16, 18, 19, 20, 25, 26, 27, and 28, have a % purity loss of about 0% to about 78% (e.g., about 0% to about 78%, about 0.1 % to about 78%, about 0.25% to about 78%, about 0.5% to about 78%, about 1 % to about 78%, about 2% to about 78%. about 3% to about 78%, about 4% to about 78%, about 5% to about 78%, about 6% to about 78%, about 7% to about 78%, about 8% to about 78%, about 9% to about 78%, about 10% to about 78%, about 20% to about 78%, about 30% to about 78%, about 40% to about 78%, about 50% to about 78%, about 60% to about 78%, or about 70% to about 78%. about 0% to about 0. 1%, about 0% to about 0.25%, about 0% to about 0.5%, about 0% to about 1%. about 0% to about 2%, about 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, about 0% to about 8%, about 0% to about 9%, about 0% to about 10%, about 0% to about 20%, about 0% to about 30%, about 0% to about 40%, about 0% to about 50%. about 0% to about 60%, or about 0% to about 70%), such as about 0%. about 0.1%, about 0.25%, about 0.5%, about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%. about 70%, or about 78%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: I has a % purity loss of about 2%. after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ IDNAI-5002272956 150NO:2 has a % purity loss of about 3%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 16 has a % purity loss of about 5%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:18 has a % purity loss of about 78%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO: 19 has a % purity loss of about 9%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:20 has a % purity loss of about 6%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:25 has a % purity loss of less than 1%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:26 has a % purity loss of less than 1%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:27 has a % purity loss of less than 1%, after about 30 days at about 37°C. In certain embodiments, the peptide represented by SEQ ID NO:28 has a % purity loss of less than 1%. after about 30 days at about 37°C.

[0202] In certain embodiments, the peptides described herein have characteristics that include an agonistic activity profile against corticotropin-releasing factor receptors. In certain embodiments, the peptides provided herein have a superior activity profile against the corticotropin-releasing factor receptor 1 (CRFR I) and / or the corticotropin-releasing factor receptor 2 (CRFR2). In certain embodiments, the peptides provided herein have a superior activity profile against the human CRFR2 isofonn a, isoform p, or isoform y. In certain embodiments, the peptides provided herein are capable of activating corticotropin releasing factor receptor 2 (CRFR2) selectively over corticotropin releasing factor receptor 1 (CRFRI ) In certain embodiments, the peptides provided herein have no detectable agonist activity towards CRFRI .

[0203] In certain embodiments, the peptides described herein exhibit potent agonistic activity at the corticotropin-releasing factor receptor 2 (CRFR2) (as indicated by low half maximal effective concentration (EC-ie) at the CRFR2) and / or at the corticotropin-releasing factor receptor 1 (CRFRI) (as indicated by low ECso at the CRFRI), for example as assessed using a cell-based assay. In certain embodiments, ECso is determined using a cell-based assay, such as a cell engineered to stably express the human CRFRZa, the human CRFR2P, the human CRFR2y, the human CRFRI , the mouse CRFR2, the rat CRFR2, the dog CRFR2, the cynomolgus monkey (cyno) CRFR2, the mouse CRFRI, the rat CRFRI, the dog CRFRI, or the cyno CRFRI.

[0204] In certain embodiments, the EC so at the CRFR2 or CRFRI is determined in the presence of an agent that blocks nonspecific binding, such as casein.NAI-5002272956 151

[0205] In certain embodiments, the EC 50 at the CRFR2 or CRFR1 is determined in the presence of an agent, such as bovine serum albumin (BSA) that is capable of binding to a fatty acid-containing side chain, such as the RL or the K* side chain of the peptides disclosed herein. In some embodiments, a decrease in potency in the presence of BSA (e.g., an increase in ECso in the presence of BSA as compared to the EC 50 in the presence of casein (e.g., in the absence of BSA)) is indicative of a higher in vivo half-life for a fatty acid-containing peptide of the disclosure, as compared to a peptide that does not experience a comparable loss in potency in the presence of BSA.

[0206] In certain embodiments, the peptides described herein have an EC 50 at the human CRFR20 in the presence of casein of about 0.004 nM to about 1.5 nM, or about 0.004 nM to about 0. 1 nM. or about 0.004 nM to about 0.05 nM (e.g.. about 0.004 nM to about 0. 1 nM, about 0.004 nM to about 0.05 nM, about 0.004 nM to about 0.01 nM, about 0.004 nM to about 0.009 nM, about 0.004 nM to about 0.008 nM, about 0.004 nM to about 0.007 nM. about 0.004 nM to about 0.006 nM, about 0.004 nM to about 0.005 nM, about 0.005 nM to about 0. 1 nM, about 0.006 nM to about 0. 1 nM, about 0.007 nM to about 0. 1 nM, about 0.008 nM to about 0. 1 nM. about 0.009 nM to about 0 1 nM. about 0.01 nM to about 0. 1 nM. or about 0 05 nM to about 0.1 nM) In some embodiments, the peptides described herein have an ECso at the human CRFR20 in the presence of casein of about 0.1 nM. about 0.05 nM, about 0.01 nM. about 0.009 nM, about 0.008 nM, about 0.007 nM, about 0.006 nM, about 0.005 nM, or about 0.004 nM.

[0207] In certain embodiments, the peptide represented by SEQ ID NO:1 has an EC50 at the human CRFR20 of about 0.01 nM, or about 0.004 nM in the presence of casein.

[0208] In certain embodiments, the peptides described herein have an EC 50 at the human CRFR20 in the presence of casein and BSA of about 0. 1 nM to about 14 nM, or about 0.1 nM to about 5 nM, or about 0.1 nM to about 1 nM (e.g, about 0.1 nM to about 5 nM, about 0.1 nM to about 2 nM, about 0.1 nM to about 1 nM, about 0.1 nM to about 0.9 nM, about 0. 1 nM to about 0.8 nM, about 0. 1 nM to about 0.7 nM, about 0. 1 nM to about 0.6 nM, about 0. 1 nM to about 0.5 nM. about 0. 1 nM to about 0.4 nM, about 0. 1 nM to about 0.3 nM, about 0. 1 nM to about 0.2 nM, about 0.2 nM to about 5 nM, about 0.3 nM to about 5 nM. about 0 3 nM to about 5 nM, about 0 4 nM to about 5 nM, about 0.5 nM to about 5 nM, about 0.6 nM to about 5 nM, about 0.7 nM to about 5 nM, about 0.8 nM to about 5 nM, about 0.9 nM to about 5 nM, about 1 nM to about 5 nM. or about 2 nM to about 5 nM). In some embodiments, the peptides described herein have an ECso at the human CRFR20 in the presence of casein and BSA of about 5 nM, about 2 nM. about 1 nM, about 0.9 nM, about 0 8NAI-5002272956 152nM, about 0.7 nM, about 0.6 nM, about 0.5 nM, about 0.4 nM, about 0.3 nM, about 0.2 nM, or about 0. 1 nM.

[0209] In certain embodiments, the peptide represented by SEQ ID NO: 1 has an ECso at the human CRFR20 of about 0.49 nM, or about 0.5 nM in the presence of casein and BSA.

[0210] In certain embodiments, the peptides described herein have tin ECso at the human CRFR1 in the presence of casein of about 0.003 nM to about 500 nM, or about 0.003 nM to about 10 nM, or about 0.003 nM to about 0.1 nM (<?.g.. about 0.003 nM to about 500 nM, about 0.003 nM to about 100 nM, about 0 003 nM to about 10 nM. about 0 003 nM to about 1 nM, about 0.003 nM to about 0.1 nM, about 0.003 nM to about 0.01 nM, about 0.003 nM to about 0.009 nM, about 0.003 nM to about 0.008 nM, about 0.003 nM to about 0.007 nM, about 0.003 nM to about 0.006 nM. about 0.003 nM to about 0.005 nM, about 0.003 nM to about 0.004 nM, about 0.004 nM to about 500 nM, about 0.005 nM to about 500 nM, about 0.006 nM to about 500 nM, about 0.007 nM to about 500 nM, about 0.008 nM to about 500 nM, about 0.009 nM to about 500 nM, about 0.01 nM to about 500 nM, about 0.1 nM to about 500 nM, about 1 n.M to about 500 nM, about 10 nM to about 500 nM, or about 100 nM to about 500 nM). In some embodiments, the peptides described herein have an ECso at the human CRFR1 in the presence of casein of about 500 nM. about 100 nM. about 10 nM, about 1 nM, about 0.1 nM, about 0.01 nM, about 0.009 nM, about 0.008 nM, about 0.007 nM, about 0.006 nM, about 0 005 nM, about 0.004 nM, or about 0.003 nM.

[0211] In certain embodiments, the peptide represented by SEQ ID NO: 1 has an ECso at the human CRFR1 of about 265 nM, or about 300 nM in the presence of casein. In certain embodiments, the peptide represented by SEQ ID NO: 1 was inactive at the human CRFR1 at a concentration of about 50 pM, in the presence of casein. In certain embodiments, the peptide represented by SEQ ID NO: 1 was inactive at the human CRFRl at a concentration of about 50 uM. in the presence of casein and BSA.

[0212] In certain embodiments, the peptides described herein have an ECso at the human CRFR2a in the presence of casein of about 0,003 nM to about 25 nM, or about 0.003 nM to about 10 nM, or about 0.003 nM to about 0. 1 nM (e.g. . about 0.003 nM to about 25 nM, about 0.003 nM to about 10 nM, about 0.003 nM to about 1 nM. about 0.003 nM to about 0 1 nM, about 0.003 nM to about 0.01 nM, about 0.003 nM to about 0.009 nM, about 0.003 nM to about 0.008 nM, about 0.003 nM to about 0.007 nM, about 0.003 nM to about 0.006 nM, about 0.003 nM to about 0.005 nM, about 0.003 nM to about 0.004 nM, about 0.004 nM to about 25 nM, about 0 005 nM to about 25 nM. about 0.006 nM to about 25 nM. about 0.007 nM to about 25 nM, about 0.008 nM to about 25 nM. about 0.009 nM to about 25NAI-5002272956 153nM, about 0.01 nM to about 25 nM, about 0.1 nM to about 25 nM, about 1 nM to about 25 nM, or about 10 nM to about 25 nM). In some embodiments, the peptides described herein have an ECso at the human CRFR2a in the presence of casein of about 25 nM. about 10 nM. about 1 nM, about 0.1 nM, about 0.05 nM, about 0.01 nM, about 0.009 nM, about 0.008 nM, about 0.007 nM, about 0.006 nM, about 0.005 nM, about 0.004 nM, or about 0.003 nM.

[0213] In certain embodiments, the peptide represented by SEQ ID NO: 1 has an ECso at the human CRFR2a of about 0.003 nM in the presence of casein.[002141 In certain embodiments, the peptides described herein have an ECso at the human CRFR2y in the presence of casein of about 1 nM to about 80 nM, or about 1 nM to about 10 nM, or about 1 nM to about 5 nM (e.g., about 1 nM to about 80 nM, about 1 nM to about 10 nM. about I nM to about 90 nM. about 1 nM to about 8 nM, about 1 nM to about 7 nM, about I nM to about 6 nM, about I nM to about 5 nM, about 1 nM to about 4 nM, about 1 nM to about 3 nM, about 1 nM to about 2 nM. about 2 nM to about 80 nM, about 3 nM to about 80 nM, about 4 nM to about 80 nM, about 5 nM to about 80 nM, about 6 nM to about 80 nM. about 7 nM to about 89 nM, about 8 nM to about 80 nM, about 9 nM to about 80 nM, or about 10 nM to about 80 nM). In some embodiments, the peptides described herein have an ECso at the human CRFR2y in the presence of casein of about 80 nM, about 10 nM. about9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, or about 1 nM.

[0215] In certain embodiments, the peptide represented by SEQ ID NO: 1 has an ECso at the human CRFR2y of about 1 .73 nM. or about 2 nM in the presence of casein.

[0216] In certain embodiments, the peptides described herein have an ECso at the mouse CRFR2 in the presence of casein of about 0.02 nM to about 25 nM, or about 0.02 nM to about 10 nM, or about 0.02 nM to about 0. 1 nM (e.g., about 0.02 nM to about 25 nM, about 0.02 nM to about 10 nM, about 0.02 nM to about 1 nM, about 0.02 nM to about 0.9 nM, about 0.02 nM to about 0.8 nM, about 0.02 nM to about 0.7 nM, about 0.02 nM to about 0.6 nM, about 0.02 nM to about 0.5 nM, about 0.02 nM to about 0.4 nM, about 0.02 nM to about 0.3 nM, about 0.02 nM to about 0.2 nM. about 0.02 nM to about 0. 1 nM. about 0.02. nM to about 0.05 nM, about 0.05 nM to about 25 nM, about 0.1 nM to about 25 nM. about 0.2 nM to about 25 nM, about 0.3 nM to about 25 nM, about 0.4 nM to abo...

Claims

1. WHAT IS CLAIMED:1 . A peptide comprising an ammo acid sequence of Formula (T) (SEQ ID NO:63);RN-Ri-R2-R3-lle-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg-Ala- Arg-Ala-Ala- Arg-Glu-Gln-Ala-R?2-Tlu--Asn-R35-Glu-Ile-R38-Glu-R4u-R4i-NH2(T’). wherein :RN is selected from RL, RI -Ser-Gly from N-terminus to C-terminus. Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to ('-terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2is selected from Gly, Ser, Aib, and Thr;Rs is selected from Lys. amK. .Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, K*» and Thr;R35 is selected from Ala, Aib. and Ac3c;R38 is selected from Nle, and Leu,Rro is selected from Thr. Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:Rr. is -(Z)i-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH2)p-X, -(Z)i-(2-[2-(2-amino-ethoxy)~ethoxy]~acetyl)!i-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(Trx)j~(CO)~ (CH2)P-X, or-((CO)-(PEGX-(CH2)2-NH)r-(gGlu)i-(CO)-(CH2)u-X; wherein the linkage to RL is via the nitrogen of the N-terminus;Rz is -(Z)a-(2- [2-(2-amino-ethoxy )-ethoxy] -acetyi)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X,-(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetylX-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGhj)e-(CO)-(CH2)g-X; each Z is independently Gly. Glu, gGlu, Lys, eLys, Ala. Gin, or His;X is -CO2H, -P(O)(OH)2, -S(O)2NH2, or -(lH-tetrazol-5-yl);NAI-5002272956 379i, n, v, m, j, and t are each independently 0, 1 , 2 or 3; p and u are each independently 14-20; s is 1-36; k is 2-16; r is 1, 2, 3, or 4; a. b, y, c, d, and e are each independently 0, 1. 2, or 3; q and g are each independently 14-20; w is 1 -36; h is 2-16, f is 1 , 2, 3, or 4; and with the proviso that when K* is present, Ri, is not present; and when RL is present, K* is not present; or a pharmaceutically acceptable salt thereof.2 The peptide of claim 1 comprising or consisting of the ammo acid sequence ofFormula (If) (SEQ ID NO: 64):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-Tle-Leu-Leu-R2o-Gln-Ala-Arg’Ala-Arg-zMa’Ala-Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile’R38-Glu-R40-R4i-NH2Of), wherein :RN is selected from RL. RI -Ser-Gly from N-terminus to C-terminus, Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, .Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;Rs is selected from l.ys. amK. Arg, Gin. Glu, and Gly;R20 is selected from Glu, and Gin;R.32 is selected from Glu, K*, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr. Glu, and Arg;R41 is selected from lie, Vai, and Glu; and wherein:Ri. is “(2-[2-(2.-ammo-ethoxy)-ethoxy]“acetc'l)a-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-O-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X; n. v . and m are each independen tly 0, 1, 2 or 3;NAI-5002272956 380p is 14-20; s is 1 -36. wherein the linkage to RL IS via the nitrogen of the N-terminus;Rz is -(Z)a-(2-[2-(2-amino-ethox}0-ethoxy]-acetyl)b-(gGlu)c-(Tfx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxj-]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH?.)g-X; each Z is independently Gly, Glu, gGlu. Lys, eLys, Ala, Gin, or His;X is -CO2H, -P(O)(OHh. -S(O)2NH2. or -( lH-tetrazoi-5-yl ); a. b, y, c. d. and e are each independently 0, 1, 2, or 3: q and g are each independently 14-20; w is 1 -36; h is 2-16; f is 1, 2, 3, or 4; and with the proviso that when K* is present, RL is not present; and when RL is present, K* is not present.

3. The peptide of claim I or 2, wherein the amino acid sequence of Formula (F) or (If) is an amino acid sequence of Formula (la’) (SEQ ID NO:65):Rr-Ri-Ra-IG-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-lle-Leu-Leu-Rzo-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-GIn-Ala-Rs2-Thr-Asn-R35-Glu-Ile-R38-Glu-R4u-R4i-lSIH2 (la'). wherein :Ri is selected from Gly, Aib, .Asp, Glu, and Pro;R2 is selected from Gly, Ser, .Aib, and Thr;Rs is selected from Lys, amK. Arg, Gin. Glu, and Gly;R20 is selected from Glu, and Gin;R.32 IS selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;NAI-5002272956 381R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 IS selected from He, Vai, and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu)m-(CO)-(CH2)p-X;X is -CO2H, -P(O)(OH)2. -S(O)2NH2, or -( lH-tetrazol-5-yl): n. v, and m are each independently 0, 1, 2. or 3; p is 14-20; s is 1-36; wherein the linkage to RL. IS via the nitrogen of the N-terminus.4 The peptide of any one of claims 1 to 3, wherein the ammo acid sequence of Formula(F) or (If) is an ammo acid sequence of Formula (la-1’) (SEQ ID NO:66):RL-Gly-R2-R3-lle-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg- Ala- Arg-Ala- Ala-Arg-Glu-GIn-Ala-R32-Thr-Asn-R35-Glu-ne-R38-Glu-R40-R4i-NH2 (la- 1 ). wherein:R2 is selected from Gly, Ser, Aib, and Thr;R3 is selected from Lys. amK. Arg, Gin, Glu. and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 IS selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from He. Vai, and Glu; and wherein :RL is -(2-[2-(2-amino-etlioxy)-ethoxy]-acet\'l)n-(gGlu)tn-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy )-ethoxy]-acetyl)n-((CO)-CH2-(PEG)8-NH)v-(gGiu)m-(CO)-(CH2)p-X;X is -CO2H, -P(O )( OT- 1 ) 2, -S(O)2NH2, or -( 1 H-ietrazol-5-yl); n, v, and m are each independently 0, 1, 2 or 3; p is 14-20; s is 1-36: wherein the linkage to Ri, is via the nitrogen of the N-terminus.382NAI-50022729565. The peptide of any one of claims 1 to 3, wherein the amino acid sequence of Formula (!’) or (If) is an amino acid sequence of Formula (la-2.' \) (SEQ ID NO:67):RL-R]-Gly-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-GIu-GIn-Ala-R32"Thr-Asn-R35-Glu-I]e-R38-Glu-R4»-R4i~NH2 (la-2’), wherein:Ri is selected from Gly, Aib, Asp, Glu, and Pro;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and ArgR41 is selected from lie, Vai, and Glu; and wherein:RL IS “(2-[2-(2-ammo-ethoxy)-ethoxy]-acetyd)n-(g<jlu)m-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CH2-(PEG)s-NH)v-(gGlu);!i-(CO)-(CH2)p-X,X is -CO2H, -P(O)(OH)2, -S(O)2NH2, or -(lH-tetrazol-5-yl), n, v, and m are each independently 0, 1. 2 or 3; p is 14-20; s is 1-36; wherein the linkage to RL is via the nitrogen of the N-tenninus.

6. The peptide of any one of claims 1 to 3, wherein the amino acid sequence of Formula (!’) or (li ’ ) is an amino acid sequence of Formula (Ta-3’) (SEQ ID NO:68):RL-Ri-Ra-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-Rio-Gln-Ala- Arg-Ala- Aig-Ala-Ala-Arg-Glu-Gln-Ala-R32-rriir-Asn-R35-Glu-Ile-R38-Glu-R40-R4J-NH2 da-3’), wherein:Ri is selected from Gly, Aib, Asp. Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;NAI-5002272956 383R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R-11 is selected from He. Vai, and Glu; and wherein :RL is -(2-[2-(2-amino-elhoxy)-ethoxy]-aceh’1)n-(gGlu)n>-(CO)-(CH2)p-CO2H or -(2-[2-(2- amino-ethoxy)-ethoxy]“acetv’l)n"((CO)"CH2"(PEG)s-NH)v“(gGlu).p.-(CO)-(CH2)p-X;X is -CO2H, -P(O)(OH)2, -S( () ) XH ■. or -( 1 H-tetrazol-5-yl); n, v, and m are each independently 0, 1, 2 or 3; p is 14-20; s is 1-36; wherein the linkage io Ri, is via the nitrogen of the N-terminus.7 The peptide of claim 1 or 2, wherein the amino acid sequence of Formula (T) or ( li ’) is an amino acid sequence of Formula (lb’) (SEQ ID NO;69);RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-GIn-Gln-Tle-Leu-Leu-R2o-Gln-Ala-JArg-Ala-Arg-zAla-Ala-Arg-Glu-Gln-Ala-K*~nir-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2(lb'), wherein ;RN is selected from Tyr-Leu from N-terminus to C -terminus, His-Pro from N-terminus to C -terminus, Gly, and pGlu. or absent;Ri is selected from Gly, Aib, .Asp, Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;Rs is selected from l.ys. amK. Arg, Gin. Glu, and Gly;R20 is selected from Glu. and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu:R40 is selected from Thr, Glu, and Arg;R4J is selected from He. Vai. and Glu; and wherein:NAI-5002272956 384Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g-X; each Z is independently Gly, Glu, gGlu, Lys, eLys, Ala. Gin, or His;X is -CO?H. -P(O)(OH)->, “S(C))2NH 2, or -(lH-tetrazol-5-yl); a, b, y, c, d, and e are each independently 0, 1. 2, or 3; q and g are each independently 14-20, w is 1-36: h is 2-16; f is 1, 2, 3, or 4.

8. The peptide of any one of claims 1. 2 and 7, wherein the ammo acid sequence of Formula (T) or (If) is an amino acid sequence of Formula (Ib-1 ’) (SEQ ID NO:70): pGlu-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-ne-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R29- Gin-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln- Ala-K*-Thr-Asn-R35-Glu-He-R38-Glu-R40-R4i- NH2(ib-n wherein:Ri is selected from Gly, Aib, Asp. Glu, and Pro;R2is selected from Gly, Ser, Aib, and Thr;R3 is selected from Lys, amK. Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from lie. Vai, and Glu; and wherein:NAI-5002272956 385Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X, -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-((CO)-CH2-(PEG)w-NH)y-(gGlu)c-(Trx)d- (CO)-(CH2)q-X, or-((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)e-(CO)-(CH2)g-X; each Z is independently Gly, Glu, gGlu, Lys, eLys, Ala. Gin, or His;X is -CO?H. -P(O)(OH)->, “S(C))2NH 2, or -(lH-tetrazol-5-yl); a, b, y, c, d, and e are each independently 0, 1. 2, or 3; q and g are each independently 14-20, w is 1-36: h is 2-16; f is 1, 2, 3, or 4.

9. A peptide comprising an amino acid sequence of Formula (I) (SEQ ID NO:32):RN-Ri-R2-R3-Ue-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Glv-Leu-Gln-Gln-Ile-Leu-Leu-R29-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gin-Ala-Rsi-Thr-Asn-Rss-Glu-Ile-Rz^-Glu-Rry-Rri-NI-fc (I), wherein:R\ is selected from Ri„ Rr ,-Ser-Gly from N-terminus to C-terminus, Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGhi, or absent; Ri is selected from Gly, Aib, Asp. Glu, and Pro;R2 is selected from Gly, Ser, Aib, and Thr;R3 is selected from Lys, amK, Arg, Gin, Glu. and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, K*, and Thr;R35 is selected from Ala, .Aib, and Ac3c;R38 IS selected from Nle, and Leu;R40 is selected from Thr, Glu. and Arg;R41 is selected from He. Vai, and Glu; and wherein :NAI-5002272956 386RL is -(Z)j-(2-[2-(2 -amino-ethoxy )-ethoxy]-acetyl)n-(gGlu)m-(Trx)j-(CO)-(CH?.)P-X or-((CO)-(PEG)k-(CH2)2-NH)r-(gGlu)i-(CO)-(CH2)u-X; wherein the linkage to RL IS via the nitrogen of the N-terminus;Rz is -(Z)a-(2-[2-(2-amino-ethox}0-ethoxy]-acetyl)b-(gGlu)c-(Tfx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH)f-(gGhj)e-(CO)-(CH2)g-X:Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO?H or -P(O)(OH)2; i, n, m, j, and I are each independently 0. 1, 2 or 3; p and u are each independently 14-20; k is 2. 4, 6, 8. 10, 12, 14, or 16; r is 1, 2, 3, or 4; a, b, c, d, and e are each independently 0, 1, 2, or 3; q and g are each independently 14-20; h is 2, 4, 6, 8, 10, 12, 14, or 16; f is 1, 2, 3, or 4; and with the proviso that when K* is present, RL is not present; and when RL is present, K* is not present; or a pharmaceutically acceptable salt thereof.

10. 'The peptide of claim 9 comprising or consisting of the amino acid sequence of Formula (li) (SEQ ID NO; 62):RN-Ri-R2-R3-Ile-Thi-Leu-Ser-Leu-Asp-VahPro-Ile-Gly-Leu-GIn-Gln-Ile-Leu-Leu-R20-Gln-Ala- Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2(li), wherein:RN is selected from RL, Rr-Ser-Gly from N-terminus to C -terminus, Tyr-Leu from N- terminus to C-terminus, His-Pro from N-terminus to C-terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, Asp. Glu, and Pro;R? IS selected from Gly, Ser, Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin, Glu, and Gly;NAI-5002272956R20 is selected from Glu, and Gin;R32 is selected from Glu, K*. and i hr.R35 is selected from .Ala, Aib, and Ac3c;R.3s is selected from Nle, and Leu;Rao is selected from Thr, Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxy)-etho.xy]-acetyl)n-(gGhi)m-(CO)-(CH2)r-CO2H; n and m are each independently 0, 1 , 2 or 3; p is 14-20; wherein the linkage to RL IS via the nitrogen of the N-terminus:NHR,J, 4K* ISHO ;Rz is -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)b-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH)f-(gGlu)s-(CO)-(CH2)£-X:Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2II or -P(O)(OH)2; a. b, c, d, and e are each independently 0, 1 , 2, or .3; q and g are each independently 14-20; h is 2, 4, 6.

8. 10, 12, 14, or 16; f is 1 , 2, 3, or 4; and with the proviso that when K* is present, Ri. is not present; and when RL is present, K* is not present.1 1 The peptide of claim 9 or 10, wherein the amino acid sequence of Formula (I) or (li) is an amino acid sequence of Formula (la) (SEQ ID NO:33):RL-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4i-NH2(la). wherein:Ri is selected from Gly, Aib, Asp, Glu, and Pro;NAI-5002272956 388Rz is selected from Gly, Ser, Aib, arid Thr;Rs is selected from Lys, amK. Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R.32 IS selected from (flu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr. Glu, and Arg;R-u is selected from lie, Vai, and Glu; and wherein:RL is -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H: n and m are each independently 0, 1, 2 or 3; p is 14-20; wherein the linkage to RL is via the nitrogen of the N-terminus.

12. The peptide of any one of claims 9 to 1 1, wherein the amino acid sequence ofFormula (I) or (li) is an ammo acid sequence of Formula (la-1 ) (SEQ ID NO:34):RL-Gly-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-lle-Leu-Leu-R2‘j-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R3?.-Thr-Asn-R35-Glu-I]e-R38-Glu-R4u-R4i-iNH2 (la-1 ). wherein :R? is selected from Gly, Ser. Aib, and Thr;R3 is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from .Ala, Aib, and Ac3c;R.3S is selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from He, Vai, and Glu; and wherein:RL IS -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)!..-(gGlu)m-(CO)-(CH2)p-CO2H; n and m are each independently 0, 1 , 2 or 3; p is 14-20; wherein the linkage to Rr. is via the nitrogen of the N-terminus.NAI-5002272956 38913. The peptide of any one of claims 9 to 1 1, wherein the amino acid sequence of Formula (I) or (li) is an amino acid sequence of Formula (la-2) (SEQ ID NO:35);RL-Rj-Gly-R5-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-He-Leu-Leu-R2o-Gln-Ala- Arg-Ala- Arg-Ala-Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R4u-R4i-NH2 (la-2), wherein :Ri is selected from Gly. Aib, .Asp, Glu. and Pro;R? is selected from Lys, amK, Arg, Gin, Glu, and Gly;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from .Ala, Aib, and Ac3c;R38 is selected from Nle, and Leu;R40 is selected from Thr, Glu, and ArgR41 is selected from He, Vai, and Glu; and wherein;RL IS -(2-|2-(2-amino-ethoxv)-ethoxy]-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H; n and m are each independently 0, 1, 2 or 3; p is 14-20; wherein the linkage to RL IS via the nitrogen of the N-terminus.14 The peptide of any one of claims 9 to i L wherein the amino acid sequence ofFormula (I) or (li) is an amino acid sequence of Formula (la-3) (SEQ ID NO:36):RL-Ri-R2-Lys-Ile-Thr-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Gln-Gln-Ue-Leu-Leu-R2o-Gln-Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-R32-Thr-Asn-R35-Glu-Ile-R38-Glu-R40-R4t-NH2 (la-3). wherein :Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly, Ser. .Aib, and Thr;R20 is selected from Glu, and Gin;R32 is selected from Glu, and Thr;R35 is selected from Ala, Aib, and Ac3c;R.3S IS selected from Nle, and Leu;R40 is selected from Thr, Glu, and Arg;R41 is selected from lie, Vai, and Glu;NAI-5002272956 390and wherein:RL is -(2-[2-(2-amino-ethoxy)-ethoxy |-acetyl)n-(gGlu)m-(CO)-(CH2)p-CO2H: n and m are each independently 0, 1, 2 or 3; p is 14-20; wherein the linkage to RL is via the nitrogen of the N-terminus.

15. The peptide of claim 9 or 10. wherein the amino acid sequence of Formula (1) or (li) is an amino acid sequence of Formula (lb) (SEQ ID NO:37):RN-Ri-R2-R3-Ile-Thr-Leu-Ser-Leu-Asp-V a)-Pro-Ile-Gly-Leu-Gln-Gln-Ile-Leu-Leu-R2o-Gln- Ala- Arg- Ala- Arg-Ala- Ala- Arg-Glu-Gln-Ala-K*-Thr-Asn-R35-Giu-Ile-R38-Glu-R40-R4i-NH2(Ib), wherein:RN is selected from Tyr-Leu from N-terminus to C -terminus, His-Pro from N-terminus toC -terminus, Gly, and pGlu, or absent;Ri is selected from Gly, Aib, Asp, Glu, and Pro;R2 is selected from Gly. Ser, Aib, and Thr;Rs is selected from Lys, amK, Arg, Gin. Glu, and Gly;R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle. and Leu;R40 is selected from Thr. Glu. and Arg;Rn is selected from lie, V al, and Glu; and wherein:Rz is -(Z)a-(2- [2-(2-amino-ethoxy )-ethoxy] -acetyi)b-(gGlu)c-(Trx)d-(C0)-(CH2)q-X or-((CO)-(PEG)h-(CH2)2-NFI)r-(gGlu)e-(CO)-(CH2)g-X;Z is independently Gly, Glu, gGlu, Lys, eLys, Ala, Gin, or His;X is -CO2H or -P(O)(OH)2; a, b, c, d, and e are each independently 0, 1, 2, or 3; q and g are each independently 14-20,NAI-5002272956 391h is 2, 4, 6, 8. 10, 12, 14, or 16; f is 1, 2, 3, or 4.

16. The peptide of any one of claims 9, 10, and 15, wherein the amino acid sequence of Formula (I) or (Ii) is an amino acid sequence of Formula (Ib-1) (SEQ ID NO 38): pGIu-Ri-R2-R3-IIe-Thr-Leu-Ser~L.eu-Asp-Val-Pro-lie-Gly-Leu-Gln~Gln-Ile~Leu~Leu-R2o~ Gin- Ala-Arg-Ala- Arg- Ala-Ala- Arg-Glu-Gln-Ala-K* -Thr- Asn-R35-Glu-lle-R38-Glu-R40-R4i- NFh(Ib-l), wherein:Ri is selected from Gly. Aib, Asp, Glu, and Pro;R? is selected from Gly, Ser. Aib, and Thr;R.? is selected from Lys, amK, Arg, Gin, Glu, and Gly:R20 is selected from Glu, and Gin;R35 is selected from Ala, Aib, and Ac3c;R38 is selected from Nle. and Leu;R40 is selected from Thr, Glu. and Arg;R-n is selected from He, Vai, and Glu; and wherein :Rzis -(Z)a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)i,-(gGlu)c-(Trx)d-(CO)-(CH2)q-X or -((CO)-(PEG)h-(CH2)2-NH)f-(gGluXCO)-(CH2)g-X,Z is independently Gly, Glu, gGlu. Lys, eLys. Ala, Gin. or His;X is -CO2H or -P(O)(OH)2; a. b, c, d, and e are each independently 0, I, 2, or 3; q and g are each independently 14-20; h is 2, 4, 6, 8.

10.

12.

14. or J 6; f is 1 , 2, 3, or 4.

17. The peptide of any one of claims 1, 2, 9, and 10, w herein RN is Rn-Ser-Gly from N-NAI-5002272956 392terminus to C-terminus.

18. The peptide of any one of claims 1. 2, 7, 9. 10 and 15, wherein RIN IS Tyr-Leu from N- ternnnus to C-terminus.

19. The peptide of any one of claims 1, 2, 7, 9, 10 and 15, wherein RN is His-Pro from N- terminus to C-terminus.

20. The peptide of any one of claims 1, 2, 7, 9, 10, and 15, wherein RN IS Gly.21 . The peptide of any one of claims 1, 2, 7, 9, 10 and 15, wherein RM is absent.

22. The peptide of any one of claims 1 to 3, 5 to 11, and 13 to 21, wherein Ri is Gly.

23. The peptide of any one of claims 1 to 3, 5 to 1 1 , and 13 to 21 , wherein Ri is Aib.

24. The peptide of any one of claims 1 to 3, 5 to 11, and 13 to 21, wherein Rj is Asp.

25. ’The peptide of any one of claims 1 to 3, 5 to 1 1, and 13 to 21. wherein Ri is Ghi.

26. The peptide of any one of claims 1 to 3, 5 to 11, and 13 to 21, wherein Ri is Pro.

27. The peptide of any one of claims 1 to 4, 6 to 12, and 14 to 26. wherein R2 is Gly.

28. The peptide of any one of claims 1 to 4, 6 to 12, and 14 to 26, wherein R? is Ser.

29. The peptide of any one of claims 1 to 4, 6 to 12, and 14 to 26, wherein R2 is Aib.30 The peptide of any one of claims 1 to 4, 6 to 12, and 14 to 26, wherein R2 is Thr.

31. The peptide of any one of claims 1 to 5, 7 to 13, and 15 to 30, wherein Rs is Lys.

32. The peptide of any one of claims 1 to 5, 7 to 13, and 15 to 30, wherein Rs is amK.NAI-5002272956 39333. The peptide of any one of claims 1 to 5, 7 to 13, and 15 to 30, wherein R -. is Arg.

34. The peptide of any one of claims 1 to 5, 7 to 13, and 15 to 30, wherein Rs is Gin.

35. The peptide of any one of claims 1 to 5, 7 to 13, and 15 to 30, wherein Rs is Glu.

36. The peptide of any one of claims 1 to 5, 7 to 13. and 15 to 30. wherein Rs is Gly.

37. The peptide of any one of claims I to 36, wherein R20 is Glu.

38. The peptide of any one of claims 1 to 36, wherein R20 is Gin.

39. The peptide of any one of claims 1 to 6, 9 to 14, and 17 to 38, wherein R32 is Glu.

40. The peptide of any one of claims 1 to 6, 9 to 14, and 17 to 38. wherein R32 is Thr.

41. The peptide of any one of claims I to 40, wherein R35 is Ala.

42. The peptide of any one of claims 1 to 40, wherein R35 is Aib.43 The peptide of any one of claims 1 to 40. wherein R35 is Ac3c.

44. The peptide of any one of claims 1 to 43, wherein Rss is Leu.

45. The peptide of any one of claims 1 to 43, wherein IGs is Nle.

46. The peptide of any one of claims to 45, wherein Rro is Thr.

47. Tire peptide of any one of claims 1 to 45, wherein R40 is Glu.

48. ’The peptide of any one of claims 1 to 45, wherein R40 is Arg.

49. The peptide of any one of claims to 47, wherein R-n is He.NAI-5002272956 39450. The peptide of any one of claims 1 to 47, wherein R41 is Vai.

51. The peptide of any one of claims 1 to 47, wherein R41 is Gin.

52. The peptide of any one of claims 1 to 6, 9 to 14, 17, 22 to 51, wherein:(1) n is 1, m is 1, p is 18;(ii) n is 2, m is 1, p is 18;(iii) n is 3, m is 1, p is 18;(iv) n is 0, m is 1, p is 18;(v) n is 1, m is 2, p is 18;(vi) n is 2, m is 2, p is 18;(vii) n is 3, m is 2, p is 18;(viii) n is 0, m is 2, p is 18;(ix) n is 1, m is 3, p is 18;(x) n is 2, m is 3, p is 18;(xi) n is 3, m is 3, p is 18;(xii) n is 0, m is 3, p is 18;(xiii) n is 1 , m is 0, p is 18;(xiv) n is 2, m is 0, p is 18;(xv) n is 3, m is 0, p is 18;(xvi) n is 1, m is 1, p is 16;(xvii) n is 2, m is 1 , p is 16;(xviii) n is 3. m is 1, p is 16;(xix) n is 0, m is 1, p is 16;(xx) n is i, m is 2, p is 16;(xxi) n is 2, m is 2, p is 16;(xxii) n is 3, rn is 2, p is 16;(xxiii) n is 0, m is 2, p is 16;(xxiv) n is 1, m is 3, p is 16;(xxv) n is 2, m is 3, p is 16;(xxvi) n is 3, m is 3, p is 16;(xxv ii) n is 0, m is 3, p is 16;(xxviii) n is 1, m is 0, p is 16;395NAI-5002272956(xxix) n is 2, m is 0, p is 16; or(xxx ) n is 3, m is 0, p is 16.

53. The peptide of any one of claims 1, 17, and 22 to 51 , wherein RL IS -(Z)i-(2-[2-(2- amino-ethoxy)-ethoxy]-acetyl)n-((CO)-CT-l2-(PEG)s-NH)y-(gCdu)m-(Trx)j-(CO)-(CH2)p-X, and wherein :(i) i is 0, n is 1. v is 0 or 1, m is L j is 0, p is 18;(ii) i is 0, n is 2, v is 0 or 1, m is 1, j is 0, p is 18;(iii) i is 0, n is 3, v is 0 or 1, m is 1 , j is 0, p is 18;(iv) i is 0, n is 0, v is 0 or 1 , m is 1 , j is 0, p is 18;(v) i is 0, n is 1, v is 0 or 1, m is 2, j is 0, p is 18;(vi) i is 0, n is 2, v is 0 or 1, m is 2, j is 0, p is 18;(vii) i is 0, n is 3, v is 0 or 1, m is 2, j is 0, p is 18;(viii) i is 0, n is 0, v is 0 or 1, m is 2, j is 0, p is 18;(ix) i is 0, n is 1, v is 0 or I, m is 3, j is 0, p is 18;(x) i is 0. n is 2, v is 0 or 1 , m is 3, j is 0, p is 18;(xi) i is 0, n is 3, v is 0 or 1, m is 3, j is 0, p is 18;(xii) i is 0, n is 0, v is 0 or 1, m is 3, j is 0, p is 18;(xiii) i is 0, n is 1 , v is 0 or 1, m is 0, j is 0, p is 18,(xiv) i is 0, n is 2, v is 0 or 1, m is 0, j is 0, p is 18;(xv) i is 0. n is 3, v is 0 or L m is 0, j is 0, p is 18;(xvi) i is 0, n is 1, v is 0 or 1, m is 1, j is 0, p is 16;(xvii) i is 0, n is 2, v is 0 or 1 , m is 1 , j is 0, p is 16;(xviii) i is 0, n is 3, v is 0 or 1 , m is 1 , j is 0, p is 16;(xix) i is 0, n is 0. v is 0 or 1, m is 1, j is 0, p is 16:(xx) i is 0, n is 1, v is 0 or 1, m is 2, j is 0, p is 16;(xxi) i is 0, n is 2, v is 0 or 1, m is 2, j is 0, p is 16;(xxii) i is 0, n is 3, v is 0 or 1, m is 2, j is 0, p is 16;(xxin) i is 0, n is 0, v is 0 or 1, m is 2, j is 0, p is 16;(xxiv) i is 0. n is 1, v is 0 or 1 , m is 3, j is 0, p is 16;(xxv) i is 0, n is 2, v is 0 or 1 , m is 3, j is 0, p is 16;(xxvi) i is 0, n is 3, v is 0 or 1, m is 3, j is 0, p is 16;(xxvii) i is 0, n is 0, v is 0 or 1, m is 3, j is 0, p is 16;(xxviii) i is 0, n is I, v is 0 or 1, m is 0, j is 0, p is 16;NAI-5002272956 396(xxix) i is 0, n is 2, v is 0 or 1, m is 0, j is 0, p is 16;(xxx) i is 0, n is 3, v is 0 or 1 , m is 0, j is 0, p is 16;(xxxi) i is 0, n is 1, v is 0 or 1, m is 1. j is 0, p is 20;(xxxii) i is 0, n is 2, v is 0 or 1, m is 1, j is 0, p is 20;(xxxii i) i is 0, n is 3, v is 0 or 1, m is 1 , j is 0, p is 20;(xxxiv) i is 0, n is 0, v is 0 or I, m is 1, j is 0, p is 20;(xxxv) i is 0, n is 1. v is 0 or 1, m is 2, j is 0, p is 2.0;(xxxvi) i is 0. n is 2, v is 0 or 1 , m is 2, j is 0, p is 20;(xxxvii) i is 0, n is 3, v is 0 or 1, rn is 2, j is 0, p is 20;(xxxviii) i is 0, n is 0, v is 0 or 1 , m is 2, j is 0, p is 20;(xxxix) i is 0, n is 1, v is 0 or 1, m is 3, j is 0, p is 20;(xl) i is 0, n is 2, v is 0 or 1, m is 3, j is 0, p is 20;(xli) i is 0, n is 3, v is 0 or 1, m is 3, j is 0, p is 20;(xlii) i is 0, n is 0, v is 0 or 1, m is 3, j is 0, p is 20;(xliii) i is 0, n is 1, v is 0 or I, m is 0, j is 0, p is 20;(xliv) i is 0. n is 2. v is 0 or 1, m is 0, j is 0, p is 20; or(xlv) i is 0, n is 3, v is 0 or 1 , m is 0, j is 0, p is 20.

54. The peptide of any one of claims 1 to 6, 9 to 14. 17, 22 to 51 , wherein Ri is(i) -(2-[2-(2-amino-ethox5')-ethoxy]-acetyl)-gGlu-(CO)-(CH2)i8-CO2H;(ii) -(2-[2-(2-amino-ethoxj')-ethoxy]-acetj?l)2-gGlu-(CO)-(CH2)i6-CO2H;(Hi) -(2-[2-(2-amino-et}ioxy)-ethoxy]-acetjl)?-gGlu2-(CO)-(CH2)is-CO2H;(iv) -(2-[2-(2-amino-e1iioxy)-ethoxy]-ace1yl)2-gGlu3-(CO)-(CH2)i8-CO2H;(v) -(2-[2-(2-amino-ethoxy)-ethoxy]-acet>'l)2-gGlu-(CO)-(CH2)i8-C02H;(vi) -(2-[2~(2"amino-ethoxy)-ethoxy]-acetyi)2-gGlu~(CO)-(CH2)2o-C02H;(vii) -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyI)2-gGlu-(CO)-(CH2)2o-P(0)(OH)2;(viii) -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)2o-S(0)2NH2;(ix) -(2-[2-(2-amino-ethoxy’)-ethoxy]-acetyl)2-gGlu-(CO)-(CH2)20-(lH-tetiazol-5-yl); or(x) -(2-[2-(2-amino-etiioxy)-ethoxy]-acety4)?-(CO)-CH?-(PEG)i?-NH-gGlu-(CO)- (CH2)20-CO2H.

55. The peptide of any one of claims 1, 2, 7 to 10, 15, 16, 18 to 38, and 41 to 51, wherein:(i) b is 2, c is I, d is 0:(ii) b is 2, c is 2, d is 0;NAI-5002272956 397(iii) b is 1, c is 1, d is 0;(iv) b is 0, c is 1 , d is 1 ;(v) b is 2. c is 1, d is 1; or(vi) b is 1. c is 1, d is 1.

56. The peptide of any one of claims 1, 2, 7 to 10, 15, 16, 18 to .38, and 41 to 51, whereinRz. is -(eLys)a-(2-[2-(2-amino-ethox\')-ethoxy]-acety'l)b-(gGlu)c-(CO)-(CH2)q-X.

57. The peptide of claim 56, wherein a is 0 or 1, b is 1 or 2 and c is 1 or 258. The peptide of any one of claims 1, 2, 7 to 10. 15, 16, 18 to 38, and 41 to 51, whereinRz is(i) -(2-[2-(2-amino-ethoxy)-ethoxy]~acetyl)2-(gGlu)-(CO)-(CH2)i6-CO2H; or(ii) -(2-[2-(2-amino-ethoxy’)-ethoxy]-acetyl)2-(gGlu)-(CO)-(CH2)is-CO2H.

59. The peptide of any one of claims 1, 2, 7 to 10.

15.

16. 18 to 38. and 41 to 51. whereinR. is -(CO)TPEG)i2-(CH2)2-NH-(gGlu)e-(CO)-(CH2)g-CO2H.

60. The peptide of claim 59, wherein e is 1 or 2 and g is 16 or 18.61 The peptide of any one of claims 1 to 6 and 9 to 14, wherein R \ is Ri.. Ri is Gly, R2 is Gly, and Ri is Lys.

62. ’The peptide of any one of claims 1 to 6 and 9 to 14, wherein RN is RL, RI is Gly, R2 is Gly, R? is Lys. R20 is Glu, R32 is Glu, R35 is Ala, Rs« is Nle, R40 is Thr, and R41 is He.

63. The peptide of any one of claims 1 to 6 and 9 to 14, wherein RN IS RL, RI IS Gly, R2 is Gly, R3 is Lys, R20 is Glu, R32 is Glu, R35 is Ala, Ras is Nle, R40 is Thr, R-n is He, and RL IS - (2-P-(2“amino-ethoxy)-ethoxy]-acetyl)n-(gGlu)m"(CO)-((;H2)p-CO?.H, and wherein n and ni are each independently 0. 1, 2 or 3: p is 14-20.

64. The peptide of any one of claims 1 to 3 and 9 to 11, wherein the peptide comprises or consists of the amino acid sequence of SEQ ID NO: 1 . SEQ ID NO:2, SEQ ID NO:

3. SEQ ID NON. SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:

7. SEQ ID NO: 8, SEQ ID NON. SEQ IDNAI-5002272956 398NO: 10, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:30, SEQ ID NO:31,SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:

57. SEQ ID NO:

58. SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61.

65. The peptide of any one of claims 1, 2, 7, 9, 10 and 15, wherein the peptide comprises or consists of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29.

66. A peptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NON, SEQ ID NON. SEQ ID NO;7, SEQ ID NO:8, SEQ ID NON, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:

15. SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:

25. SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:

30. SEQ ID NO:31 . SEQ ID NO:43, SEQ ID NO: 44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO: 54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO: 61.

67. A peptide consisting of the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2,SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NON, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NON, SEQ ID NO: 10, SEQ ID NO: 1 I, SEQ ID NO: 12, SEQ ID NO:

13. SEQ IDNO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:

25. SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO 30. SEQ ID NO:31, SEQ ID NO:

43. SEQ ID NO:44, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO-69, or SEQ ID NO.6 !68. A compound comprising the peptide of any one of claims 1 to 67.

69. A pharmaceutically acceptable salt of the peptide of any one of claims 2 to 67 or theNAI-5002272956 399compound of claim 68.

70. A formulation comprising the peptide of any one of claims 1 to 67, or the compound of claim 68, in admixture with one or more pharmaceutically acceptable excipients.

71. A formulation comprising the pharmaceutically acceptable salt of claim 69, in admixture with one or more pharmaceutically acceptable excipients.

72. A method of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of the peptide of any one of claims 1 to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71.

73. The method of claim 72, wherein the disease or disorder is selected from: (i) type 2 diabetes, type-2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon, sarcopenia, gallbladder disease, and sleep apnea; (ii) a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity -linked inflammation, obesity-linked sarcopenia, obesity-linked gallbladder disease, and obesity- induced sleep apnea; (iii) a skeletal muscle wasting disease or age-related muscle loss; (iv) muscle wasting during cancer cachexia; (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure, hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronaiy heart disease and stroke; (vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis; (viii) addiction / nicotine withdrawal syndrome; (ix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) Bardet-Biedl syndrome (BBS); (xii) Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD); (xiii ) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy; (xvi) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated fatty liver disease (MAFLD); and (xvii) alcohol use disorder.

74. The method of claim 72 or 73, wherein the treatment results in the combination of weight loss and the preservation or building of muscle mass.NAI-5002272956 40075. A method of reducing body weight, increasing w eight loss, reducing body weight without loss of muscle mass, reducing body weight while preserving or building muscle mass, and / or preserving or building muscle mass in a subject comprising administering to the subject a therapeutically effective amount of the peptide of any one of claims 1 to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71.

76. A method of reducing food intake and / or inducing satiety m a subject comprising administering to the subject a therapeutically effective amount of the peptide of any one of claims 1 lo 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71.

77. The peptide of any one of claims 1 to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 for use in treating a disease or disorder.

78. The peptide, the compound, the pharmaceutically acceptable salt, or the formulation for use of claim 77, wherein the disease or disorder is selected from: (i) type 2 diabetes, type- 2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon, sarcopenia, gallbladder disease, and sleep apnea; (li) a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity-linked inflammation, obesity-linked sarcopenia, obesity -linked gallbladder disease, and obesity -induced sleep apnea; (iii) a skeletal muscle wasting disease or age-related muscle loss; (iv) muscle wasting during cancer cachexia; (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure, hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease and stroke; (vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis; (viii) addiction / nicotine withdrawal syndrome; (ix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) Bardet-Biedl syndrome (BBS); (xii) Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD); (xiii) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy; (xvi) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated fattyliver disease (MAFLD); and ( xvii ) alcohol use disorder.NAI-5002272956 40179. The peptide of any one of claims 1 to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 for use in reducing body weight, increasing weight loss, reducing body weight without loss of muscle mass, reducing body weight while presenting or building muscle mass, and / or preserving or building muscle mass in a subject.80 The peptide of any one of claims 1 to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 for use in reducing food intake and / or inducing satiety in a subject.

81. Use of the peptide of any one of claims I to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 in the manufacture of a medicament for the treatment of a disease or disorder.

82. The use of claim 81, wherein the disease or disorder is selected from: (i) type 2 diabetes, type-2 diabetes associated with insulin resistance, rheumatologic or inflammatory disorders, skin inflammation, acute inflammatory response due to gram-negative bacteria in the colon, sarcopenia, gallbladder disease, and sleep apnea; (li) a disease associated with excess body weight selected from obesity, obesity-linked type 2 diabetes, obesity -linked inflammation, obesity-linked sarcopenia, obesity -linked gallbladder disease, and obesity- induced sleep apnea; (hi) a skeletal muscle wasting disease or age-related muscle loss: (iv) muscle wasting during cancer cachexia; (v) a cardiovascular disease wherein the cardiovascular disease is selected from heart failure, hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease and stroke, (vi) chronic kidney disease and / or diabetic kidney disease; (vii) myalgic encephalomyelitis; (viii) addiction / nicotine withdrawal syndrome; fix) acute pancreatitis; (x) Prader-Willi syndrome; (xi) Bardet-Biedl syndrome (BBS); (xii) Becker Muscular Dystrophy (BMD) or Duchenne Muscular Dystrophy (DMD); (xiii) anxiety, depression, or stress; (xiv) chronic fatigue syndrome; (xv) muscle atrophy; (xvi) metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction -associated fatty liver disease (MAFLD); and (xvii) alcohol use disorder83. The use of the peptide of any one of claims 1 to 67, the compound of claim 68. the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 in the manufacture of a medicament for reducing body weight, increasing weight loss, reducingNAI-5002272956 402body weight without loss of muscle mass, reducing body weight while preserving or building muscle mass, and / or preserving or building muscle mass in a subject.

84. The use of the peptide of any one of claims I to 67, the compound of claim 68, the pharmaceutically acceptable salt of claim 69, or the formulation of claim 70 or 71 in the manufacture of a medicament for reducing food intake and / or inducing satiety in a subject.NAI-5002272956 403

Images